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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Introduction
In creased  a c tiv ity  of the sym p a th e tic  n e rvo u s system  is a w e ll-k n o w n  fea tu re  o f a 
n u m b e r of ca rd io va scu la r c o n d itio n s  such as ch ro n ic  heart fa ilu re  and m yocardial 
ischem ia.1'3 In the fa ilin g  heart, incre ase d  sym p ath e tic a ctiv ity  is p art of a reflex- 
m ed iated  c o m p e n sa to ry  m ech anism  to m aintain  ca rd iac o u tp u t and preserve  
o rg an p e rfu sio n . S u p p ressio n  of arterial b a ro re fle x  fu n c tio n  as w ell as en h a n ce d  
sy m p a th o -e x cita to ry  reflexes in resp o n se  to loss of ca rd iac o u tp u t seem  to be 
part of this pro ce ss.410 In ca rd iac ischem ia the o x y g e n -d e p riv e d  m yo cardium  
releases su b sta n ce s like b ra d y k in in  w h ich  stim ulate sym p ath e tic affe re nts resid ing 
in the m yo cardial w all, resu ltin g  in an increase in e ffe ren t sym p ath e tic  o u tflo w .11'15 
In h y p e rte n sive  patients, ch a n g e s in re g u la to ry  m ech anism s co n tro llin g  central 
sym p a th e tic  a c tiv ity  seem  to p lay a p ivotal role in the increase in sym p ath e tic 
o u tflo w  .1617
Irre sp e ctiv e  of the m ech anism  and p u rp o se  of the increase in sym p ath e tic 
ou tflo w , a p ro lo n g e d  state of high sym p ath e tic  o u tflo w  is d etrim e ntal in patients 
w ith  c a rd io v a sc u la r d isease . In cre a se d  h o sp ita liz a tio n  and m o rb id ity  rates, 
red u ced  m yo cardial fu n c tio n  and red u ced  su rv iv a l have all b een associated  w ith  
a p ro lo n g e d  state of high sym p ath e tic activity.118'21
Several p a th o p h y sio lo g ica l m ech anism s have b een put fo rw a rd  to e xp la in  
these clear deleterious effects in cardiovascular disease. First, chronically increased 
sym p a th e tic  a c tiv ity  in cre ase s p e rip h e ral v a so co n strictio n  and th e re b y  v a scu la r 
resistance. In p atients w ith a fa ilin g  heart this m ay fu rth e r co m p ro m ise  ca rd iac 
o u tp u t and s u b se q u e n t tissu e  p e rfu sio n . In m yo cardial ischem ia, the p ositive  
ino tropic and chronotropic effects of sym pathetic stim ulation are disadvantageous 
fo r the a lre ad y  o x y g e n -d e p riv e d  m yo cardial tissue. In ad d itio n , the su b se q u e n t 
in c re a se d  m yo card ial e x c ita b ility  m ay in d u ce  life -th re a te n in g  arrh yth m ia s. 
E x tra ca rd ia lly , ch ro n ic  s y m p a th o e x c ita tio n  in d u ce s u n fa v o u ra b le  ch a n g e s in 
in su lin  sen sitivity, renal h o m e o sta sis and platelet a c tiv a tio n .2223 For this reason, 
a llevia tio n  of th is p e rm an e n t state of h igh sym p ath e tic  a c tiv ity  is the fo rem o st 
goal of cu rre n t tre atm e nt strateg ie s fo r p atie n ts w ith ca rd io va scu la r d isease.
A logical first step to restore excessive sym pathoexcitation w ould be to rem ove 
the trig g e r or cause. In case of m yo cardial ischem ia d u e  to co ro n a ry  artery  d isease, 
th is can be o b tain e d  by im p ro vin g  m yo cardial p e rfu sio n . In several other
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ca rd io v a scu la r d iso rd e rs the e xact trig g e r of excessive  sym p ath e tic  a c tiv ity  is less 
clear, irre v e rsib le  or not accessib le  for in te rve n tio n . In these cases, current 
th e ra p e u tic  strateg ie s fo cu s on b lo ck in g  a d re n e rg ic  rece p to rs. In d e e d , p ro te ctio n  
o f the h e a rtfro m  (excessive) sym p ath e tic stim u latio n  by b e ta -a d re n e rg ic  recepto r 
b lo ck e rs has b ee n  sh o w n  to increase su rv iv a l and red u ce  m o rb id ity  in a n u m b e r 
of card io va scula r co n d itio n s.24,25 Such a sp ecific  strategy how ever, shields organs 
p a rtia lly  and leaves the increased  sym p a th e tic  n e rve  tra ffic  itse lf una ffe cted  
(fig u re  1). C o n seq u en tly , sym p a th e tic  a c tiv ity  and its m ajor n e u ro tran sm itte r 
n o rep inephrine (NE) will act on other unblocked receptors like the alpha-adrenergic 
receptors.
a-adrenergic
receptor
sympathetic nerve 
traffic
t
jS-blocker
, ^ -adrenergic 
receptor
Figure 1
A schematic illustration of efferent sympathetic nerve traffic and its effect on a target 
organ through the a -and (3-adrenergic receptor via release of norepinephrine (NE). 
Beta-blockers shield the (3-adrenergic receptor, but leave the a-adrenergic pathway 
unaffected.
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A m ore e ffe ctiv e  a p p ro a ch  w o u ld  be to red u ce  sym p ath e tic a c tiv ity  at a m ore 
central level. The re g u la to ry  centres of sym p a th e tic  nerve a c tiv ity  reside in sp e cific  
n u cle i in the brain and from  anim al e xp e rim e n ta l stu d ie s th ese  n u cle i are 
su sce p tib le  to (p h a rm a co lo g ica l) m o d u la tio n .26'28 Ideally, p h arm aco lo g ical 
in te rve n tio n s sh o u ld  be easy a p p lic a b le , have few  to no side e ffe cts and w ork 
irre sp e ctiv e  of the cause of the increase in sym p a th e tic  activity. In p atients w ith 
ca rd io v a scu la r d isease  this co n ce p t is even m ore c h a lle n g in g . Potential drug 
in te ra ctio n s, h e m o d y n a m ic s id e -e ffe cts, as w ell as a sm all th e ra p e u tic  range often 
lim it the a p p lic a b ility  o f new  poten tia l p h a rm a co lo g ica l in te rve n tio n s. F o llo w in g  
th e  su ccess of (3-b lo c k e r th e ra p y  in c a rd io v a sc u la r d ise ase , a n u m b e r of 
in ve stig a to rs have fo cu se d  on re d u cin g  sym p ath e tic a c tiv ity  at a central level, 
using agents like m o xonidin e and clo n id in e . M o xo n id in e  stim ulates im idazoline-1 
( I ) receptors in the brain stem , thereby d ecreasing central sym p athetic o u tflo w .29 
A lth o u g h  both ag e n ts have b een sh o w n  to red u ce  plasm a n o re p in e p h rin e  (NE) 
levels and w ere assu m ed  to have b e n e fits  in p atients w ith  ch ro n ic  heart failure, 
the long-term  M oxonidine C ongestive heart failure (MOXCON) trial w as term inated 
p rem atu re ly  b eca u se  of an increased  m o rta lity  in the m o x o n id in e  g ro u p .30'33 
T here are several e xp la n a tio n s for th is fa ilu re  in im p ro vin g  the p ro g n o sis  in 
p atie n ts w ith co n g e stive  heart fa ilu re  by in h ib itio n  of central sym p a th e tic  o utflo w . 
O ne of the p o ssib ilitie s  is that the total d aily  dose of the slo w  release (SR) 
fo rm u la tio n  of m o x o n id in e  w as too high, as th is w as seve ra l-fo ld  h ig h e r than that 
of the m arketed im m e d iate-re lea se  fo rm u la tio n . In a d d itio n , re d u ctio n  in plasm a 
NE levels m ight have b een too stron g. The MOXCON trial also used a forced  
d o se -titra tio n  stu d y  d esig n , w h e re as a m ore g rad ua l dose titratio n m ight have 
red u ced  ad ve rse  effe cts. Finally, the data safe ty  m o n ito rin g  b oard  that oversaw  
this trial recom m ended a change in the dose regim en but the trial w as prem aturely 
term in ated  by the sp o n so r b efore e n d p o in ts  w ere reached . C lo n id in e  is a m ixed 
ag o n ist that stim u lates both a 2- and ^-recep to rs centrally. A se rio u s d ra w b a ck  of 
c lo n id in e  is its a 2-a d re n o ce p to r related s id e -e ffe cts, m aking  it a less su ita b le  
ca n d id a te  fo r use in ca rd io v a scu la r d isease, e sp e cia lly  heart fa ilu re. Since skeletal 
m uscles, heart, blood vessels and kidney, all suffer from  adverse con sequen ces of 
sym pathetic overactivity, pharm acological intervention of the prolonged increased 
sym p ath e tic  a c tiv ity  rem ains an a ttractive  poten tia l goal.
A novel m ech anism  by w h ich  an 'o ld ' d ru g  m ight red u ce  central sym p ath e tic 
o u tflo w  is H M G -C oA  re d u cta se  in h ib itio n  by statins. Several anim al stu d ie s have 
su g g e ste d  that statins, in d o ses that low er plasm a ch o lestero l, also red u ce  central
13
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sym p a th e tic  o u tflo w .34 From these stu d ie s it has b ee n  su g g e ste d  that statins 
increase central nitric o xid e  (NO) co n ce n tra tio n s in the p a ra v e n tricu la r reg io n  and 
d o w n re g u la te  a n g io te n sin  t y p e -1 rece p to r e xp re ssio n  and NAD(P)H fo rm a tio n  in 
th e  rostral ve n tro la te ral m ed ulla  of the brain stem .35 Both areas are w ell kno w n 
sym p a th e tic  centres w h e re  sym p a th e tic  o u tflo w  is reg u late d . NO is a w ell kno w n 
in h ib ito r of sym pathetic activity, w hereas NAD(P)H stim ulates sym pathetic activity 
by fo rm a tio n  of reactive o xy g e n  sp ecie s (ROS). A m ore in d epth d iscu ssio n  on the 
e ffe ct of statins on central sy m p ath e tic a c tiv ity  is p ro vid e d  in ch a p te r 2 . Statins 
are rela tive ly  safe d ru g s and m ore im p o rtan tly, m ost ca rd io v a scu la r p atie n ts do 
need this d ru g  an yw a y fo r lo w e rin g  plasm a ch o lestero l. In this thesis w e so u g h t to 
e stab lish  w h e th e r statins in c lin ica lly  used d o sag e s, do also red u ce  central 
sym p a th e tic  a c tiv ity  in hum ans.
An im p o rta n t e ffe ct of p e rsiste n t incre ase d  sym p ath e tic  a c tiv ity  is a re d u ctio n  
in insulin sensitivity. Insulin resistance, d efin ed  as a decreased b io lo gical response 
to insu lin , is associated  w ith  ca rd io v a scu la r d ise ase .36'39 The p a th o p h y sio lo g ica l 
role of the sym p ath e tic n e rvo u s system  in im p airin g  in su lin  se n sitiv ity  seem s 
m u ltifacto ria l. H igh plasm a NE levels red u ce g lu co se  to le ra n ce  and in d u ce  insu lin  
resistance, possibly m ediated by lipolysis and increased fatty acid concentrations.40 
In creases in plasm a NE levels raise fastin g  g lu co se  levels by a tra n sien t increase in 
basal h e p atic g lu co se  o u tp u t.41 A d d itio n ally , ad re n e rg ic  recepto r stim u latio n  may 
d ire ctly  affe ct the in su lin  s ig n a llin g  p ath w ay or ce llu la r g lu co se  tra n sp o rt.42 
Sym path etic a c tiv ity  m ay also affe ct skeletal m uscle  g lu co se  u ptake by re d u cin g  
ca p illa ry  skeletal m uscle  p e rfu sio n  (n u tritive  flo w ) th ro u g h  v a so co n strictio n  and 
th e re fo re  d e liv e ry  of in su lin  and g lu co se  to the skeletal m uscle. V a so co n strictio n  
in skeletal m uscle  is m ed iated  by the a -a d re n e rg ic  receptor. Therefore, 
a -a d re n e rg ic  rece p to r b lo ck a d e  m ig ht im p ro ve  m icro va scu la r p e rfu sio n  and 
c o n se q u e n tly  m uscle  g lu co se  u ptake and in su lin  sen sitivity.
Assessment of sympathetic nervous system activity
The sym p ath e tic  n e rvo u s system  is part o f the a u to n o m ic n e rvo u s system  and 
plays an im p o rta n t role in ca rd io v a scu la r re g u latio n  in both health and d isease. 
The sym p ath e tic  n e rvo u s system  can m o d ulate  p e rip h e ral v a scu la r resistance and 
ca rd iac o u tp u t to p ro v id e  a d e q u a te  tissue p e rfu sio n  of m ost org an s. Sym path etic 
o u tflo w  o rig in a te s from  sp e cific  sym p ath e tic  n u cle i in the central n e rvo u s system  
and is regulated by a n u m ber of sp ecific  brain stem nuclei (p arave n tricula r nuclei, 
n u cle u s  tra ctu s so litariu s e.g.).43'46 The rece p tive  p art o f the sym p a th e tic  n e rvo u s
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system  is co n stitu te d  by all kinds of v isceral sen so rs w h ich , th ro u g h  afferent 
fib e rs, relay in fo rm atio n  from  the d ifferen t org an s to the central n u cle i. Sensors 
located  in the carotid  sinu s and ao rtic  arch are ca lled  arterial b aro re ce p to rs, w h ile  
sen so rs in the atria, v e n tric le s  and lu n g s are ca lled  ca rd io p u lm o n a ry  b aro rece p to rs. 
A ffe ren t in p u t and in p u tfro m  h ig h e r central centers like co rtex and h yp o th ala m u s, 
is translated  into e fferen t sym p ath e tic o u tp ut. Several an atom ical and fu n ctio n a l 
levels of the e ffe ren t sym p ath e tic resp o n se  can be d istin g u ish e d . First, e lectrical 
sym pathetic discharges from central sym pathetic nuclei are "transported" by efferent 
sym p athetic nerve fib e rs w hich fin a lly  term inate in differen t organs. From the 
afferent sym pathetic nerve e n d in g s the neuro tran sm itter NE is released by electrical 
im pulse-m ediated exocytosis into the synaptic cleft. After release into the synaptic 
cleft, the m ajo rity  o f the NE is cleared  by p re sy n a p tic  reup take (uptake 1) and 
uptake in no nneu ral tissue w h e re  it is d eactivated  (uptake 2). O nly a small fraction 
of the ne u ro n ally  released NE w ill reach the c ircu lato ry  com partm e nt (Figure 2). 
The fu n ctio n  of NE is to translate the electrical signal into a biochem ical signal 
by stim ulating a  and (3 ad ren erg ic receptors. Stim ulation of these post-synaptic 
ad re n e rg ic  rece p to rs w ill fin a lly  in d u ce  an o rg an resp o n se  (va so co n strictio n , 
ch ro n o tro p ic  cardiac response) by sp ecific  signal tra n sd u ctio n  pathw ays.
In the stu d ie s p resen ted  in this thesis w e assessed  sym p ath e tic  a ctiv ity  by 
d iffe re n t te ch n iq u e s: m icro n e u ro g ra p h y  of the p e ro n ea l n e rve  w as used to assess 
e ffe ren t sym p ath e tic  n e rve  tra ffic  (e lectrical d isch a rg e  fre q u e n cy , f ig u re  3). T his is 
referred to as m uscle  sym p ath e tic n e rve  a ctiv ity  (MSNA). MSNA re fle cts  v a s o ­
co n stricto r sig n als g o ve rn e d  by b aro refle xes. These o ccu r in b u rsts and are 
strictly  b o u n d  to ca rd iac rhythm . M e asu rem en t of MSNA from  p e rip h e ra l nerves 
in h u m ans is safe, accurate, q u a n tifia b le  and re p ro d u cib le .47 S im u lta n e o u s 
m ea su rem en ts of sym p ath e tic n e rve  a c tiv ity  from  d ifferen t lim b s sh o w  id en tical 
b u rst fre q u e n c ie s  and m o rp h o lo g y , m aking m easu rem en ts from  on e lim b 
re p re se n tative  for w h o le  b o d y  skeletal m uscle  sym p ath e tic  activity.48 M icro ­
n e u ro g ra p h y  re co rd in g s are p e rfo rm e d  u n d e r b aselin e  co n d itio n s  (p atie n t in 
su p in e  p osition), but can also be p e rfo rm e d  d u rin g  v a rio u s  stim u li that increase 
sym p ath e tic  a c tiv ity  (cold stress, o rth o sta tic  stress, m ental stress).49 O ne im p o rtan t 
lim itatio n of th is te ch n iq u e  is that it p ro v id e s sele ctiv e  info rm ation of sym p ath e tic 
a c tiv ity  to the skeletal m uscle  co m p artm e n t. Since there are su b sta n tia l d ifferen ces 
in sym p ath e tic a c tiv ity  b etw ee n  d iffe re n t organ s, MSNA d o e s not represent 
overall sym p a th e tic  activity.
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M onoar  
V  oxida:Synapticvesicle
Norm al
norepinephrine
transporter
20%
N orepinephrine
N o rm a l N o re p in e p h r in e  T ra n s p o rt  
Axon
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Adrenergic - 
receptors
Cytoplasm
Cell
m em brane
Figure 2
Schematic outlay of the presynaptic membrane of a sympathetic nerve ending and 
the postsynaptic cell membrane of a target organ
(Shannon et al. New Engl JM ed  2000;342:541-9). DHPG = dihydroxyphenylglycol.
An additional way to obtain information of sympathetic activity is to measure 
quantitatively the neuronal release of NE. The most easiest way to estimate this 
release is measurement of the plasma NE concentration. Measurement of the 
plasma NE concentration has the advantage to be easy and only minimally 
invasive. On the other hand, the value of the plasma NE concentrations as a 
representative of total body sympathetic activity is clearly limited.50 The plasma 
level of NE is the net result of the rate by which NE enters the circulatory 
compartment (total body spillover) and the volume of plasma that is cleared of 
NE (total body clearance). However, the neuronal release is not the same as the 
spillover rate since this spillover rate is also determined by blood flows and
16
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30 seconds
Figure 3
Top: A schematic representation of m icroneurography of the peroneal nerve.
Bottom: an example of a recording of muscle sympathetic nerve activity (30 sec).
clearance of NE from organs. Consequently, elevated plasma NE levels do not 
discriminate between increased neuronal release or reduced clearance of NE. 
There are profound regional differences in the activity and control of sympathetic 
function, posing a major limitation to the use of plasma NE as marker for "overall" 
sympathetic activity. Finally, reproducibility of plasma NE is also lower than that 
of MSNA.51
To assess the final organ response of sympathetic stimulation, we used the 
technique of heart rate variability (HRV) analysis. Power spectral analysis of HRV is 
a frequently used non-invasive technique for assessment of autonomic indices of 
neuronal cardiac control (figure 4).52 Heart rate variability refers to beat-to-beat 
interval alterations. Fluctuations in the beat-to-beat interval occur at a certain 
rhythm and frequency. Sympathetic activity is represented by the low frequency 
(LF) spectrum although parasympathetic activity has also an effect on LF. In 
contrast, the high frequency spectrum is determined solely by parasympathetic 
activity. Dividing low frequency power by high frequency power provides an 
estimate of "autonomic balance", with a high ratio indicating sympathetic 
dominance.
17
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Rest Head-up tilt
o Hz 0.5 0 Hz
Figure 4
A graphic representation of power spectral density per frequency domain.
LF = low-frequency power, HF: high-frequency power. Left: during rest;
Right: during head up tilt (increases sympathetic activity).
Outline of the thesis
The first part of this thesis focuses on sympathetic activity in several cardio­
vascular conditions. Pathophysiological mechanisms underlying the increase in 
sympathetic activity are discussed and different interventions to reduce this 
increased sympathetic activity are assessed. Specific attention is given to a 
possible sympathoinhibitory effect of statins. The second part of the thesis 
focuses on an important detrimental effect of increased sympathetic activity; 
reduced insulin sensitivity. The effects of some interventions from part one on 
insulin sensitivity are described and new interventions explored .
Chapter 2 is devoted to an overview of different triggers and mechanisms 
responsible for the increase in sympathetic activity in myocardial ischemia, heart 
failure and hypertension, as well as to potential pathways to intervene with these 
mechanisms. In Chapter 3 the effect of improving myocardial perfusion on 
sympathetic activity in stable angina is assessed. In myocardial ischemia, 
stimulation of cardiac sympathetic afferents by ischemia-induced release of 
certain substances, results in a reflex-mediated increase in sympathetic output. 
In a group of patients with proven myocardial ischemia and stable but persisting 
symptoms despite optimal pharmacological therapy, the effect of percutaneous
18
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coronary intervention (PCI) on sympathetic activity was examined. In other 
cardiovascular disorders like chronic heart failure, removal of the trigger is not 
possible. Pharmacological interventions in an effort to modulate sympathetic 
activity might prove to be helpful in these patients. Animal experimental data 
suggest two key pathways that ultimately determine sympathetic output: the 
angiotensin II (stimulatory) and the NO (inhibitory) pathway. In animal experiments 
it was shown that HMG-coA reductase inhibitors (statins) interfere with these 
pathways and it was postulated that by this route statins might be able to reduce 
sympathetic activity. In two studies reported in this thesis this hypothesis was 
tested in two groups of patients: patients with chronic congestive heart failure 
(Chapter 4) and in patients with primary hypertension (Chapter 5). The final step 
in the angiotensin II pathway is formation of reactive oxygen species (ROS). For 
this reason the angiotensin II pathway may be susceptible for antioxidants. If true, 
the use of antioxidants that pass the blood-brain barrier might also result in a 
reduction of sympathetic activity. Chapter 6 reports the effects of a high dose 
ascorbic acid, a well-known antioxidant, on sympathetic activity in patients with 
congestive heart failure.
Increased sympathetic activity has also negative extracardiac effects and one 
of these effects is a reduction in insulin sensitivity, rendering the patient more 
insulin resistant. One of the consequences of high sympathetic tone is a reduction 
in skeletal muscle blood flow by a-adrenergic vasoconstriction. With the reduction 
of skeletal muscle perfusion, tissue delivery of glucose and insulin is also reduced 
(reduced nutritive flow). By blocking the a-adrenergic receptors, skeletal muscle 
perfusion, nutritive blood flow as well as insulin signalling may be improved, 
ultimately resulting in a stimulation of skeletal muscle glucose uptake and a 
reduction in insulin resistance. In Chapter 7, a study that examines the effect of 
phentolamine, an alpha-adrenergic receptor blocker, on forearm glucose uptake 
in chronic heart failure patients is described. In Chapter 8 the effects of 
sympathetic ganglionic blockade on forearm glucose uptake is reported. Since 
inflammation also plays a key role in insulin resistance, we tested the hypothesis 
that PCI increases insulin resistance by inducing an inflammation in patients with 
stable angina (Chapter 9).
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Intervening with sympathetic activity 
in cardiovascular disease

Alternative modalities for treating 
high sympathetic tone in heart failure, 
myocardial ischemia and hypertension: 
a common pathway?

ALTERNATIVE MODALITES FOR TREATING HIGH SYMPATHETIC TONE
Introduction
Sympathoexcitation is a key feature of cardiovascular disease such as congestive 
heart failure (CHF), myocardial ischemia and hypertension.1'5 The activation of the 
sympathetic nervous system in congestive heart failure and myocardial ischemia 
is reflex-mediated and is triggered by stimulation of sympathetic afferents. In 
contrast, in hypertension the observed increase in sympathetic activity probably 
plays a causal role in the pathophysiology. On the long-term, however, sym­
pathoexcitation has proven to be detrimental in patients with cardiovascular 
disease.6'9 In patients with CHF, sympathoexcitation leads to an increase in 
myocardial cell death, arrhythmias, reduced patient survival and increased hospi­
talization and morbidity rates.89 Hemodynamically, chronic sympathoexcitation 
has profound effects on peripheral vascular resistance, compromising cardiac 
function further. Finally, chronic sympathoexcitation will also induce unfavourable 
changes in insulin sensitivity, renal function and platelet activation.1011
Counteracting sympathoexcitation by (3-adrenoceptor blocking agents improves 
survival and reduces morbidity and has therefore become a cornerstone in 
modern treatment of cardiovascular disease.12'14 This strategy shields organs from 
high sympathetic tone only partially and leaves the increased sympathetic nerve 
traffic itself, the increased neuronal release of norepinephrine and its effect on 
unblocked a-adrenergic receptors (alpha-receptor) unaffected. A more effective 
approach would be to reduce sympathetic activity at a more central level. The 
regulatory centres of sympathetic nerve activity reside in specific nuclei in the 
brain and animal experimental studies have shown that these nuclei are susceptible 
to pharmacological modulation.15'17 Generally, pharmacological interventions 
should be easy applicable, have little or no side effects and should be effective 
irrespective of the cause of the increase in sympathetic activity. In patients with 
cardiovascular disease this concept is even more challenging. Potential drug 
interactions, hemodynamic side-effects, as well as a small therapeutic range often 
limit the search for potential pharmacological interventions. The present chapter 
describes the mechanisms that are involved in the increase in sympathetic nervous 
system activity and potential ways to intervene.
Triggers of sympathetic activity
The mechanisms that underlie the increase in sympathetic activity in patients 
with cardiovascular disease are incompletely understood. Triggers of sympathetic
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activity seem to differ between patients with CHF, myocardial ischemia and 
hypertension. However, a common pathway seems likely since in all conditions 
there is an increased central sympathetic outflow.
a. Triggers of sympathetic activity in patients with CHF
It has been suggested that chronic sympathoexcitation in patients with CHF is 
initiated as a compensatory mechanism for loss of cardiac output and serves to 
preserve vital organ perfusion.918 The extent of increased sympathetic activity is 
thought to reflect the severity of cardiac dysfunction.19 A variety of peripheral 
reflexes and central influences seem to determine the ultimate level of sympathetic 
outflow in CHF. An abnormal arterial baroreflex function has long been held 
responsible for the chronic increase in sympathetic outflow in CHF.20'24 In sino- 
aortic denervated dogs, however, pacing-induced CHF still resulted in a significant 
rise in plasma norepinephrine levels.25 This suggests that arterial baroreflex 
dysfunction is not the sole mechanism for the increase in sympathetic activity in 
CHF. A number of sympatho-excitatory reflexes seem also enhanced in CHF.26 
Afferent nerve endings residing in the myocardial wall can be stimulated by 
different substances like bradykin and specific conditions like ischemia, eliciting 
cardiac sympathetic afferent reflex activity (CSAR). The degree to which these 
peripheral inputs are translated into an increase in central sympathetic outflow 
seems to be highly dependent on regulatory mechanisms residing within the 
central nervous system.1627 A growing body of evidence now suggests that 
angiotensin II (Ang II) and nitric oxide (NO)-mechanisms are strongly involved in 
generating an enhanced central sympathetic outflow.16'2728 Increased central Ang 
II concentrations enhance CSAR gain, whereas blocking the Ang II effects by 
intracerebroventricular infusion of the Ang II receptor blocker losartan reduces 
the central gain of CSAR.1729 NO has the opposite effect. Given a similar afferent 
stimulus, low NO concentrations in the central nervous system result in a larger 
CSAR gain, resulting in a larger sympathetic outflow. In contrast, increased levels 
of NO reduce the CSAR response in dogs with CHF ,27'30'31 Irrespective of the 
intensity of the afferent stimulus, changing central Ang II and NO concentrations 
clearly affect sympathetic outflow in different models.2932'34
b. Triggering sympathetic activity in myocardial ischemia
In myocardial ischemia the sympathoexcitatory response is in part mediated by 
the sinoaortic baroreflex in response to a decrease in blood pressure and/or stroke 
volume from the acutely dysfunctional ischemic left ventricle. However, even in
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sinoaortic denervated and vagotomized dogs a reflex excitatory response 
mediated by left ventricular sympathetic afferents can be demonstrated during 
transmural myocardial ischemia.35'37 In an animal model, Minisi et a I. demonstrated 
that left ventricular receptors with sympathetic afferent fibers are activated by 
myocardial ischemia and elicit changes in central sympathetic outflow.37 This 
afferent nerve activation is induced by a number of substances that are released 
during ischemia within the myocardial wall.38'41 Since these sympathetic afferents 
from the myocardial wall project to the same brain stem nuclei as those in CHF, it 
seems likely that the central sympathetic response will also be affected by similar 
central regulatory mechanisms.4243 Zahner et al. demonstrated that central 
sympathetic outflow, as measured by changes in renal sympathetic nerve activity 
(RSNA), following myocardial sympathetic afferent stimulation with substances 
similar to those released during ischemia, was dependent on paraventricular 
nucleus tone.43
c. triggering sympathetic activity in hypertension
The mechanism of sympathoexcitation in hypertension is less clear. First, one 
should differentiate if the increase in sympathetic activity is a cause or a 
consequence of the increased blood pressure. Current literature focuses on the 
neurohumoral communication at a central level between somatic signals and 
sympathetic reaction.44'47 In rats, stimulation of the sciatic nerve induces a pressor 
reflex, the somatosympathetic reflex, that is mediated by activation of sym- 
pathoexcitatory neurons located within the rostral ventrolateral medulla 
(RVLM).4849 These neurons are responsible for regulating the sympathetic drive to 
heart and blood vessels.50 Ruggeri et al. demonstrated that the cardiovascular 
response elicited by sciatic nerve stimulation was enhanced in spontaneous 
hypertensive rats (SHR).45 They also demonstrated that the increase in somato­
sympathetic reflexes in SHR did not depend upon either impairment in baroreflex 
function, or levels of mean arterial pressure and heart rate.45 The enhanced 
responsiveness of the sympathetic nervous system to somatic stimuli with normal 
baroreceptor function and without any dependence on blood pressure and/or 
heart rate levels, suggests involvement of central mechanisms instead of structural 
changes. This suggestion is supported by data showing that the organization of 
the somatosympathetic reflex is identical in hypertensive and normotensive rats.47 
The reflex excitability of the sympathetic nervous system in SHR is increased and 
the RVLM seems to play the most important role.47'5152
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Neurons residing within the RVLM seem susceptible to angiotensin peptides.53 
Topical application or local microinjection of Ang II into the RVLM produces 
increases in blood pressure and renal nerve activity.52'54 These findings seem 
consistent with a high expression of AT, receptors in this region.55 56 In accordance, 
ATM receptor antagonists are capable of abolishing the pressor effect of Ang II at 
the RVLM.57 The blood pressure lowering effect of ATM receptor antagonists, 
however, is limited to hypertensive animals, with ATM receptor antagonists in 
normotensive animals being ineffective or resulting in a minor decrease in blood 
pressure.5859 These findings have suggested a dual role for angiotensin in blood 
pressure control with angiotensin having sympatho-inhibitory properties in 
normotensives, compared to clearsympathoexcitatory properties in hypertensives 
animals. Fontes et al. suggested that the effect of angiotensin in the RVLM might 
be dependent on differential sensitivity of inhibitory versus excitatory sympathetic 
neurons or differential access of the peptide to subregions within the RVLM.60 
Assessing this problem using the Goldblatt (hypertensive) animal model, Carvalho 
et al. suggested that the difference in the role of the RVLM in the control of arterial 
pressure in the hypertensive (Goldblatt) and normotensive rats could be explained 
by the fact that there is an increase in the glutaminergic drive to RVLM premotor 
neurons mediated by endogenous Ang II in the hypertensive rats.61 
In addition to the Ang II mechanism, nitric oxide (NO) also seems to play an 
important role in the pathophysiology of hypertension at a central level.46'62 63 
From animal experimental models it has been clearly proven that NO has an 
inhibitory effect on central sympathetic outflow.6465 In spontaneous hypertensive 
rats, a clear reduction in central NO synthase (NOS) activity has been 
demonstrated.66 Stimulating intrinsic NO production had no effect while adding a 
NO donor reduced blood pressure level. This led to the belief that hypertensive 
rats are unable to produce the appropriate amounts of central NO to decrease 
sympathetic output, most likely by a decrease in nNOS mRNA expression.63 67
A common pathway
Although baroreflexes and cardiac sympathetic afferent reflexes have clearly 
demonstrated to contribute to sympathoexciation in cardiovascular disease, the 
translation in an actual increase in central efferent sympathetic activity seems 
highly dependent on central acting mechanisms. Of these mechanisms the Ang II 
and NO mechanism seem the most likely candidates. Although most studies 
focused on assessing these mechanisms in CHF, similar effects can be found in 
hypertension and myocardial ischemia. It has been well proven that Ang II is a
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Figure 1
A schematic illustration of the cerebral angiotensin II and NO pathway affecting central 
sympathetic output and the sympathetic reflex arch (grey arrow).
Statins inhibit the angiotensin II pathway and stimulate the NO pathway.
sympathoexcitatory peptide affecting different locations in the central nervous 
system.68'70 A clear Ang II effect was demonstrated in the paraventricular nucleus 
(PVN), nucleus tractus solitarius (NTS) and rostroventrolateral medulla (RVLM).71'73 
Remarkably, cardiac sympathetic afferent nerve endings project to these nuclei. 
It has now been suggested that Ang II modulates the response to the different 
afferent stimuli, determining the degree of amplification and the subsequent 
intensity of central efferent sympathetic output.1774 Ganten et al. demonstrated in 
1978 the existence of an independent brain renin-angiotensin system, including 
all precursors and enzymes necessary for synthesis, conversion and degradation 
of Ang II.75 A number of studies have now focused on the pathway by which Ang II 
modulates central sympathetic outflow.
In experimental studies intracerebral (i.c.v.) Ang II administration stimulates 
the AT^receptor, which results in increased sympathetic outflow.15'17 On top of 
stimulating the AT^receptor, Ang II also upregulates AT^receptor expression, 
further boosting central sympathetic outflow.76 Stimulation of the AT^receptor 
increases formation of reactive oxygen species (ROS).7778 The increase in cerebral 
ROS is now thought to play a pivotal role in increasing sympathetic outflow.77'7980
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ROS are formed by NAD(P)H-oxidase in a number of central nuclei. Zucker 
demonstrated upregulation of the NAD(P)H-oxidase complex by Ang II. Taken 
together, increases in central Ang II concentrations, stimulate and upregulate the 
AT^receptor as well as NAD(P)H-oxidase expression. NAD(P)H-oxidase results in 
increased ROS formation. ROS may increase sympathetic outflow in a number of 
ways. First, ROS reduces cerebral NO.81 Because NO is a well-known sympathoin- 
hibitory substance, a reduction in the bioavailability of NO will predispose local 
neurons in the hypothalamus and medulla to become more excitable, thus 
enhancing sympathetic outflow. Superoxide anion has also been shown to 
modulate calcium-channel function in the central nervous system.82 This 
mechanism may also contribute to neuronal excitability.
NO itself has also a regulatory role on sympathetic outflow at a central level.64,65 
Although it is not exactly known how NO modulates sympathetic outflow, several 
scenarios have been suggested. The most important mechanism is that neuronal 
NO production by neuronal NO synthase (nNOS) causes a release of y-amino 
butyric acid (GABA) that in turn reduces sympathetic outflow.83 Abnormalities in 
the NO-mechanism may contribute to the high sympathetic output state of CHF 
and hypertension. The main locations of actions of nitric oxide are the PVN, NTS 
and RVLM.84 Recent studies suggest that an interaction between Ang II and NO 
exists.85 Angiotensin II stimulates NO production, thus counteracting excitatory 
effect of Ang II on sympathetic outflow.86 In the case of prolonged increased levels 
of Ang II, however, the effects reverses and results in downregulation of nNOS 
mRNA and NO production.87 The reduced NO synthesis then loses its inhibitory 
effect on Ang II. If NO itself is reduced, this only results in increased levels of 
sympathetic activity if Ang II levels are increased. This makes the effect of NO 
reduction on sympathetic activity Ang II dependent. In summary, it seems likely 
that a negative feedback mechanism exists, where Ang II acutely increases NO 
synthesis limiting the increase in sympathetic outflow. However, when Ang II 
levels remain increased, Ang II causes a decrease in nNOS gene expression. 
The latter mechanism might be the basis of the high sympathetic outflow state in 
a number of cardiovascular disease states.
Counteracting sympathetic overactivity in cardiovascular disease
In counteracting sympathetic overactivity in cardiovascular disease, a logical first 
step would be to remove the trigger for the increase in sympathetic activity. In a 
wide variety of conditions, like chronic heart failure or microvascular ischemia.
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however, this is not possible. In addition we have seen that the effect of triggering 
sympathetic activity is highly dependent on its translation at a central level. In 
hypertension for instance, sympathetic activity could simply be caused by over­
amplification of "normal" sympathetic triggers. This might even be a potential 
explanation for hypertension refractory to pharmacological therapy. Identifying a 
common sympathomodulatory pathway within the central nervous system provides 
the opportunity to intervene with sympathetic outflow at a central level.
Following the success of (3-blocker therapy in cardiovascular disease, a number 
of studies focused on reducing sympathetic activity at a central level, using agents 
like moxonidine and clonidine. Moxonidine stimulates the brain stem imidazoline-1 
receptor to decrease sympathetic outflow.88 Although both moxonidine and 
clonidine have been shown to reduce plasma NE levels, the Moxonidine Congestive 
heart failure (MOXCON) trial was terminated prematurely because of increased 
mortality in the moxonidine group.89'92 A more recent concept is blocking the AT, 
receptor to prevent the effects of Ang II.7393 Wang et al demonstrated a clear 
reduction in sympathetic activity after intracerebroventricular (i.c.v.) infusion of 
losartan, a known AT, receptor antagonist.73 Others have focused on the NAD(P) 
H-oxidase complex. Reducing NAD(P)H-oxidase formation by administration of 
aponycin or phenylarsine oxide , also reduced central sympathetic outflow.94 An 
alternative approach is to reduce the formation and availability of ROS. Although 
blocking the ATI receptor or reducing NAD(P)H-oxidase formation will also result 
in decreased ROS formation, a more direct effect can be accomplished by using 
substances like tempol.77 While therapeutic interventions in the early part of the 
cascade seem the most logic, up to know no clear data are available regarding the 
beneficial effects of such strategies. Sympathetic outflow can also be changed by 
affecting central NO concentrations. All the above reported data have been 
obtained from animal experiments, mostly by directly injecting different 
substances in the brain. Obviously, this approach cannot be used in human 
subjects, leaving us with data from animal studies amongst which some might 
also be applicable in humans. In one of these animal experiments, Zucker et al. 
discovered that statins reduced sympathetic outflow in CHF rabbits.9596This effect 
was explained by downregulation of the AT, receptor and NAD(P)H-oxidase 
expression by the statin, resulting in lower ROS formation.78 In addition, statins 
increased local NO concentrations.97
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Potential benefit of reducing the increased central efferent sympathetic 
activity
One may question which interventions in central sympathetic activity will provide 
additional benefits to current (3-blocker and ACE inhibitor therapy in CHF patients. 
Potential benefits of central-acting agents on long-term endpoints like mortality 
and morbidity, are not yet proven in large randomized trials. Current therapy with 
beta-blockers has mainly focused on shielding organs from high sympathetic 
tone. Consequently, effects of sympathetic activity through different (unblocked) 
a-adrenergic receptors as well as effects of the persistently high levels of 
norepinephrine remain still a target. An example of an effect of sympathetic 
action through a-adrenoceptors, is a change in insulin sensitivity. Insulin resistance 
has been related to increased sympathetic activity. A potential explanation is an 
a-adrenergic mediated reduction in muscle blood flow (nutritional flow) due to 
sympathoexcitation, altering tissue delivery of glucose and insulin and reducing 
muscle glucose uptake.98 A reduction in muscle blood flow by vasoconstriction 
seems another part of the explanation. Compared with infusion of norepinephrine, 
physiological vasoconstriction in humans by increased sympathetic activity is 
associated with a greater reduction in forearm glucose uptake despite similar va­
soconstriction.99 This phenomenon may be explained by an additional more direct 
effect of locally released norepinephrine. Accordingly, skeletal muscle blood flow 
and local norepinephrine release might be important determinants of muscle 
glucose uptake.
Summary
In this chapter we have described a number of mechanisms responsible for 
increasing sympathetic activity in heart failure, myocardial ischemia and 
hypertension. As discussed, the increase in sympathetic activity has detrimental 
long term effects in these patients and these effects stretch beyond the 
(3-adrenergic receptor. Reduction of sympathetic overactivity remains therefore 
still a cornerstone in the treatment of patients with cardiovascular disease. 
Attempts to reduce sympathetic activity using central acting sympatholytic 
agents up to now have not proven successful. Undesirable side-effects and 
inadequate dosing might have undermined the success of older central acting 
sympatholytic agents. Nevertheless, the concept of reducing central efferent 
sympathetic outflow as treatment option in cardiovascular patients should not 
yet be completely disregarded. The theoretical basis of this concept remains 
promising. From animal experiments it has been learned that the Ang II and NO
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pathways are important modulators of central sympathetic outflow. As already 
shown in animal studies, HMG-CoA reductase inhibitors might also have a central 
sympathoinhibitory effect, but whether this effect is also present in human 
subjects remains to be elucidated.
37
CHAPTER 2
References
1. Francis GS, Goldsmith SR, Levine TB, Olivari 
MT, Cohn JN. The neurohumoral axis in 
congestive heart failure. Ann Intern Med 
1984;101:370-377.
2. Patel KP. Role of paraventricular nucleus in 
mediating sympathetic outflow in heart 
failure. Heart Fail Rev 2000;5:73-86.
3. Fu Q, Zhang R, Witkowski S, rbab-Zadeh A, 
Prasad A, Okazaki K, Levine BD. Persistent 
sympathetic activation during chronic 
antihypertensive therapy: a potential 
mechanism for long term morbidity? 
Hypertension 2005;45:513-521.
4. Mary DA, Stoker JB. The activity of single 
vasoconstrictor nerve units in 
hypertension. Acta PhysiolScand 
2003;177:367-376.
5. Hogarth AJ, Mackintosh AF, Mary DA. The 
sympathetic drive after acute myocardial 
infarction in hypertensive patients. Am J  
Hypertens 2006;19:1070-1076.
6. Benedict CR, Shelton B, Johnstone DE, 
Francis G, Greenberg B, Konstam M, 
Probstfield JL, Yusuf S. Prognostic 
significance of plasma norepinephrine in 
patients with asymptomatic left 
ventricular dysfunction. SOLVD 
Investigators. Circulation 1996;94:690-697.
7. Packer M, Lee WH, Kessler PD, Gottlieb SS, 
Bernstein JL, Kukin ML. Role of 
neurohormonal mechanisms in 
determining survival in patients with 
severe chronic heart failure. Circulation 
1987;75:IV80-IV92.
8. Swedberg K, Eneroth P, Kjekshus J, 
Wilhelmsen L. Hormones regulating 
cardiovascular function in patients with 
severe congestive-heart-failure and their 
relation to mortality. Circulation 
1990;82:1730-1736.
9. Cohn JN, Levine TB, Olivari MT, Garberg V, 
Lura D, Francis GS, Simon AB, Rector T. 
Plasma norepinephrine as a guide to 
prognosis in patients with chronic 
congestive heart failure. N Engl J  Med 
1984;311:819-823.
10. Reaven GM, Lithell H, Landsberg L. 
Hypertension and associated metabolic 
abnormalities-the role of insulin 
resistance and the sympathoadrenal 
system. N Engl J  Med 1996;334:374-381.
11. Packer M. The neurohormonal hypothesis: 
a theory to explain the mechanism of 
disease progression in heart failure. JAm  
Coll Cardiol 1992;20:248-254.
12. The SOLVD Investigators. Effect of 
enalapril on survival in patients with 
reduced left ventricular ejection fractions 
and congestive heart failure. N Engl J  Med 
1991;325:293-302.
13. Swedberg K. Effects of Enalapril on 
Mortality in Severe Congestive-Heart- 
Failure - Results of the Cooperative-North- 
Scandinavian-Enalapril-Survival-Study 
(Consensus). New Eng J  of Med 
1987;316:1429-1435.
14. Di Lenarda A, Sabbadini G, Moretti M, 
Sinagra G. Long-term oral carvedilol in 
chronic heart failure. Expert Opin 
Pharmacother 2004;5:U59-U72.
15. Bains JS, Potyok A, Ferguson AV. 
Angiotensin II actions in paraventricular 
nucleus: functional evidence for 
neurotransmitter role in efferents 
originating in subfornical organ. Brain Res 
1992;599:223-229.
16. Ma R, Schultz HD, Wang W. Chronic central 
infusion of ANGII potentiates cardiac 
sympathetic afferent reflex in dogs. Am J  
Physiol 1999;277:H15-H22.
38
A L T E R N A T IV E  M O D A L IT IE S  F O R  T R E A T IN G  H IG H  S Y M P A T H E T IC  T O N E
17. Zhu GQ, Patel KP, Zucker IH, Wang W. 
Microinjection of ANG II into 
paraventricular nucleus enhances cardiac 
sympathetic afferent reflex in rats. Am J  
Physiol 2002;282:H2039-H2045.
18. Joyner MJ. Go with the flow: sympathetic 
control of blood flow during recovery from 
heart failure. JAppIPhysiol 2006;101:3-4.
19. Ferguson DW, Berg WJ, Sanders JS. Clinical 
and hemodynamic correlates of 
sympathetic nerve activity in normal 
humans and patients with heart failure: 
evidence from direct microneurographic 
recordings. JAm  Coll Cardiol 1990,16:1125- 
1134.
20. Mancia G. Sympathetic activation in 
congestive heart failure. Eur Heart J  1990,11 
Suppl A:3-11.
21. Ferguson DW, Abboud FM, Mark AL. 
Selective impairment of baroreflex- 
mediated vasoconstrictor responses in 
patients with ventricular dysfunction. 
Circulation 1984;69:451-460.
22. Niebauer M, Zucker IH. Static and dynamic 
responses of carotid sinus baroreceptors in 
dogs with chronic volume overload. J  
Physiol 1985;369:295-310.
23. Dibner-Dunlap ME, Thames MD. Baroreflex 
control of renal sympathetic nerve activity 
is preserved in heart failure despite 
reduced arterial baroreceptor sensitivity. 
CircRes 1989;65:1526-1535.
24. Wang W, Chen JS, Zucker IH. Carotid sinus 
baroreceptor sensitivity in experimental 
heart failure. Circulation 1990;81:1959- 
1966.
25. Brandie M, Patel KP, Wang W, Zucker IH. 
Hemodynamic and norepinephrine 
responses to pacing-induced heart failure 
in conscious sinoaortic-denervated dogs. J
Appl Physiol 1996;81:1855-1862.
26. Wang W, Ma R. Cardiac sympathetic 
afferent reflexes in heart failure. Heart Fail 
Rev 2000;5:57-71.
27. Ma R, Zucker IH, Wang W. Reduced NO 
enhances the central gain of cardiac 
sympathetic afferent reflex in dogs with 
heart failure. Am J  Physiol 1999;276:H19- 
H26.
28. Ma R, Zucker IH, Wang W. Central gain of 
the cardiac sympathetic afferent reflex in 
dogs with heart faWure. Am J  Physiol 
1997;273:H2664-H2671.
29. DiBona GF, Jones SY, Brooks VL. ANG II 
receptor blockade and arterial baroreflex 
regulation of renal nerve activity in cardiac 
faWure. Am J  Physiol 1995;269:R1189-R1196.
30. Liu JL, Murakami H, Zucker IH. Effects of 
NO on baroreflex control of heart rate and 
renal nerve activity in conscious rabbits. 
Am J  Physiol 1996;270:R1361-R1370.
31. Garthwaite J, Boulton CL. Nitric oxide 
signaling in the central nervous system. 
Annu Rev Physiol 1995;57:683-706.
32. Hjelmqvist H, Ullman J, Hamberger B, 
Rundgren M. Cardiovascular and renal 
effects of intracerebroventricular 
angiotensin II in conscious sheep. Acta 
Physiol Scand 1992;145:25-32.
33. Sakuma I, Togashi H, Yoshioka M, Saito H, 
Yanagida M, Tamura M, Kobayashi T, 
Yasuda H, Gross SS, Levi R. NG-methyl-L- 
arginine, an inhibitor of L-arginine-derived 
nitric oxide synthesis, stimulates renal 
sympathetic nerve activity in vivo. A role 
for nitric oxide in the central regulation of 
sympathetic tone? CircRes 1992;70:607- 
611.
34. Togashi H, Sakuma I, Yoshioka M, 
Kobayashi T, Yasuda H, Kitabatake A, Saito
39
C H A P T E R  2
H, Gross SS, Levi R. A central nervous 
system action of nitric oxide in blood 
pressure regulation. J  Pharmacol Exp Ther 
1992;262:343-347.
35. Minisi AJ, Thames MD. Activation of 
cardiac sympathetic afferents during 
coronary occlusion. Evidence for reflex 
activation of sympathetic nervous system 
during transmural myocardial ischemia in 
the dog. Circulation 1991;84:357-367.
36. Dibner-Dunlap ME, Kinugawa T, Thames 
MD. Activation of cardiac sympathetic 
afferents: effects of exogenous adenosine 
and adenosine analogues. Am J  Physiol 
1993;265:H395-H400.
37. Minisi AJ. Ventricular reflex interactions 
during transmural myocardial ischemia. 
Auton Neurosci 2005;119:9-15.
38. Staszewska-Woolley J, Woolley G, Regoli D. 
Specific receptors for bradykinin-induced 
cardiac sympathetic chemoreflex in the 
dog. EurJ Pharmacol 1988;156:309-314.
39. Uchida Y, Murao S. Potassium-induced 
excitation of afferent cardiac sympathetic 
nerve fibers. Am J  Physiol 1974;226:603- 
607.
40. Uchida Y, Murao S. Acid-induced excitation 
of afferent cardiac sympathetic nerve 
fibers. Am J  Physiol 1975;228:27-33.
41. Thames MD, Kinugawa T, bner-Dunlap ME. 
Reflex sympathoexcitation by cardiac 
sympathetic afferents during myocardial 
ischemia. Role of adenosine. Circulation 
1993;87:1698-1704.
42. Li DP, Pan HL. Responses of neurons in 
rostral ventrolateral medulla to activation 
of cardiac receptors in rats. Am J  Physiol 
2000;279:H2549-H2557.
43. Zahner MR, Pan HL. Role of Paraventricular 
Nucleus in the Cardiogenic Sympathetic
Reflex in Rats.Am J Physiol 2005;288:R420-
6 .
44. Lundin S, Ricksten SE,Thoren P. Interaction 
between mental stress and baroreceptor 
control of heart rate and sympathetic 
activity in conscious spontaneously 
hypertensive (SHR) and normotensive 
(WKY) rats. J  HypertensSupp11983;1:68-70.
45. Ruggeri P, Cogo CE, Picchio V, Ermirio R, 
Mary DA. Reflex cardiovascular responses 
to somatic stimulation in spontaneously 
hypertensive rats. JHypertens 2000;18:595- 
600.
46. Pontieri V, Venezuela MK, Scavone C, 
Michelini LC. Role of endogenous nitric 
oxide in the nucleus tratus solitarii on 
baroreflex control of heart rate in 
spontaneously hypertensive rats. J  
Hypertens 1998;16:1993-1999.
47. Shcherbin Yl, Tsyrlin VA. Comparison of the 
somatosympathetic reflex in 
normotensive and spontaneously 
hypertensive rats. Neurosci Behav Physiol 
2004;34:563-567.
48. Ermirio R, Ruggeri P, Molinari C, Weaver LC. 
Somatic and visceral inputs to neurons of 
the rostral ventrolateral medulla. Am J  
Physiol 1993;265:R35-R40.
49. Stornetta RL, Morrison SF, Ruggiero DA, 
Reis DJ. Neurons of rostral ventrolateral 
medulla mediate somatic pressor reflex. 
Am J  Physiol 1989;256:R448-R462.
50. Dampney RA. Functional organization of 
central pathways regulating the 
cardiovascular system. Physiol Rev 
1994;74:323-364.
51. Dampney RA. The subretrofacial 
vasomotor nucleus: anatomical, chemical 
and pharmacological properties and role 
in cardiovascular regulation. Prog
40
A L T E R N A T IV E  M O D A L IT IE S  F O R  T R E A T IN G  H IG H  S Y M P A T H E T IC  T O N E
Neurobiol 1994;42:197-227.
52. Ito S, Sved AF. Blockade of angiotensin 
receptors in rat rostral ventrolateral 
medulla removes excitatory vasomotor 
tone. Am J  Physiol 1996;270:R1317-R1323.
53. Hirooka Y, Potts PD, Dampney RA. Role of 
angiotensin II receptor subtypes in 
mediating the sympathoexcitatory effects 
of exogenous and endogenous 
angiotensin peptides in the rostral 
ventrolateral medulla of the rabbit. Brain 
Res 1997;772:107-114.
54. Andreatta SH, Averill DB, Santos RA, 
Ferrario CM. The ventrolateral medulla. A 
new site of action of the renin-angiotensin 
system. Hypertension 1988;11:1163-1166.
55. Mendelsohn FA, Allen AM, Clevers J, 
Denton DA, Tarjan E, McKinley MJ. 
Localization of angiotensin II receptor 
binding in rabbit brain by in vitro 
autoradiography. J  Comp Neurol 
1988;270:372-384.
56. Gehlert DR, Gackenheimer SL, Schober DA. 
Autoradiographic localization of subtypes 
of angiotensin II antagonist binding in the 
rat brain. Neuroscience 1991;44:501-514.
57. Averill DB, Tsuchihashi T, Khosla MC, 
Ferrario CM. Losartan, nonpeptide 
angiotensin ll-type 1 (ATI) receptor 
antagonist, attenuates pressor and 
sympathoexcitatory responses evoked by 
angiotensin II and L-glutamate in rostral 
ventrolateral medulla. Brain Res 
1994;665:245-252.
58. Fontes MA, Martins Pinge MC, Naves V, 
Campagnole-Santos MJ, Lopes OU, Khosla 
MC, Santos RA. Cardiovascular effects 
produced by microinjection of 
angiotensins and angiotensin antagonists 
into the ventrolateral medulla of freely
moving rats .Brain Res 1997;750:305-310.
59. Santos RA, Campagnole-Santos MJ, 
Baracho NC, Fontes MA, Silva LC, Neves LA, 
Oliveira DR, Caligiorne SM, Rodrigues AR, 
Gropen JC , . Characterization of a new 
angiotensin antagonist selective for 
angiotensin-(1-7): evidence that the 
actions of angiotensin-(1-7) are mediated 
by specific angiotensin receptors. Brain Res 
Bull 1994;35:293-298.
60. Fontes MA, Baltatu O, Caligiorne SM, 
Campagnole-Santos MJ, Ganten D, Bader 
M, Santos RA. Angiotensin peptides acting 
at rostral ventrolateral medulla contribute 
to hypertension of TGR(mREN2)27 rats. 
Physiol Genomics 2000;2:137-142.
61. Carvalho TH, Bergamaschi CT, Lopes OU, 
Campos RR. Role of endogenous 
angiotensin II on glutamatergic actions in 
the rostral ventrolateral medulla in 
Goldblatt hypertensive rats. Hypertension 
2003;42:707-712.
62. Hojna S, Kadlecova M, Dobesova Z, 
Valouskova V, Zicha J, Kunes J. The 
participation of brain NO synthase in 
blood pressure control of adult 
spontaneously hypertensive rats. Mol Cell 
Biochem 2007;297:21-29.
63. Kagiyama S, Tsuchihashi T, Abe I, Fujishima 
M. Enhanced depressor response to nitric 
oxide in the rostral ventrolateral medulla 
of spontaneously hypertensive rats. 
Hypertension 1998;31:1030-1034.
64. Krukoff TL. Central actions of nitric oxide in 
regulation of autonomic functions. Brain 
Res Brain Res Rev 1999;30:52-65.
65. Patel KP, Li YF, Hirooka Y. Role of nitric 
oxide in central sympathetic outflow. 
Experimental Biology and Medicine 
2001;226:814-824.
41
C H A P T E R  2
66. Alaghband-Zadeh J, Das I, Hanson MR, 
MacGregor CA, de Wardener HE, Laycock 
JF. Hypothalamic and plasma total nitrate/ 
nitrite concentrations in spontaneously 
hypertensive rats. Exp Physiol 1996,81:881- 
883.
67. Qadri F, Arens T, Schwarz EC, Hauser W, 
Dendorfer A, Dominiak P. Brain nitric oxide 
synthase activity in spontaneously 
hypertensive rats during the development 
of hypertension. J Hypertens 2003;21:1687- 
1694.
68. Dorward PK, Rudd CD. Influence of brain 
renin-angiotensin system on renal 
sympathetic and cardiac baroreflexes in 
conscious rabbits. Am J  Physiol 
1991;260:H770-H778.
69. Reid I A. Interactions between ANGII, 
sympathetic nervous system, and 
baroreceptor reflexes in regulation of 
blood pressure. Am J  Physiol 
1992;262:E763-E778.
70. Saxena PR. Interaction between the renin- 
angiotensin-aldosterone and sympathetic 
nervous systems. J  CardiovascPharmacol
1992,19 Suppl 6:S80-S88.
71. Li DP, Pan HL. Angiotensin II attenuates 
synaptic GABA release and excites 
paraventricular-rostral ventrolateral 
medulla output neurons . J  Pharmacol Exp 
Ther 2005;313:1035-1045.
72. Cato MJ,Toney GM. Angiotensin II excites 
paraventricular nucleus neurons that 
innervate the rostral ventrolateral medulla: 
an in vitro patch-clamp study in brain 
slices. J  Neurophysiol 2005;93:403-413.
73. Wang HJ, Zhang F, Zhang Y, Gao XY, Wang 
W, Zhu GQ. ATI receptor in paraventricular 
nucleus mediates the enhanced cardiac 
sympathetic afferent reflex in rats with
chronic heart failure. Auton Neurosci 
2005;121:56-63.
74. Wang WZ, Gao L, Pan YX, Zucker IH, Wang 
W. ATI receptors in the nucleus tractus 
solitarii mediate the interaction between 
the baroreflex and the cardiac 
sympathetic afferent reflex in 
anesthetized rats. Am J  Physiol 
2007;292:R1137-R1145.
75. Ganten D, SpeckG. The brain renin- 
angiotensin system: a model for the 
synthesis of peptides in the brain. Biochem 
Pharmacol 1978;27:2379-2389.
76. Gao L, Wang W, Li YL, Schultz HD, Liu D, 
Cornish KG, Zucker IH. Sympathoexcitation 
by central ANG II: roles for ATI receptor 
upregulation and NAD(P)H oxidase in 
RVLM. Am J  Physiol 2005;288:H2271 -H2279.
77. Gao L, Wang W, Li YL, Schultz HD, Liu D, 
Cornish KG, Zucker IH. Superoxide 
mediates sympathoexcitation in heart 
failure: roles of angiotensin II and NAD(P)H 
oxidase. CircRes 2004;95:937-944.
78. Gao L, Wang W, Li YL, Schultz HD, Liu D, 
Cornish KG, Zucker IH. Simvastatin therapy 
normalizes sympathetic neural control in 
experimental heart failure: roles of 
angiotensin II type 1 receptors and NAD(P) 
H oxidase. Circulation 2005;112:1763-1770.
79. Chan SH, Hsu KS, Huang CC, Wang LL, Ou 
CC, Chan JY. NADPH oxidase-derived 
superoxide anion mediates angiotensin 
ll-induced pressor effect via activation of 
p38 mitogen-activated protein kinase in 
the rostral ventrolateral medulla. CircRes 
2005;97:772-780.
80. Erdos B, Broxson CS, King MA, Scarpace PJ, 
Turner N. Acute pressor effect of central 
angiotensin II is mediated by NAD(P) 
H-oxidase-dependent production of
42
A L T E R N A T IV E  M O D A L IT IE S  F O R  T R E A T IN G  H IG H  S Y M P A T H E T IC  T O N E
superoxide in the hypothalamic 
cardiovascular regulatory nuclei. J  
Hypertens 2006;24:109-116.
81. Lassegue B, Griendling KK. Reactive 
oxygen species in hypertension; An 
update./Am J  Hypertens 2004;17:852-860.
82. Zimmerman MC, Sharma RV, Davisson RL. 
Superoxide mediates angiotensin 
ll-induced influx of extracellular calcium in 
neural cells. Hypertension 2005;45:717-723.
83. Zanzinger J, Czachurski J, Seller H. 
Neuronal nitric oxide reduces sympathetic 
excitability by modulation of central 
glutamate effects in pigs. CircRes 
1997;80:565-571.
84. Zanzinger J. Role of nitric oxide in the 
neural control of cardiovascular function. 
Cardiovasc Res 1999;43:639-649.
85. Zucker IH, Liu JL. Angiotensin ll-nitric 
oxide interactions in the control of 
sympathetic outflow in heart failure. Heart 
Fail Rev 2000;5:27-43.
86. Bains JS, Ferguson AV. Angiotensin II 
neurotransmitter actions in 
paraventricular nucleus are potentiated by 
a nitric oxide synthase inhibitor. RegulPept 
1994;50:53-59.
87. Liu JL, Murakami H, Zucker IH. Angiotensin 
ll-nitric oxide interaction on sympathetic 
outflow in conscious rabbits. CircRes 
1998;82:496-502.
88. Ziegler D, Haxhiu MA, Kaan EC, Papp JG, 
Ernsberger P. Pharmacology of 
moxonidine, an 11-imidazoline receptor 
agonist. J  Cardiovasc Pharmacol 1996;27 
Suppl 3:S26-S37.
89. Dickstein K, Manhenke C, Aarsland T, Kopp 
U, McNay J, Wiltse C. Acute hemodynamic 
and neurohumoral effects of moxonidine 
in congestive heart failure secondary to
ischemic or idiopathic dilated 
ca rd iomyopathy. Am J  Cardiol 
1999;83:1638-1644.
90. Swedberg K, Bristow MR, Cohn JN, Dargie
H, Straub M, Wiltse C, Wright TJ. Effects of 
sustained-release moxonidine, an 
imidazoline agonist, on plasma 
norepinephrine in patients with chronic 
heart failure. Circulation 2002;105:1797- 
1803.
91. Azevedo ER, Newton GE, Parker JD. Cardiac 
and systemic sympathetic activity in 
response to clonidinein human heart 
failure. JAm  Coll Cardiol 1999;33:186-191.
92. Coats AJ. Heart Failure 99 — the MOXCON 
story. In tJ Cardiol 1999;71:109-111.
93. Zhu GQ, Gao L, Patel KP, Zucker IH, Wang 
W. ANG II in the paraventricular nucleus 
potentiates the cardiac sympathetic 
afferent reflex in rats with heart failure. J  
Appl Physiol 2004;97:1746-1754.
94. Zhang Y, Yu Y, Zhang F, Zhong MK, Shi Z, 
Gao XY, Wang W, Zhu GQ. NAD(P)H oxidase 
in paraventricular nucleus contributes to 
the effect of angiotensin II on cardiac 
sympathetic afferent reflex. Brain Res 
2006;1082:132-141.
95. Pliquett RU, Cornish KG, Peuler JD, Zucker
IH. Simvastatin normalizes autonomic 
neural control in experimental heart 
failure. Circulation 2003;107:2493-2498.
96. Pliquett RU, Cornish KG, Zucker IH. Statin 
therapy restores sympathovagal balance 
in experimental heart failure. J  Appl Physiol 
2003;95:700-704.
97. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, 
Takeshita A. Atorvastatin causes depressor 
and sympatho-inhibitory effects with 
upregulation of nitric oxide synthases in 
stroke-prone spontaneously hypertensive
43
C H A P T E R  2
rats. JHypertens 2003;21:379-386.
98. Jamerson KA, Julius S, Gudbrandsson T, 
Andersson O, Brant DO. Reflex 
sympathetic activation induces acute 
insulin resistance in the human forearm. 
Hypertension 1993;21:618-623.
99. Jamerson KA, Smith SD, Amerena JV, Grant 
E, Julius S. Vasoconstriction with 
norepinephrine causes less forearm insulin 
resistance than a reflex sympathetic 
vasoconstriction. Hypertension 
1994;23:1006-1011.
44
ALTERNATIVE MODALITIES FOR TREATING HIGH SYMPATHETIC TONE
45

Improving myocardial perfusion 
by percutaneous coronary intervention 
reduces central sympathetic activity 
in stable angina
Marc E Gomes 
Wim R Aengevaeren 
Jacques W  Lenders 
Freek W  Verheugt 
Paul Smits 
Cees J Tack
Clinical Cardiology 2010;33:E16-21
C H A PT ER  3
Abstract
Background By stimulating sympathetic afferents, (repetitive) myocardial ischemia 
induces a state of increased sympathetic tone. Removing the ischemic trigger by 
revascularization using percutaneous coronary intervention (PCI) might thus 
reduce central sympathetic activity in symptomatic stable angina patients. 
Methods A total of 20 patients with stable angina > New York Heart Association 
(NYHA) class II with persistent symptoms despite maximal pharmacological 
therapy and a clinical indication for PCI, were included in our study. Sympathetic 
nervous system activity was measured before and one month after PCI by a 
combination of techniques: direct muscle sympathetic nerve activity (MSNA), 
neurochemical (plasma catecholamine levels) and heart rate variability (HRV). 
Results All patients completed the study. After PCI there was a significant reduction 
in MSNA (pre PCI 72±4 to post PCI 53±4 burst/100 beats, P<0.05) and LF/HF ratio 
(3.7±0.6 vs. 2.4±0.4, P<0.05) consistent with a decline in sympathetic activity. 
Plasma norepinephrine levels were reduced after PCI, but this difference did not 
reach statistical significance (1.84±0.17 vs. 1.73±0.13 nmol/L, p=NS).
Conclusion Coronary revascularization by PCI reduces sympathetic activity in 
patients with established myocardial ischemia.
IMPROVING MYOCARDIAL PERFUSION REDUCES SYMPATHETIC ACTIVITY
Introduction
Sympathetic activation has been closely correlated with myocardial ischemia.12 
The most likely explanation is stimulation of sympathetic afferents in the myocardial 
wall due to ischemia-induced release of a number of afferent-stimulating substances.3,4 
If the ischemic stimulus is strong enough, a reflex increase in central sympathetic 
output occurs, despite current pharmacological interventions.2'5 In myocardial 
infarction as well as in unstable angina this state of sympathetic hyperactivity 
appears to be protracted for several months after the occurrence of the ischemic 
event, suggesting a persistent change in central autonomic balance.1 Patients 
with documented coronary artery disease (CAD) and exercise-provoked angina 
(stable angina) show a similar state of sympathetic hyperactivity, although the 
persistence of this effect in time is less well established.6 As myocardial ischemia 
seems to be the trigger of this state of sympathetic hyperactivity, removing this 
trigger would be expected to reduce sympathetic overactivity. Thus, improving 
myocardial perfusion by percutaneous coronary intervention (PCI) might have 
beneficial effects on central sympathetic activity in ischemia-triggered 
sympathetic hyperactivity. We hypothesized that a revascularization procedure in 
patients with stable angina on maximal pharmacological treatment, should 
decrease central sympathetic activity. We tested this hypothesis in a group of 
patients with stable angina who underwent PCI.
Methods
Participants
The patients that participated in this study met the following criteria. Patients had 
stable angina, defined as: chest discomfort that occurs predictable and reproducible 
at a certain level of exertion which was relieved by rest or nitroglycerin. Signs of 
angina remained despite optimal pharmacological treatment (regulation of blood 
pressure, heart rate and other risk factors like lipid levels, were already optimal). 
Planned for PCI. Age between 24 and 75 years. Sinus rhytm. Exclusion criteria 
were: diabetes, (chronic) heart failure or a left ventricle ejection fraction of <40%, 
known (chronic) disease of the autonomic nervous system, treatment with tricyclic 
antidepressants or a, -or a 2-adrenoreceptor inhibitors. Ischemia was confirmed 
by a positive ischemia detection test prior to PCI (myocardial scintigraphy or 
exercise test) in eighteen patients, two patients had a classical history of angina.
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All patients underwent a ventricular angiogram to assess ventricular function, or, 
if ventricular angiography was not possible, echocardiography. For adequate 
heart rate variability analysis, patients needed to have sinus rhythm. Succesful PCI 
was defined as: no significant coronary artery pathology had to persist (all 
stenoses of > 60% should be reduced by > 20% and residual stenosis should be < 
50% for each vessel). The institutional review committee approved the study and 
informed consent was obtained from all patients before participation in the study. 
The study was performed in accordance with the Declaration of Helsinki.
Study protocol
Sympathetic activity was assessed using three different approaches: measurement 
of muscle sympathetic nerve activity (MSNA) by microneurography, heart rate 
variability (HRV) and arterial plasma catecholamine concentrations. Measurements 
were performed before and 1 month after PCI. All experiments started at 8.00 AM 
after an overnight (10-hour) fast with the patient in supine position in a quiet 
temperature-controlled room (23 - 24 °C). All subjects had to abstain from caffeine, 
tea, alcohol, chocolates and smoking for at least 12 hours. All experiments were 
carried out after voiding to prevent reflex sympathoexcitation. After complete 
instrumentation, 30 minutes of rest were included to attain stable baseline before 
data collection. Hereafter HRV measurement was performed for 10 minutes. Finally, 
arterial blood samples were drawn and microneurography was performed.
Sympathetic nerve traffic (microneurography)
Muscle sympathetic nerve activity (MSNA) was measured as previous described.78 
In short, the peroneal nerve was localized at the site of the fibula head using 
transdermal electrical impulses (40-60 mV, 0.2 ms, 1 Hz) through a small electrode. 
After localization, a sterile Tungsten microelectrode was inserted manually 
through the skin in the underlying peroneal nerve posterior to the fibular head. 
A second reference electrode was placed subcutaneously approximately 3 cm 
from the recording electrode. An electrode position within a muscle nerve 
fascicle was identified by evoking of muscle twitches by electrical stimuli (1-5 mV, 
0.2 ms, 1 Hz) and provoking of afferent, mechanoreceptive activity by the 
stretching of the appropriate muscle. MSNA signal was confirmed using the 
Vasalva maneuver. From the original signal, multi-unit MSNA (m-MSNA) bursts 
were obtained as the average voltage after filtering (bandwidth of 700 to 2,000 
Hz) and integrating (time constant 0.1 s). Bursts were identified using an 
automated computer program with prefixed settings to exclude observer bias.
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A preset triangle with a base of 0.8 sec., correlated to the known delay between 
R-peak in the ECG and the postganglionic burst, was used to scan the MSNA 
signal and identify sympathetic bursts. Hereafter the maximal and average 
amplitude were calculated and potential bursts were correlated to a percentage 
of the maximal amplitude. The computer derived measures hereafter were 
visually confirmed by an investigator so that noise artifacts were not being 
counted and if so, noise artifact were removed. Only bursts with a sufficient 
discriminating signal-to-noise ratio (>3) were analyzed.89 Microneurography 
recordings were performed under basal conditions (patient in supine position) 
and quantified as bursts per 100 beats. This quantification has shown to have 
high intra-individual reproducibility.10 All measurements were performed between 
9:30-11:30, to prevent confounding by circadian variation.1112
Heart rate variability
Using a two-channel Holter (Medilog 4500-3, Oxford Intruments Ltd., Engeland) a
10 minute ECG recording was performed for each patient at each visit. Ectopic 
beats and arrhythmias were excluded using the Oxford scanning software version
6.0. R-R interval selection was performed using a beat-to-beat filter set at N-N-N, 
whereby the interval being considered must start and end in a "normal" beat and 
so must the preceding R-R interval. Rejected intervals were interpolated over the 
invalid area. Before converting the interval tachogram to frequency domain, the 
mean R-R interval was calculated from the tachogram and subtracted from each 
R-R interval to reduce spectral leakage. A fast Fourier transformation (FFT) was 
performed from the interpolated tachogram resampled at 292 msec, using the 
Oxford spectral analysis software package. Results from the 10 minute interval 
were averaged to form a composite spectrum. Total power between 0.003 and 
0.40 Hz was calculated. This represents the total variance for a 10 minute interval. 
Power was quantified as total power, high frequency (HF) 0.15-0.40 Hz and low 
frequency (LF) 0.04-0.15 Hz power.
Arterial plasma catecholamine levels
Arterial blood samples were drawn from an arterial catheter, after 40 minutes of 
rest. Plasma catecholamines concentrations were measured using high 
performance liquid pressure chromatography (HPLC) analysis with fluorometric 
detection.13 Within- and between-run coefficients of variance (cv) for plasme 
epinephrine were 4,1% and 8.1% at a level of 0.166 nmol/l and for norepinephrine 
4.1% and 6.1% at a level of 1.76 nmol/l respectively. Analytical detection limits
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were 0.003 and 0.002 nmol/l for epinephrine and norepinephrine respectively. 
Catecholamines were collected in ice-chilled 10 ml Vacutainer tubes (Becton- 
Dickenson Co., Franklin Lakes, NJ) containing 0.2 ml of a solution of EGTA (0.25 
mol/L) and gluthatione (0.20 mol/L).
Statistical analysis
Data are expressed as mean±SEM unless indicated otherwise. Differences between 
visits were assessed using parametric (student f-testfor paired observations) or 
nonparametric (paired Wilcoxon) tests as appropriate. A two-tailed p-value of 
<0.05 was considered to be statistically significant. It was calculated that at least 9 
patients were needed (with each patient as its own control) in order to detect a 
15% reduction in MSNA based on resolution of ischemia after PCI, with a power of 
80% at a significance level of 0.05. Per visit success rate for retrieval of adequate 
MSNA signal was estimated at 70%, as reported in the literature.14 Patient inclusion 
was continued until sufficient paired observations were collected. Power spectral 
data and plasma catecholamines are presented for all patients and each was 
sufficiently powered.
Results
A total of 20 patients were included in the study to retrieve paired MSNA data in
11 patients, corresponding with a per visit success rate of 75%. Patients with and 
w ithout successful MSNA did not differ in BMI, age, gender and medication use. 
For this reason results on power spectral analysis and plasma catecholamines are 
presented for all patients. Patient characteristics are shown in table 1. All patients 
remained on the same medication at both visits. All but one patient used 
beta-blockers (metoprolol or atenolol n=15, mean dosage 80 mg/day, bisoprolol 
n=4, mean dosage 3.75 mg/day). Remaining medication: aspirin n=20, statin n=16, 
ACEI n=4, calcium channel blockers n=5. All patients received stent implantation. 
In those patients where clopidogrel was added for stent implantation, 
measurements were performed after discontinuation of clopidogrel (one month 
after PCI and stent implantation, according to clinical protocols). In 5 patients 
however a drug-eluting stent was used and measurements were performed 
during clopidogrel. Results did not differ between the patients with and without 
a drug-eluting stent or on different medication. Using the predefined criteria, PCI 
was successful in all patients. At the second visit all patients were free of angina.
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Table 1 Baseline and procedural characteristics
Variable Statistic
Age (years) 59±8
Sex (male/female) 13/7
BMI (kg/m2) 27.9±3.8
Hypertension, n (%) 5 (25%)
Prior Ml, n (%) 1 (5%)
Prior PCI, n (%) 6 (30%)
Prior CABG, n (%) 1 (5%)
NYHA class 2.9±0.6
Fasting blood glucose (mmol/L) 5.9±0.6
Positive ischemia detection test, n (%) 18(90%)
CAD angiographic grade
■ One vessel disease (n) 17
■ Two vessel disease (n) 3
Vessel with significant lesions
■ LAD (n) 14
■ RCA (n) 6
■ RCX(n) 3
Number of stents implanted 1.4±0.6
After PCI, MSNA significantly decreased from 72±4 pre-PCI to 53±4 bursts/100 
beats post-PCI, p<0.05 (figure 1). Similar results were found when MSNA was 
expressed as bursts/min (42±2 bursts/min pre-PCI vs. 30±3 post-PCI, p<0.05). After 
PCI, the LF/HF ratio was significantly lower 2.4±0.4, compared to pre-PCI, 3.7±0.6 
(p<0.05), consistent with a reduction in sympathetic dominance (figure 2). For 
those patients with successful microneurography values for the LF/HF ratio were 
4.5±1.0 pre-PCI and 2.5±0.8 post-PCI. Total spectral power, LF and HF values 
before and after PCI did not differ significantly. Arterial plasma norepinephrine 
concentrations tended to be lower after PCI, but this was not significant (pre-PCI 
1.84±0.17 vs. 1.73±0.13 nmol/L post-PCI). For those patients with successful micro­
neurography, values were 1.94±0.36 nmol/L pre-PCI and 1.59±0.16 nmol/L 
post-PCI. Plasma epinephrine levels were significantly lower at the second visit 
(0.33±0.03 vs. 0.22±0.02 nmol/L, p<0.05).
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MSN A
PCI
Figure 1
Mean muscle sympathetic nerve activity before and one month after percutaneous 
coronary intervention. *P<0.05. MSNA = muscle sympathetic nerve activity;
PCI = percutaneous coronary intervention
LF/HF
before after
PCI
Figure 2
Mean low-frequency/high-frequency ratio before and one month after percutaneous 
coronary intervention. *P<0.05. LF/HF = mean low-frequency/high-frequency ratio;
PCI = percutaneous coronary intervention
Systolic blood pressure was significantly reduced 1 month after PCI, 146±7 vs. 
136±6 mmHg, p<0.05 (figure 3), while diastolic blood pressure, MAP and heart 
rate remained unchanged.
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Figure 3
Changes in systolic, diastolic and mean arterial pressure before and one month after 
percutaneous coronary intervention. *P<0.05. MAP = mean arterial pressure;
PCI = percutaneous coronary intervention
Discussion
This study provides evidence that revascularization by PCI is able to reduce central 
sympathetic outflow in patients with stable angina. This conclusion is based on 
the finding that muscle sympathetic nerve activity (MSNA), representing central 
sympathetic outflow, significantly decreased after PCI. In accordance, 
sympathovagal balance shifted towards reduced sympathetic predominance 
(reduction in LF/HF ratio). Plasma norepinephrine levels appeared to be lower 
after PCI, albeit nonsignificant. Finally, systolic blood pressure fell significantly in 
the absence of any change in cardiovascular medication.
Myocardial ischemia is closely related to an increase in central sympathetic 
activity.215 Sympathetic afferents residing in the myocardial wall are triggered by 
a number of substances released during ischemia.3'5 When afferent stimulation is 
sufficient, a reflex mechanism ensues, increasing central sympathetic outflow, 
with the degree of ischemia being correlated with the degree of central 
sympathoexcitation.2 This state of increased sympathetic tone seems to persist 
beyond the ischemic event.1 To our knowledge, there are no studies that have 
shown that reversal of ischemia by PCI reduces central sympathetic tone. In our
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patient group, sympathetic nervous system activity was indeed clearly increased. 
Baseline MSNA levels were similar to those of patients with acute onset unstable 
angina (72±4 bursts/100 beats vs. 78±4 bursts/100 beats for unstable angina) and 
clearly increased compared to patients with asymptomatic stable coronary artery 
disease (CAD, 54±4 bursts/100 beats).2 This strongly suggests that ischemia is an 
important determinant of the sustained sympathetic stimulation. Improving 
myocardial perfusion by successful PCI should therefore improve myocardial 
oxygenation, reduce afferent stimulation, and subsequently decrease central 
sympathetic outflow. The present study does show a significant reduction in 
central sympathetic nerve traffic after PCI. It should however be noted that 
"complete" revascularization was based on angiographic findings (no remaining 
stenosis >50%) and thus any persistent microvascular ischemia cannot be 
excluded. The elimination of anginal symptoms in our patients, however, supports 
improved myocardial oxygenation. The reduction in MSNA is in accordance with 
the observed change in sympathovagal balance as assessed by heart rate spectral 
analysis.
As MSNA is the best measure for central sympathetic activity, our study was 
specifically designed to have sufficient power to detect an effect of PCI on MSNA. 
Based on power calculations, at least 9 paired successful microneurography 
measurements were needed to assess reliably, potential changes in MSNA after 
PCI. As such, 20 patients were included, resulting in sufficiently high-quality MSNA 
data in 11 patients. This corresponds to a 75% success rate per visit, which is still in 
the upper range of the values proposed in literature.14 The relatively high failure 
rate in retrieving adequate MSNA data for analysis is a well-known limitation of 
this technique. Although nerve activity recording failure is at least in part operator 
related, it occurred randomly in our study. Comparing baseline characteristics 
between those patients with and without successful microneurography showed 
no significant between group difference and therefore HRV, catecholamine and 
hemodynamic analysis were performed for the group as a whole. For all these 
parameters, statistical power was sufficient.
As stated, central sympathetic activity was clearly increased, despite (3-blocker 
treatment in all patients. Increased sympathetic activity has proven to be 
detrimental in CAD.16 Current therapy in ischemic heart disease has mainly 
focussed on shielding the (3-adrenergic receptor from high sympathetic tone. 
Although effective, this solves only part of the problem. Alfa-adrenergic receptor
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mediated effects and consequences of increased norepinephrine concentrations 
have proven to be vicious effects of increased sympathetic tone.1517 It was 
demonstrated that carvedilol, a combined a-and (3-adrenergic receptor blocker 
had superior hemodynamic and metabolic effects compared to single (31-receptor 
blockade in conscious dogs with dilated cardiomyopathy and clear sympathoex- 
citation.18 These results were in accordance with those obtained in the COMET 
trial, which compared carvedilol and metoprolol.19 These findings suggest that 
strategies aimed at reducing sympathetic tone at a central level might be 
beneficial.
Several factors might have confounded our results. First, MSNA prior to PCI 
could have been increased by anxiety based on unfamiliarity with the study 
protocol and the pending PCI. Reduction in MSNA after PCI could then be 
explained by reduced anxiety. Whether this also explains the drop in systolic 
blood pressure remains uncertain. Heart rate did not differ between the two 
sessions. At each visit, patients gene rally reported being relaxed and measurements 
were taken after at least 30 minutes of rest. However this possibility, although 
unlikely, cannot be excluded. Secondly, it is possible that angiographically 
restored myocardial perfusion improved left ventricular function and cardiac 
output. A reduction in central sympathetic activity could then solely be based on 
the improved hemodynamic state rather than on a reduction in myocardial 
ischemia. It seems highly improbable, however, that myocardial function improves 
without improvement of myocardial oxygenation. Differentiating reduced 
sympathetic afferent stimulation from improved cardiac output as the mechanism 
for reduced central sympathetic activity is difficult. Catecholamine levels are 
variable. The lack of a significant reduction in plasma norepinephrine levels might 
be explained by the fact that plasma NE levels are determined by release, 
metabolism and re-uptake of neuronal released NE, possible obscuring increased 
release from the presynaptic neuron.20
In summary, the present study shows that cardiac revascularization by PCI 
reduces central sympathetic activity in patients with clinically established 
myocardial ischemia, which may add beneficial effects to the increased myocardial 
perfusion.
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Abstract
Background Increased (central) sympathetic activity is a key feature of heart 
failure and associated with a worse prognosis. Animal studies suggest that statin 
therapy can reduce central sympathetic outflow. This study assessed statin effects 
on (central) sympathetic activity in human patients with chronic heart failure 
(CHF).
Methods Sympathetic activity was measured in eight patients with CHF during, 
eight weeks after discontinuation and four weeks after restart of statin therapy 
by: microneurography for direct muscle sympathetic nerve recording (MSNA) and 
measurement of arterial plasma norepinephrine concentrations.
Results During discontinuation of statin therapy, MSNA was significantly increased 
(73±4 vs. 56±5 and 52±6 bursts/100 beats, p=0.01). Burst frequency was significantly 
higher after statin discontinuation (42±3 bursts/min without statin vs. 32±3 and 
28±3 bursts/min during statin therapy, p=0.004). Mean normalized burst amplitude 
and total normalized MSNA were significantly higher after statin discontinuation 
(mean normalized burst amplitude 0.36±0.04 without statin vs. 0.29±0.04 and 
0.22±0.04 during statin, p<0.05; total normalized MSNA 15.70±2.78 without statin, 
vs. 9.28±1.41 and 6.56±1.83 during statin, p=0.009). Arterial plasma norepinephrine 
levels and blood pressure were unaffected.
Conclusion Statin therapy inhibits central sympathetic outflow in CHF patients, as 
measured by MSNA.
SYMPATHOINHIBITORY EFFECT OF STATINS IN CHRONIC HEART FAILURE
Introduction
A number of cardiovascular conditions like chronic heart failure (CHF) is 
characterized by an increased sympathetic tone, reflecting the functional severity 
of CHF.1 On the long term, this sympathetic overactivity has been shown to be 
detrimental, leading to an increased myocardial cell death, arrhythmias, reduced 
survival and increased hospitalization and morbidity rates.2'5 Nowadays, reduction of 
sympathoexcitation by specific treatment has become a cornerstone in modern 
treatment of these conditions. Beta-adrenergic receptor antagonists and angiotensin 
converting enzyme (ACE) inhibitors have been shown to increase survival and 
reduce morbidity.6,7 However, although these specific strategies shield target 
organs from increased sympathetic tone, the increased sympathetic nerve traffic 
itself remains unaffected.
In an animal model of pacing-induced CHF, studies have shown that 3-hydroxy- 
3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce 
the enhanced sympathetic activity. However, the exact mechanism of this action 
of statins has not yet been clarified.8
The primary aim of the present study was to test the hypothesis that statin 
therapy can inhibit sympathetic nerve activity also in humans. In this proof-of- 
concept study, we investigated patients with CHF, because CHF is accompanied 
by increased sympathetic activity. Since patients with CHF are usually treated by 
statins, we hypothesized that temporary discontinuation of their statin therapy 
would increase sympathetic activity and restart of statin therapy would reduce it 
again. If statins do reduce sympathetic nerve activity in patients with CHF, this 
effect might provide an additional explanation for the beneficial effects of statins 
in these patients.9
Methods
Participants
Eight patients diagnosed with CHF according to the modified Framingham Clinical 
Criteria, New York Heart Association (NYHA) 11 -1V, were included in our study.10 
Inclusion criteria were: left ventricular ejection fraction (LVEF) < 40% as assessed 
by 2D echocardiography, stable statin treatment for at least 3 months prior to the 
study and sinus rhythm. Exclusion criteria were: necessity of short-term percutaneous
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coronary intervention (PCI), coronary artery bypass grafting (CABG) or heart 
transplantation, chronic disease of the autonomic nervous system, diabetes 
mellitus, an obligatory reason for not interrupting statin therapy (recent myocardial 
or cerebral infarction e.g.), use of tricyclic antidepressant drugs or a-adrenergic 
receptor antagonists (or (3-adrenergic receptor antagonists with a-adrenergic 
receptor antagonizing properties). The investigation was performed in accordance 
with the principles outlined in the Declaration of Helsinki. The institutional review 
committee approved the study and informed consent was obtained from all 
patients before participation in the study.
Study protocol
Sympathetic activity was assessed using different approaches: direct measurement of 
muscle sympathetic nerve activity (MSNA) by microneurography and measurement 
of arterial plasma catecholamine concentrations. Effects on blood pressure, heart 
rate and cholesterol levels were recorded. Measurements were performed at 3 
different time points: during statin therapy (visit 1), 8 weeks after discontinuation 
(visit 2) and 4 weeks after restart of (original) statin therapy (visit 3). Experiments 
were conducted at 8.00 AM after an overnight (10-hour) fast with the patient in 
supine position in a quiet temperature-controlled room (23 - 24 °C). Subjects had 
to abstain from caffeine, tea, alcohol, chocolates and smoking for at least 12 
hours prior to the test procedure. All experiments were carried out after voiding 
to prevent reflex sympathoexcitation. A catheter (Angiocath: 20-gauge, 48 mm, 
Becton Dickinson and Co., Sandy, Utah) was inserted under local anesthesia 
(lidocaine 2 % ) into the brachial artery to obtain arterial blood samples and to 
have blood pressure measurements. After complete instrumentation, 30 minutes 
of rest were included to return to stable baseline conditions before data 
collection. Hereafter arterial blood samples were drawn and microneurography 
was performed.
Sympathetic nerve traffic (microneurography)
The peroneal nerve was localized at the site of the fibular head using transdermal 
electrical impulses (40-60 mV, 0.2 ms, 1 Hz) by a small electrode. After localization, 
a sterile Tungsten microelectrode was inserted manually through the skin in the 
underlying peroneal nerve posterior to the fibular head. Electrode position within 
a muscle nerve fascicle was identified by evoking muscle twitches by electrical 
stimuli (1-5 mV, 0.2 ms, 1 Hz) and through provoking afferent, mechanoreceptive 
activity by the stretching of the appropriate muscle. Then, minor adjustments of
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the electrode position were made to optimize the characteristic pattern of 
multi-unit MSNA. From the original signal, multi-unit MSNA (m-MSNA) bursts were 
obtained as the average voltage after filtering (bandwidth of 700 to 2,000 Hz) and 
integrating (time constant 0.1 s). The frequency and amplitude of MSNA bursts 
were obtained from bursts with a signal to noise ratio of >3." Bursts were identified 
using an automated computer program with prefixed settings to exclude observer 
bias. A preset triangle with a base of 0.8 sec., correlated to the known delay 
between R-peak in the electrocardiogram (ECG) and the postganglionic burst, 
was used to scan the MSNA signal and identify sympathetic bursts. Hereafter the 
maximal and average amplitude were calculated and potential bursts were 
correlated to a percentage of the maximal amplitude. The computer derived 
measures hereafter were visually confirmed by an investigator so that noise 
artefacts were not being counted and if so, noise artefacts were removed. From 
the MSNA neurogram thefollowing descriptors were used in the analysis: (1) burst 
frequency (burst number/minute), (2) burst incidence (burst number/ 100 heart 
beats), (3) mean normalized burst amplitude (burst amplitude normalized to the 
maximal burst in the recording) and (4) total normalized MSNA (sum of normalized 
burst amplitudes per minute).12 Microneurography recordings were performed 
under baseline conditions (patient in supine position), which has a high intra­
individual reproducibility.13 Measurements were performed between 9:30-11:30, 
to prevent confounding by circadian variation.14
Arterial plasma catecholamine levels
After a period of 20 minutes rest, plasma catecholamine concentrations were 
measured using high performance liquid pressure chromatography (HPLC) analysis 
and fluorometric detection.15 Within- and between-run coefficient of variances 
for plasme epinephrine (E) were 4,1% and 8.1% at a level of 0.166 nmol/l and for 
norepinephrine (NE) 4.1% and 6.1% at a level of 1.76 nmol/l respectively. Analytical 
detection limits were 0.003 and 0.002 nmol/l for E and NE respectively. 
Catecholamines were collected in ice-chilled 10 ml Vacutainer tubes (Becton- 
Dickenson Co., Franklin Lakes, NJ, USA) containing 0.2 ml of a solution of EGTA (0.25 
mol/L) and gluthatione (0.20 mol/L).
Heart rate and blood pressure
Heart rate was measured continuously for a period of 10 minutes using a cardio- 
tachometer triggered by the R wave of an ECG lead. Simultaneously, intra-arterial 
systolic and diastolic blood pressure was measured using a standard transducer
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connected to the intra-arterial line. For further analysis, an average value for the 
10-minute interval was calculated for each parameter.
Blood sampling
Arterial blood samples were drawn 40 minutes after instrumentation. Fasting total 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and 
triglyceride levels were measured at each visit to assess the effect of statin therapy.
Statistical analysis
Data are expressed as mean±SEM unless indicated otherwise. Prior to the study, 
sample size needed to find a difference in sympathetic nervous system activity of 
20% with a power of 80% was calculated to be n=8. Two-way ANOVA with the 
factors patient and visit was used to test the contrast for the difference between 
the visit during the withdrawal period and the mean of the visits during statin 
treatment . The distribution of some variables was skewed (heterogeneity) and 
these were log transformed which resulted in approximately Gaussian distributions 
and removed heterogeneity. A two-tailed p-value of <0.05 was considered to be 
statistically significant.
Results
All eight male patients completed the study: mean NYHA class (±SD) was 2.6±0.9, 
age 55±8 years and body mass index (BMI) 31.4±6.6 kg/m2. All patients suffered 
from residual myocardial ischemia after a previous myocardial infarction. Mean 
LVEF amounted to 30±9% (table 1). Seven patients used simvastatin (40 mg daily), 
one atorvastatin (40 mg daily). All patients used a p-blocker (5 patients atenolol, 
dosage ranging from 50-100 mg daily; 2 patients metoprolol (25-200 mg daily); and 
one patient bisoprolol (5 mg daily), all patients were on aspirin and an ACE-inhibitor 
(enalapril, n=1; losartan, n=2, perindopril, n=3; candesartan, n=1; quinapril, n=1). 
Seven patients used a diuretic (furosemide, n=2; bumethanide, n=1; spironolactone, 
n=4) and one patient used a nitrate. These baseline medications remained unchanged 
throughout the course of the study in all patients.
Sympathetic nerve traffic (microneurography)
After 8 weeks of discontinuation of statins, MSNA was increased to 73±4 bursts/100 
beats (p= 0.01), while levels during statin therapy were 56±5 and 52±6 bursts/100
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Table 1 Baseline echocardiographic characteristics
Parameter Value (±SD)
EF (%) 30±9
LVIDd (mm) 61±9
RVIDd (mm) 32±6
LVESV (ml) 141±47
LVEDV (ml) 188±55
E/A 1.8±1.3
S/D 1.1 ±0.6
EF = ejection fraction; LVIDd = diastolic left ventricle internal diameter;
RVIDd = diastolic right ventricle internal diameter; LVESV =: left ventricle end-systolic
volume; LVEDV = left ventricle end-diastolic volume; E/A = mitral valve E/A ratio;
S/D = pulmonary vein S/D ratio.
beats (figure 1). Burst frequency was significantly higher after statin discontinuation 
(42±3 burst/min without statin vs. 32±3 and 28±3 burst/min during statin therapy, 
p=0.004). Mean normalized burst amplitude and total normalized MSNA were 
significantly higher after statin discontinuation (mean normalized burst amplitude 
0.36±0.04 without statin vs. 0.29±0.04 and 0.22±0.04 during statin, p<0.05; total 
normalized MSNA 15.70±2.78 without statin, vs. 9.28±1.41 and 6.56±1.83 during 
statin, p=0.009). In one out of the eight patients we were unable to obtain 
qualitatively sufficient microneurography results to include in the analysis. No 
difference in MSNA responses to statins were found between patients with or 
without diuretics (or nitrate).
Arterial plasma catecholamine levels and hemodynamics
Discontinuation of statin therapy did not affect arterial plasma NE and E levels 
(table 2). Short-term statin discontinuation had no significant effect on systolic or 
diastolic blood pressure and heart rate (table 2).
Plasma cholesterol levels
Discontinuation of statin therapy resulted in a significant increase in total 
cholesterol and LDL in all patients (table 2), with no significant change in HDL 
cholesterol. These changes occurred consistently in all patients, consistent with 
good compliance to the study protocol.
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Figure 1
Muscle sympathetic nerve activity (MSNA) in the individual CHF patients in bursts/100 
heart beats at visit 1 (during statin therapy, n=7), visit 2 (8 weeks after statin 
discontinuation, n=7) and visit 3 (4 weeks after statin restart, n=6). MSNA was significantly 
higher after statin discontinuation. *P=0.01.
Table 2 Statin effects
Visit 1 Visit 2 Visit 3
(statin) (no statin) (statin)
MSNA (bursts/100 beats) 56±5 73±4* 52±6
MSNA (burst/min) 32±3 42±3* 28±3
MSNA (Mean normalized amplitude) 0.29±0.04 0.36±0.04* 0.22±0.04
MSNA (Normalized total MSNA) 9.28±1.41 15.70±2.78* 6.56±1.83
NE (pg/ml) 323±47 286±39 275±47
E (pg/ml) 40±7 29±4 31 ±4
Systolic BP (mmHg) 116±5 118±6 117±9
Diastolic BP (mmHg) 61 ±3 65±3 60±3
MAP (mmHg) 83±3 85±4 82±5
Heart rate (bpm) 59±2 60±3 57±3
Total plasma cholesterol (mmol/L) 3.4±0.4 5.5±0.5* 3.5±0.4
LDL (mmol/L) 1.8±0.4 3.5±0.4* 1.7±0.2
HDL (mmol/L) 1.0±0.1 1.0±0.1 0.9±0.1
Triglycerides (mmol/L) 1.4±0.2 2.5±0.4* 2.4±1.2
BP = blood pressure; E = arterial plasma epinephrine concentration; HDL = high density 
lipoprotein; LDL = low density lipoprotein; MAP = mean arterial pressure; MSNA = 
muscle nerve sympathetic activity; NE = arterial plasma norepinephrine concentration. 
*P<0.05 versus statin.
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Discussion
The present study provides evidence that statin therapy is able to suppress MSNA 
in CHF patients. During statin withdrawal, MSNA increased significantly. Short-term 
withdrawal of statins had no effect on arterial plasma catecholamine levels and 
blood pressure.
Our findings are in accordance with earlier data obtained in animal studies.1617 
In normolipidemic rabbits with pacing-induced CHF, incremental doses of simvastatin 
reduced the increased renal sympathetic nervous system activity (RSNA) by nearly 
50% compared to untreated animals. Gao et al. showed a similar decrease in RSNA 
by statins in rabbits with pacing-induced CHF.8 In our study, MSNA increased by 
approximately 30% after statin discontinuation. As compared to the animal 
studies, this at a 4-8 fold lower mean dosage of statin as calculated kg 'body 
w eightxday1. A recent study in patients with coronary artery disease also showed 
that atorvastatin shifted sympathovagal balance towards decreased sympathetic 
dominance.18 In contrast, two prior studies in CHF patients failed to show an effect 
of 20 mg simvastatin or 10 mg atorvastatin on HRV, but this might be explained by 
the relative low-dose of statins used in these studies.1920 Our patients used twice 
the dosage of statins and since previous studies demonstrated a dose-effect 
relationship between statins and sympathetic activity, it is possible that the 
effects of statins on MSNA are only apparent at higher statin doses.
To date, the underlying mechanism by which statins reduce sympathetic outflow 
has not been resolved. Most hypothesis are derived from animal experimental 
data. Statins seem to enhance central nitric oxide (NO) concentrations in the 
paraventricular region, and down regulate Angiotensin Type-1 receptor expression 
and NAD(P)H formation in the rostral ventrolateral medulla (RVLM).8,21 Increases in 
central angiotensin (Ang) II concentrations as seen in CHF, stimulate and up 
regulate the AT^receptor as well as NAD(P)H-oxidase expression.8 Stimulating the 
AT^receptor in turn stimulates NAD(P)H-oxidase, resulting in increased reactive 
oxygen species (ROS) formation.8 ROS increases sympathetic outflow in a number 
of ways. First, increases in ROS concentrations seem to reduce cerebral NO, a 
sym pathoinhibitory substance.22 Formed NO is immediately converted to 
peroxynitrite at high levels of intracerebral superoxide generation. Because NO is 
a well-known sympathoinhibitory substance, a reduction in bioavailability of NO, 
would predispose local neurons in the hypothalamus and medulla to become
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more excitable and thereby generate an enhanced sympathetic outflow. Superoxide 
anion has also been shown to modulate calcium-channel function in the central 
nervous system.23 This mechanism may contribute to neuronal excitability. 
Additionally, NO itself has also demonstrated to have a regulatory role on 
sympathetic outflow at a central level.24 Although it is not exactly known how NO 
modulates sympathetic outflow, several scenarios have been suggested. Of these, 
the most important is the suggestion that NO production by neuronal nitric oxide 
synthase (nNOS) causes y-amino butyric acid (GABA) release, that in turn produces 
a reduction in sympathetic outflow.25 Abnormalities in the NO-mechanism may 
contribute to the high sympathetic outflow state of CHF and hypertension. Gao et 
al. demonstrated in CHF rabbits that treatment with simvastatin down regulated 
AT^receptor mRNA and protein expression and NAD(P)H oxidase components in 
the RVLM.8 If statins downregulate Angiotensin Type-1 receptor expression and 
NAD(P)H formation, as well as increase NO formation, this might offer a potential 
explanation how statins can reduce central sympathetic outflow. The current study, 
however, cannot differentiate between these mechanisms.
In our study, the changes in MSN A were not translated in a decrease in arterial 
plasma NE levels. How could this be explained? It might be possible that for an 
effect on plasma NE levels, higher doses of statins might be required. This is 
supported by a study in pacing-induced CHF rabbits. Plasma NE concentrations 
were only reduced when administering statin doses up to 3 mg/kg/day, e.g..16 This 
dose level exceeds byfarthe  normal human statin dose that was used in ourstudy. 
In the low-dose group (0.3 mg/kg/day), plasma NE concentrations were not 
affected and this is in agreement with our study where the mean statin dosage 
was 0.4 mg/kg/day. Higher doses may be able to suppress plasma NE levels as is 
suggested by a recent study, demonstrating a significant reduction in plasma NE 
concentrations after administering atorvastatin in a dose of 80 mg to patients 
with coronary artery disease.18 Thus, the lack of change in plasma arterial NE levels 
is in accordance with animal studies and may be explained by the relative low 
statin dose. An alternative explanation might be that the plasma NE level is the 
net result of plasma NE spillover and NE clearance. A decrease in neuronal NE 
release by the decrease in MSNA might be translated into a decreased plasma NE 
spillover. However, a concomittant increase in plasma NE clearance might mask 
any effect of plasma NE spillover on plasma NE levels, leaving the latter unaltered. 
Finally, it should be noted that MSNA reflects only the sympathetic outflow to the 
muscle compartment while plasma NE levels represent merely global total body
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sympathetic nerve activity. So, even if statins reduce sympathetic nerve traffic to 
the muscle compartment, any contrasting change in sympathetic nerve traffic to 
another compartment might result in an unaltered plasma NE level. In line with 
the decrease in sympathetic nerve traffic, one would expect a decrease in blood 
pressure or heart rate, but this was not observed. This is probably due to the fact 
that effects on blood pressure and heart rate are also determined by other 
compensatory regulatory mechanisms like the renin-angiotensin-aldosteron 
system.2 Although non-compliance to the drug might also explain this effect, the 
decrease in plasma lipids in all patients argues against this possibility. Alternatively, 
the sympathoinhibitory effect of this dose statins is not large enough to be 
translated into a decrease in blood pressure or heart rate. Despite a reduction in 
plasma NE levels, statin dosis as high as 3 mg/kg/day did not affect hemodynamics 
in CHF rabbits 16.
One might question whether the sympatho-inhibitory effect of statin therapy 
would have any additional beneficial effect on top of betablocking therapy in 
patients with CHF. Beta-adrenoreceptor antagonists protect the cardiovascular 
system from sympathetic stimulation by blocking the (3-adrenoceptors. However, 
vascular postsynaptic a- adrenoreceptors are left unblocked and are therefore 
still operational in determining peripheral vascular resistance. The uninterrupted 
stimulating effect of increased sympathetic nerve traffic on these a- adreno­
receptors might be detrimental for the cardiovascular system.26 If statins indeed 
reduce sympathetic outflow, as suggested by our study, they may offer an 
additional pathway to counteract the increased sympathetic tone, thereby 
reducing it's detrimental effects.26 Two recent large clinical trials (GISSI-HF and 
CORONA) could not establish a beneficial effect of statins on clinical outcome in 
CHF patients.2728 This suggests that the reduction of sympathetic nerve traffic by 
statins is possibly insufficient to be translated into beneficial effects on long term 
cardiovascular morbidity and mortality. An alternative explanation is that CHF in 
these large studies was caused by different underlying cardiac disorders or that 
different statins and/or doses that were used in these studies.
In conclusion, the results of this study suggest that statins may have a 
sympathoinhibitory in patients with CHF. If this effect is confirmed by larger scale 
studies, statins might play an additional protective role in cardiovascular patients 
apart from their effects on lipids, since an increased sympathetic tone may be 
detrimental on the long term.
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CHAPTER 5
Abstract
Background Experimental animal data suggest that HMG CoA reductase inhibitors 
(statins) might reduce enhanced sympathetic activity, a hall mark of hypertensive 
patients. We tested this hypothesis for the first time in patients with primary 
hypertension.
Methods Using a prospective, randomized, placebo-controlled, double-blind, 
cross-over design, we performed a proof-of-principle trial in 13 patients with mild 
to moderate primary hypertension, who were randomly assigned to a regimen of 
atorvastatin (80 mg/day) for 3 weeks, followed by placebo for 3 weeks or to a 
regimen of placebo for 3 weeks, followed by atorvastatin (80 mg/day) for 3 weeks. 
Sympathetic nervous system activity was measured at the end of each treatment 
period by microneurography for measurement of muscle sympathetic nerve activity 
(MSNA), heart rate variability (HRV) and plasma norepinephrine concentrations. 
Additionally, effects on blood pressure and heart rate were assessed by 24 hour 
ambulatory blood pressure measurement.
Results Atorvastatin reduced postganglionic MSNA (atorvastatin 35.0±2.0 vs. 
placebo: 39.2±1.5 bursts/min, P=0.008) and heart frequency corrected MSNA 
(atorvastatin: 58.5±2.0 vs. placebo: 64.7±3.0 bursts/100 beats, P=0.02). Atorvastatin 
had no significant effect on plasma norepinephrine levels, HRV and blood pressure 
or heart rate.
Conclusion In patients with mild to moderate hypertension, atorvastatin reduces 
post-ganglionic muscle sympathetic nerve activity. This finding supports the 
hypothesis that HMG CoA reductase plays a role in sympathetic nervous system 
activity.
SYMPATHOINHIBITION BY ATORVASTATIN IN HYPERTENSIVE PATIENTS
Introduction
Hypertension is a major public health concern and increases the risk of stroke, 
myocardial infarction, and congestive heart failure.12 Despite improved treatment 
modalities, a substantial number of patients with hypertension are refractory to 
medical intervention.2 Apart from well known mechanisms that explain refractory 
hypertension, another potential contributing mechanism may be an augmented 
sympathetic activ ity3'5. Several studies have shown that, despite adequate blood 
pressure lowering therapy, the increased central sympathetic tone persists.6 
Maybe more importantly, it has been suggested that an increased sympathetic 
activity itself may play an additional pathophysiological role in the development 
of cardiovascular complications.78
In animal studies 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins) have been shown to reduce renal sympathetic nerve traffic.9 
In stroke-prone spontaneously hypertensive rats atorvastatin reduced systolic 
blood pressure and urinary norepinephrine excretion.10 Szramka et al. showed a 
sympatho-inhibitory effect of atorvastatin in patients with coronary artery 
disease (CAD).11 Up to now, the underlying mechanism by which statins reduce 
sympathetic outflow has not been elucidated. An effect on central nitric oxide 
(NO) and reactive oxygen species (ROS) formation, as well as regulation of the 
AT^receptor expression have been proposed as possible explanations.1214
We hypothesized that, as sympathoexcitation is a clear feature of primary 
hypertension, administration of a statin to hypertensive patients will reduce 
sympathetic nervous system activity.
Methods
Participants
Thirteen patients with primary hypertension were included in this proof-of-priciple 
trial. Inclusion criteria were: age 18-70 years, a body mass index (BMI) of 18-35 kg/m2, 
and a history of mild to moderate hypertension (defined as average awake systolic 
blood pressure, SBP, between 140-179 mmHg, or diastolic blood pressure, DBP, 
between 90-109 mmHg). Secondary hypertension was excluded according to 
standard clinical criteria. If treated with antihypertensive drugs, the drug regime
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had to be stable for 2 months. Subjects were excluded from the study if they had 
suffered a cardiovascular event within the last 6 months, had renal disease (plasma 
creatinine concentrations >120 |amol/L for females or >133 |amol/L for males, 
albuminuria >300 mg/day), diabetes, or any other severe medical condition. The 
institutional review committee approved the study and written informed consent 
was obtained from all patients before participation in the study.
Study protocol
Using a prospective, double-blind, cross-over design, patients were randomly 
assigned to a regimen of atorvastatin (80 mg/day) for 3 weeks, followed by 
placebo for 3 weeks or to a regimen of placebo for 3 weeks, followed by 
atorvastatin (80 mg/day) for 3 weeks. In patients already using statins, patients 
were included after a washout period of 2 weeks (n=4). At the end of each 
treatm ent period (atorvastatin or placebo) m easurements were perform ed. 
Muscle sym pathetic nervous system activ ity (MSNA) was assessed by m icroneu­
rography of the peroneal nerve. In addition, heart rate variab ility (HRV) and 
venous plasma catecholamine concentrations were determ ined. Prior to each 
v isit, am bulatory 24-hour blood pressure monitoring was perform ed. Experim ents 
were conducted at 8.00 AM after an overnight (10-hour) fast and with the patient 
in supine position in a quiet tem perature-controlled room (23 -  24 °C). Subjects 
had to abstain from caffeine, tea, alcohol, chocolates and smoking for at least 12 
hours prior to the test procedure. All experim ents were carried out after voiding 
to prevent reflex sym pathoexcitation. After complete instrumentation, 30 minutes 
of rest were included. Hereafter HRV measurement was performed for 10 minutes. 
Finally, blood samples were drawn and m icroneurography was performed.
M easurem ent o f sym pathetic activity
Multi-unit postganglionic sym pathetic nerve traffic was recorded using m icrone­
urography of the peroneal nerve at the fibular head 1516. All measurements were 
performed by the same investigator (MG). The peroneal nerve was located using 
an electrical probe delivering transdermal electrical impulses (40-60 mV, 0.2 ms, 1 
Hz). Hereafter, a sterile Tungsten m icroelectrode was inserted percutaneously in 
the underlying peroneal nerve posterior to the fibular head. Multi-unit MSNA 
(m-MSNA) bursts were obtained as the average voltage after filtering (bandwidth 
of 700 to 2,000 Hz) and integrating (time constant 0.1 s). MSNA registration is 
defined optimal w hen: a) electrical stimulus induces muscle tw itches, w ithout 
concom itant paresthesia, b) stretching of the appropriate muscle elicites afferent.
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m echanoreceptive activity, w ithout the occurrence of m echanoreceptive afferent 
signals after gentle touch or pressure w ithin the cutaneous receptive field of the 
nerve (if paresthesia is provoked, w ithout concomitant muscle tw itch or m ech­
anoreceptive afferent signals are recorded after touch or pressure, sym pathetic 
skin nerve activ ity (SSA) is measured, this lies outside the scope of our study), c) 
MSNA occurs in bursts strictly bound to the cardiac rhythm, and increases in 
frequency and amplitude during Vasalva maneuver. To quantify the frequency of 
MSNA bursts, only bursts with a signal to noise ratio of >3 were included 1718. Bursts 
were identified using an automated computer program with prefixed settings to 
exclude observer bias. A preset triangle with a base of 0.8 sec., correlated to the 
known delay between R-peak in the electrocardiogram (ECG) and the 
postganglionic burst, was used to scan the MSNA signal and identify sym pathetic 
bursts. Maximal and average amplitude were calculated and potential bursts were 
correlated to a percentage of the maximal amplitude. The computer derived 
measures hereafter were visually confirmed by the investigator to indentify and 
exclude noise artefacts . M icroneurography recordings were quantified as bursts 
per 100 beats, which has a high intra-individual reproducibility and bursts per 
minute 19.
Laboratory determ inations
Fasting total cholesterol, HDL and triglyceride levels were measured at the end of 
each treatm ent period by automated enzym atic methods. Low-density lipoprotein 
cholesterol was calculated using the Friedewald equation. For detecting potential 
statin side-effects, plasma liver enzymes and creatine kinase (CK) levels were 
measured at each visit (baseline, 3 weeks, 6 weeks).
Plasma catecholamine concentrations were measured using high performance 
liquid pressure chromatography (HPLC) analysis and fluorom etric detection 20. 
Within- and between-run cv's for plasma epinephrine were 4,1% and 8.1% at a 
level of 0.166 nmol/l and for norepinephrine 4.1% and 6.1% at a level of 1.76 
nmol/l respectively. Analytical detection limits were 0.003 and 0.002 nmol/l for 
epinephrine and norepinephrine respectively. Catecholamines were collected in 
ice-chilled 10 ml Vacutainer tubes (Becton-Dickenson Co., Franklin Lakes, NJ) 
containing 0.2 ml of a solution of EGTA (0.25 mol/L) and gluthatione (0.20 mol/L).
Heart rate variability
Using a two-channel Holter (Medilog 4500-3, Oxford Intruments Ltd., Engeland) a 
10-minute ECG recording was performed in each patient at each visit. Ectopic
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beats and arrhythm ias were excluded using the Oxford scanning software version
6.0. R-R interval selection was performed using a beat-to-beat filter set at N-N-N, 
whereby the interval being considered should start and end in a "normal" beat 
and so should the preceding R-R interval. Rejected intervals were interpolated 
over the invalid area. Before converting the interval tachogram to frequency 
domain analyses, the mean R-R interval was calculated from the tachogram and 
subtracted from each R-R interval to reduce spectral leakage. A Fast Fourier 
Transformation (FFT) was performed from the interpolated tachogram resampled 
at 292 msec, using the Oxford spectral analysis software package. Results from 
the 10-minute interval were averaged to form a composite spectrum . Total power 
between 0.003 and 0.40 Hz was calculated. This represents the total variance for a 
10-minute interval. Power was quantified as total power, high frequency (HF) 
0.15-0.40 Hz and low frequency (LF) 0.04-0.15 Hz power. HF represents para­
sym pathetic contribution to the spectrum , whereas LF represents a combination 
of parasym pathetic and sym pathetic influences.21 The LF/HF ratio is a measure of 
autonomic balance with an increasing ratio representing sympathetic predominance.
24-hour am bulatory blood pressure m easurem ent
Twenty-four hours prior to each experim ent, a validated 24-hour indirect blood 
pressure monitor (Mobil-O-Graph CE0434, Firmware version 1 2 ,1.E.M. Industrielle 
Entwicklung Medizintechnik GmbH, Stolberg, Germany) was connected.
Statistical analysis
Data are expressed as mean±SEM unless indicated otherwise. Differences between 
measurements performed during atorvastatin administration or placebo were 
assessed using parametric (student f-testfor paired observations) or nonparametric 
(paired Wilcoxon) tests as appropriate. A power calculation assuming a basal 
sym pathetic activ ity of 60±15 bursts/100 beats, revealed that in order to detect a 
difference of 25% in burst frequency with a power of 80% at a significance level of 
0.05 (a), 11 subjects needed to be included. Allowing for a dropout and failure rate 
of m icroneurography of 20%, 13 patients needed to be included. A two-tailed 
p-value of <0.05 was considered to be statistically significant. Correlations 
between parameters were calculated using Pearson correlation coefficients.
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Results
Table 1 presents the baseline characteristics of the study population. At entry, 10 
of the 13 patients had a blood pressure level over 130 mmHg systolic or 80 mmHg 
diastolic. All patients, except one, were on antihypertensive medication. These 
baseline medications remained unchanged throughout the course of the study in 
all patients. All patients completed the study but in one patient one of the two 
MSN A measurements failed due to technical reasons. Thus paired MSN A recordings 
were available in 12 of the 13 patients. There were no significant differences in 
baseline characteristics between the groups of patients with regard to the 
sequence of atorvastatin or placebo.
Tab le  1 Baseline characteristics
Age (years) 54±16
Sex (male/female) 9/4
BMI (kg/m2) 26.7±1.0
SBP (mmHg) 152±12
DBP (mmHg) 92±3
HR(bpm) 71 ±3
Concomitant medication, (n)
(5-blockers 7
aspirin 3
diuretics 7
calcium antagonist 8
ACEI/ARB 8
statin 4
Mean±SD. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; HR = heart rate; ACEI = ACE inh ib ito r; ARB = angiotensin receptor blocker.
Atorvastatin reduced total plasma cholesterol and low-density lipoprotein 
(LDL) cholesterol levels in all patients (total cholesterol; from 5.4±0.3 to 3.5±0.2 
mmol/L, P<0.001 and LDL cholesterol; from 3.3±0.3 to 1.7±0.2 mmol/L, P<0.001). 
High-density lipoprotein cholesterol levels and triglyceride levels were not 
significantly altered.
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Muscle sym pathetic nerve activity was significantly lower during atorvastatin 
80 mg, as compared to placebo (figure 1), (total MSNA, atorvastatin: 35.0±2.0 vs. 
placebo: 39.2±1.5 bursts/min, P=0.008; frequency corrected MSNA: atorvastatin: 
58.5±2.0 vs. placebo: 64.7±3.0 bursts/100 beats, P=0.02;). Although MSNA values 
were positively correlated with plasma cholesterol levels (all measurements 
combined, r=0.50, P=0.01, figure 2), the reduction in MSNA was independent of 
the degree of change in plasma cholesterol levels (r=0.24, P=0.45) and did not 
correlate with change in LDL cholesterol levels (r=-0.22, P=0.51). This suggests 
that the effect was caused by atorvastatin itself instead of a change in cholesterol 
level. The atorvastatin effect on MSNA was independent of baseline blood 
pressure, heart rate, age and BMI. Plasma concentrations of norepinephrine 
(atorvastatin: 2.7±0.4 vs. placebo: 2.4±0.2 nmol/L) and epinephrine (atorvastatin: 
0.16±0.03 vs. placebo: 0.15±0.03 nmol/L) levels were similar during atorvastatin 
and during placebo. Day-time and night-time systolic and diastolic blood pressure, 
as assessed by 24-hours am bulatory blood pressure measurement, were not 
significantly different between atorvastatin and placebo (table 2). There was no 
difference in HRV between atorvastatin and placebo (table 3).
Figure 1
Individual levels of muscle sympathetic nerve activity (MSNA) o f the hypertensive patients 
(bursts/100 heart beats and bursts/min for total MSNA) during placebo (left) and atorvastatin 
(right) administration.
P=0.008
-------- 1-------------------------------------------------1--------------
placebo atorvastatin
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Table 2 24-hour am bulatory blood pressure levels during atorvastatin 
and placebo
Atorvastatin Placebo
Day time Nighttime Daytime Night time
Systolic BP (mmHg) 139±3 130±4 143±5 133±5
Diastolic BP (mmHg) 89±3 83±4 90±3 83±3
MAP (mmHg) 105±3 98±4 107±3 98±4
HR (beats/min) 81 ±5 68±5 78±4 62±4
Mean±SEM MAP: mean arterial blood pressure; HR: heart rate.
Table 3 Heart rate variab ilty values during atorvastatin and placebo
Atorvastatin Placebo
LF (ms2) 1480±736 1513±729
HF (ms2) 711±248 532±136
LF/HF 1.84±0.37 2.97±0.97
Total PSD (ms2) 5090±1473 4579±1830
LF: low-frequency power; HF: high-frequency power; LF/HF: low frequency/high 
frequency ratio; Total PSD: Total power spectral density
Figure 2
40
0.0 2.5 5.0 7.5 10.0
plasma total cholesterol (mmol/L)
Relation between MSNA and plasma total cholesterol levels. The Pearson correlation 
coefficient is 0.50, (P=0.01). Open dots = during atorvastatin, closed dots = during placebo.
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Discussion
This study provides evidence that a high dose of atorvastatin produces a 
significant reduction in post-ganglionic sym pathetic nerve activ ity in patients 
w ith primary hypertension. This conclusion is based on the finding of a nearly 9% 
lower MSNA on atorvastatin treatm ent as compared to placebo. The lower MSNA 
levels were not translated in lower venous plasma norepinephrine levels or lower 
blood pressure levels, nor in a change in heart rate variability. The reduction in 
MSNA seemed to be related to the use of atorvastatin and not the reduction in 
plasma cholesterol but our study is too small to draw conclusions on this point.
The results of the present study are in line with earlier findings in animal 
experimental models. Kishi et al observed a significant reduction in 24h urinary 
norepinephrine concentrations after treating stroke-prone spontaneous hypertensive 
rats for 30 days with atorvastatin.10 Pliquette et al. demonstrated a significant 
reduction in renal sympathetic activ ity and plasma norepinephrine levels when 
treating rabbits with heart failure with simvastatin.9 The hypothetical concept that 
underlies these findings is that statins downregulate mRNA and protein expression of 
Ang II type 1 receptor and NAD(P)H oxidase subunits and inhibit NAD(P)H oxidase 
activity in the rostral ventrolateral medulla u . The subsequent decline in ROS 
form ation, a well-known stimulator of sympathetic activity, results in reduced 
sympathetic outflow. In addition, statins enhance NO synthesis in areas related to 
integration of sympathetic activity and since NO suppresses central sympathetic 
outflow, the resulting effect of statins is sympathoinhibition.
Up to now only few  studies have assessed the effects of statins on sym pathetic 
activ ity in humans. Most of these studies have focused on catecholamine levels 
and heart rate variab ility (HRV). These parameters are surrogate indices of 
sym pathetic activ ity and are subject to large intraindividual variation. To our 
knowledge, only one study has used m icroneurography to measure directly 
changes in post-ganglionic sym pathetic nerve activity after treatm ent with 
atorvastatin .22 These authors also found a significant reduction in MSNA after 
8-weeks of treatm ent w ith atorvastatin. However, in that study a parallel group 
design was used, comparing 10 hypertensive patients with 8 healthy controls 
while only the hypertensive patients received atorvastatin. In our study, we used 
a randomized, placebo-controlled, double-blind, cross-over design, which has 
stronger statistical power.
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The fact that the reduction in MSNA after administering atorvastatin 80 mg 
was not translated in a change in plasma norepinephrine levels is not completely 
unexpected. First, the plasma norepinephrine level is a global marker for assessing 
noradrenergic sympathetic tone. The plasma norepinephrine level is the net result 
of neuronal release and clearance of norepinephrine. It is possible that a reduced 
neuronal release of norepinephrine is masked if there is also a reduced clearance. 
An alternative explanation is that the MSNA results just refer to sym pathetic 
activ ity to the skeletal muscle compartm ent while plasma norepinephrine levels 
is the resultant of all vascular beds. Indeed, it is well established that there are 
significant regional differences in sym pathetic activ ity .23 Finally, there might be 
a dose-effect relationship for the effect of statins on plasma norepinephrine levels 
and this explanation is supported by a previous study in animals 24. In pacing- 
induced CHF rabbits, plasma norepinephrine levels were only reduced when 
administering a simvastatin dose of up to 3 mg/kg/day, whereas the effects on 
MSNA were already found at much lower do ses9. The 3 mg/kg/day dose in rabbits 
exceeds by far the usual dose (simvastatin 40 mg one a day, e.g.) in human subjects.
Several studies have shown that statins are able to reduce blood pressure 
significantly in hypertensive patients. 2526 That this effect did not occur in the 
current study might be due to several reasons. First, the sym pathoinhibitory 
effect of this dose of atorvastatin might not be large enough to be translated into 
a significant decrease in blood pressure or heart rate. Even a simvastatin dose as 
high as 3 mg/kg/day did not affect hemodynamics in CHF rabbits, although RSNA 
was reduced 9. In accordance with this animal study and our findings, atorvastatin 
80 mg administered to patients with coronary artery disease had no effect on 
blood pressure despite a significant reduction in plasma norepinephrine levels 11. 
Second, it is possible that the size of our study population was not sufficiently 
large to uncover a decrease in blood pressure. In addition, our patients were only 
treated and observed for a short period of time. Therefore, our study can not 
exclude that statins do reduce blood pressure on the long term. Finally, 
non-compliance with the statin administration might be considered as an 
explanation but the decrease in plasma total and LDL cholesterol in all patients 
argues against this possibility.
Several potential lim itations of our study should be discussed. All but one 
patients were on antihypertensive treatm ent. Although this might interfere with 
the statin, it is unlikely that this might have confounded the results since all
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patients remained on the exact same m edication, both during the atorvastatin 
and during the placebo administration. Our study encompasses a relatively small 
group of subjects but due to the cross-over design it was adequately powered for 
the assessment of the MSNA. Although it is d ifficult to dissect the contribution of 
atorvastatin itself from the reduction in LDL cholesterol to the sympathoinhibi- 
tion, there was no indication that the degree of reduction in LDL cholesterol was 
correlated with the MSNA effect, thus favouring but not proving a pleiotropic 
effect of atorvastatin.
It is too premature to state that the findings of the present study have clinical 
im plications. Although the decrease in sym pathetic activ ity did not result in a 
change in blood pressure or norepinephrine concentrations, this does not mean 
that this finding has no clinical relevance. High sym pathetic tone has been 
associated to insulin resistance, metabolic effects and reduced skeletal muscle 
perfusion. 27-29 All of these effects are mainly alfa-adrenergic mediated and not 
assessed in this study. Patients with hypertension frequently have increased 
plasma lipids and are treated with statins. If statins indeed lower sym pathetic 
activity, this might, apart from their effects on plasma lipids, contribute to their 
beneficial cardiovascular effects on the long term .30
In conclusion, the present study shows a small but significant reduction in 
sym pathetic nerve traffic after short term atorvastatin administration in patients 
w ith primary hypertension. Although these findings need confirmation in larger 
groups of patients, they do suggest an additional beneficial mechanism by which 
statins reduce cardiovascular complications.
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CHAPTER 6
Abstract
Background  The increased central sym pathetic activ ity typ ically associated with 
chronic heart failure (CHF) is probably mediated by formation of reactive oxygen 
species (ROS) in the brain. Our objective was to undertake a trial to test our 
hypothesis that administration of the well-known antioxidant and ROS scavenger 
ascorbic acid, would reverse or reduce the sym pathetic overactivity in CHF 
patients.
M ethods In a prospective, randomized, placebo-controlled, double-blind, cross­
over trial, eleven CHF patients were treated with ascorbic acid 2g/day or placebo 
for 3 days. At the end of each treatm ent period, sym pathetic nervous system 
activ ity was measured by m icroneurography for direct muscle sym pathetic nerve 
recording (MSNA), analysis of heart rate variab ility (HRV) and measurement of 
plasma norepinephrine concentrations.
Results During ascorbic acid administration, plasma vitam in C levels were higher 
than during placebo (74.9±6.0 versus 54.8±4.6 |amol/L, P=0.03). Ascorbic acid had 
no effect on sym pathetic activ ity: MSNA (ascorbic acid: 66.8±3.3 vs. placebo 
66.9±3.2 bursts/100 beats, p=0.98). In addition, HRV and plasma norepinephrine 
levels did not differ.
Conclusion  Short-term administration of the antioxidant ascorbic acid in CHF 
patients does not reverse the increased sym pathetic activ ity as measured by 
m icroneurography, HRV and plasma norepinephrine levels. The use of higher oral 
dosages seems not feasible due to accompanying side-effects.
HIGH DOSE ASCORBIC ACID DOES NOT REVERSE SYMPATHETIC OVERACTIVITY
Introduction
One of the characteristic features of chronic heart failure (CHF) is an increased 
sym pathetic nervous system activity.1 As this has been proven to be detrimental, 
reduction of sym pathoexcitation has become the cornerstone in modern 
treatm ent of CHF. Most strategies have focussed on shielding organs from the 
high sym pathetic outflow (for instance by (3-adrenergic receptor antagonists).23 
However, these interventions leave the increased sym pathetic nerve traffic, 
originating from the central nervous system, unaffected.
In animal CHF studies, a key elem ent in modulating sym pathetic activ ity at a 
central level is the formation of reactive oxygen species (ROS).4 In CHF rabbits, 
NAD(P)H oxidase expression and activity, the main enzym e for reactive oxygen 
formation (ROS) form ation, was upregulated in the rostral venterolateral medulla 
(RVLM), the primary central site for the maintenance of sym pathetic nerve activ ity .5 
In addition, decreasing central superoxide anion concentrations by tem pol, a 
superoxide dismutase (SOD) m imetic, reduced sym pathetic outflow  in CHF 
rabbits, whereas administration of the SOD inhibitor diethyldithiocarbam ic acid, 
significantly augmented sym pathetic outflow .5 Reducing cerebral ROS might 
therefore be a potential mechanism for counteracting high central sympathetic 
outflow . Ascorbic acid (vitamin C) is a well-known scavenger of ROS. The 
advantages of ascorbic acid are that it is safe and passes the blood brain barrier, 
making it applicable in humans. If ascorbic acid reduces sym pathoexcitation in 
patients with CHF, this drug might provide an additional strategy to oppose 
sym pathoexcitation in patients with CHF.
The primary aim of the present study was to test the hypothesis that ascorbic 
acid reverses or reduces central sym pathetic overactivity in CHF patients. Using a 
double-blind, randomized, placebo-controlled, cross-over design, CHF patients 
were administered ascorbic acid or placebo.
Methods
Participants
Eleven patients diagnosed with CHF according to the modified Framingham 
Clinical Criteria for the diagnosis of heart failure were included in our study.6
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Inclusion criteria were: CHF severity between NYHA 11 - IV, left ventricular ejection 
fraction (LVEF) < 40% as assessed by 2D echocardiography, age 20 to 80 years. 
Patients needed to have sinus rhythm, suitable for analysis of heart rate variability. 
Patients had to be in a stable condition and all other medication had to remain 
unchanged during the study period .Thefo llow ing exclusion criteria were defined: 
necessity of short-term PCI, CABG or heart transplantation, chronic disease of the 
autonomic nervous system, diabetes m ellitus, use of tricyclic antidepressant 
drugs, a-adrenergic receptor antagonists. The study conformed to the principles 
outlined in the Declaration of Helsinki. The institutional review committee 
approved the study and informed consent was obtained from all patients before 
participation in the study.
Study protocol
This study had a prospective, randomized, placebo-controlled, double-blind, 
cross-over design. Patients were randomly assigned to ascorbic acid 2g/day or 
placebo. Treatment periods were 3 days, w ith a 4-day washout period between 
treatm ent periods. A recent study showed that plasma ascorbic acid levels reach 
steady state 2 hours after oral adm inistration.7 Twenty-four hours after first 
ingestion, ascorbic acid levels returned to baseline.7 Sympathetic activ ity was 
measured following each treatm ent period. Sympathetic activ ity was assessed 
using three different approaches: direct measurement of muscle sym pathetic 
nerve activity (MSNA) by m icroneurography, analysis of heart rate variab ility 
(HRV) and measurement of plasma catecholamine concentrations. Blood pressure 
and heart rate were also recorded. Experim ents were conducted w ithin 24-hours 
after ingestion of placebo or ascorbic acid at 8.00 AM after an overnight (10-hour) 
fast with the patient in supine position in a quiet tem perature-controlled room 
(23 -  24 °C). Subjects had to abstain from caffeine, tea, alcohol, chocolates and 
smoking for at least 12 hours prior to the test procedure. All experim ents were 
carried out after voiding to prevent reflex sym pathoexcitation. After complete 
instrum entation, 30 minutes of rest were included to return to stable baseline 
conditions before data collection. Hereafter, HRV measurement was performed 
for 10 minutes. Finally, blood samples were drawn and m icroneurography was 
performed.
Sym pathetic nerve traffic (microneurography)
M icroneurography permits direct recording of the post ganglionic sym pathetic 
nerve traffic to skeletal muscles.89 The peroneal nerve was localized at the site of
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the fibular head using transdermal electrical impulses (40-60 mV, 0.2 ms, 1 Hz) by 
a small electrode. After localization, a sterile Tungsten m icroelectrode was 
inserted manually through the skin in the underlying peroneal nerve posterior to 
the fibular head. A second reference electrode was placed subcutaneously 
approxim ately 3 cm from the recording electrode. From the original signal, 
multi-unit MSNA (m-MSNA) bursts were obtained as the average voltage after 
filtering (bandwidth of 700 to 2,000 Hz) and integrating (time constant 0.1 s). The 
frequency of MSNA bursts was obtained from bursts with a signal to noise ratio of 
>3.1011 Bursts were identified using an automated computer program with prefixed 
settings to exclude observer bias. A preset triangle with a base of 0.8 sec., 
correlated to the known delay between R-peak in the ECG and the postganglionic 
burst, was used to scan the MSNA signal and identify sym pathetic bursts. Hereafter 
the maximal and average amplitude were calculated and potential bursts were 
correlated to a percentage of the maximal amplitude. The computer derived 
measures hereafter were visually confirmed by an investigator so that noise 
artefacts were not being counted and if so, noise artefact were removed. Micro­
neurography recordings were performed under baseline conditions (patient in 
supine position) and quantified as bursts per 100 beats, which has a high intra­
individual reproducibility.12 Measurements were performed between 9:30-11:30, 
to prevent confounding by circadian variation.13
Heart rate variability
Using a two-channel Holter (Medilog 4500-3, Oxford Intruments Ltd., Engeland) a 
10-minute ECG recording was performed in each patient at each visit. Ectopic 
beats and arrhythmias were excluded using the Oxford scanning software version
6.0. R-R interval selection was performed using a beat-to-beat filter set at N-N-N, 
whereby the interval being considered should start and end in a "normal" beat 
and so should the preceding R-R interval. Rejected intervals were interpolated 
over the invalid area. Before converting the interval tachogram to frequency 
domain analyses, the mean R-R interval was calculated from the tachogram and 
subtracted from each R-R interval to reduce spectral leakage. A Fast Fourier 
Transformation (FFT) was performed from the interpolated tachogram resampled 
at 292 msec, using the Oxford spectral analysis software package. Results from 
the 10-minute interval were averaged to form a composite spectrum . Total power 
between 0.003 and 0.40 Hz was calculated. This represents the total variance for a 
10-minute interval. Power was quantified as total power, high frequency (HF)
0.15-0.40 Hz and low frequency (LF) 0.04-0.15 Hz power. HF represents parasym ­
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pathetic contributio n to the spectrum , w hereas LF represents a co m b inatio n  of 
parasym path etic and sym p athetic influences.14 The LF/HF ratio is a m easure of 
autonom ic balance with an increasing ratio representing sym pathetic predominance.
Blood sampling
After a period of 40 m inutes rest, blood sam ples were collected for m easurem ent 
of plasm a ca techo lam ine co ncentrations (using high perform ance liquid  pressure 
chrom atography, HPLC, analysis and fluorom etric detection).15 W ith in - and 
b etw een-run  cv's for plasm a ep in ep hrine  were 4,1%  and 8.1%  at a level of 0.166 
n m o l/l and for n o rep inep h rin e  4.1%  and 6.1%  at a level of 1.76 n m o l/l respectively. 
A na lytica l detection lim its were 0.003 and 0.002 n m o l/l for ep in ep hrine  and 
n o rep inep h rin e  respectively. C atecho lam ines were collected in ice -ch ille d  10 ml 
Vacu tain er tubes (B ecton-D ickenso n Co., Franklin  Lakes, NJ) co ntain ing 0.2 ml of a 
solution of EGTA (0.25 m ol/L) and g luthatio ne (0.20 m ol/L). Blood sam ples for 
m easurem ent of plasm a ascorbic acid were collected using a sim ilar 10 ml 
Vacu tain er tube (B ecton-D ickenso n Co., Franklin  Lakes, NJ) w rapped in a lum inium  
foil to prevent degradation  by light. Sam ples for ascorbic acid were analyzed by 
HPLC w ith p re-co lu m n  derivatization. No v ita m in e  C degradation  occurred under 
processing and storage co nditio ns.
Heart rate and blood pressure
Heart rate was m easured co ntinuo usly for a period of 10 m inutes using a ca rd io - 
tachom eter triggered by the R w ave of an ECG lead. Blood pressure was m easured 
by sp h yg m o m an o m etry and the average of tw o m easurem ents was used for 
analysis.
Statistical analysis
The num ber of p artic ipants included in the stud y was based on a prior power 
ca lculatio n. In a previous study, the app licatio n  of statins to intervene w ith the 
angio tensin  II and ROS pathw ay resulted in a near 20%  reduction in sym pathetic 
a ctiv ity  , w hich was statistically  s ig n ifica nt in a sm all sam ple size.16 In order to 
detect a 20%  difference in CHF patients w ith a resting sym pathetic a ctiv ity  of 
67±12 bursts/100 beats17 (equaling 13.4 bursts/100 beats), w ith a pow er of 80% ,  at 
the usual s ig n ifica nce level of 0.05 (double sided), we calculated that a total of 9 
paired m easurem ents w ould be required (the crossover design has a high 
statistical power, e sp ecia lly  w ith m easurem ents w ith a re latively low intra­
ind iv id u al variab ility).18 We accounted for the fact that M SNA is o n ly successful in
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approxim ately 80%  of the cases. D ifferences betw een m easurem ents perform ed 
during v itam in  C treatm ent and p lacebo were assessed using param etric (student 
f-test for paired observations) or n o n p aram etric (paired W ilcoxon) tests as 
appropriate. A tw o -ta iled  p -v a lu e  of < 0.05 was considered to be statistically 
sig n ificant. Correlatio ns betw een param eters were calculated using Pearson 
correlation coefficients.
Results
All patients com pleted the study: m ale/fem ale 7/4 , m ean NYHA class (±SD) was 
2.2± 0.3, age 56±10 years and BMI 25.5± 3.8 kg /m 2. Eight patients suffered from 
ischem ic heart failure. Three patients had a d ilated cardio m yo pathy. M ean LVEF 
was 34± 7% .  M edication: p -b lo cker n=11 (2 patients atenolol, 9 patients m etoprolol), 
aspirin  n = 7, ACEI or ARB n = 7, statin n = 9, d iuretic n = 9, nitrate n = 2 . Baseline 
m edication rem ained unchang ed  thro u g h o u t the stud y in all patients. Plasma 
v itam in  C levels were s ig n ifica n tly  h igher during ascorbic acid adm in istration  
74.9± 6.0 vs. 54.8 |im o l/L  during placebo, p = 0.03.
Effect on sym pathetic activity
A scorbic acid treatm ent had no effect on m uscle sym pathetic nerve a ctiv ity  as 
m easured by m icro n eu ro g rap h y (figure 1), (ascorbic acid: 66 .8± 3.3 vs. placebo: 
66 .9± 3.2 bursts/100 beats, p = 0 .98). There was no correlation betw een plasm a 
v itam in  C levels and M SNA (figure 2). A dm inistratio n  of ascorbic acid also had no 
effect on total pow er (ascorbic acid: 1028.4± 381.9 vs. p lacebo: 989.7± 196.2 m s2, 
p = 0.87); lo w -freq u ency pow er (LF), (ascorbic acid: 196.0± 41.0 vs. placebo: 
281.4± 70.8 m s2, p = 0 .14); h ig h -fre q u e n cy pow er (HF), (ascorbic acid: 183.5± 100.2 
vs. p lacebo: 205.6± 91.1 m s2, p = 0.24) and LF/HF ratio, (ascorbic acid: 1.98± 0.46 vs. 
placebo: 2 .21± 0.48 m s2, p = 0.71 ). The h ig her v itam in  C levels during ascorbic acid 
adm in istratio n  did not affect plasm a co ncentrations of no rep inep h rin e  (ascorbic 
acid: 3 .3± 0.5 vs. p lacebo: 3.4± 0.6 nm ol/L) and ep in ep hrine  (ascorbic acid: 0.14± 0.02 
vs. p lacebo: 0.14± 0.02 nm ol/L) levels. In accordance w ith these fin d in g s, blood 
pressure and heart rate were not affected by ascorbic acid adm inistration (figure 3).
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Figure 1
Muscle sympathetic nerve activity (MSNA) in the individual CHF patients in bursts/100 
heart beats during ascorbic acid and placebo administration.
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administration.
Discussion
The present study show s that ascorbic acid treatm ent for 3 days does not reverse 
the sym pathetic overactiv ity in patients w ith CHFs despite a s ig n ifica nt rise in 
plasm a v itam in  C level. M uscle sym pathetic nerve traffic (MSNA), w hich is 
representative for central sym pathetic outflow , heart rate v a ria b ility  and 
sym p a th o -va g a l balance (LF/HF ratio) were not affected by ascorbic acid 
adm in istratio n. W ith regard to plasm a ca techo lam ine and blood pressure levels 
no differences were found betw een ascorbic acid and p lacebo adm in istration.
As expected, central sym pathetic a ctiv ity  (sym pathetic burst frequency) was 
elevated in our CHF patients.19 It has been suggested that high cerebral 
co ncentratio ns of ROS m ight, at least in part, be responsible for this increase.20 
The precise m echanism  or trigger for this increase in ROS form ation is still a mater 
of debate. An increased expression of NAD(P)H oxidase, the enzym e responsible 
for ROS form ation, provides one of the potential explanations.20 ROS can increase 
sym pathetic outflow  in a num ber of w ays. First, increases in ROS co ncentrations 
seem  to reduce cerebral NO, a sym p a th o in h ib ito ry m o lecule.21 At high levels of 
intracerebral superoxide generation, form ed NO is im m ed iate ly converted to 
peroxynitrite. Because NO is a well-know n sym pathoinhibitory substance, a reduction 
in b io a va ila b ility  of NO w ould predispose local neurons in the h ypothalam us and
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m edulla  to becom e m ore excitable and thereby generate an enhanced sym pathetic 
outflow . Supero xide anion has also been show n to m odulate ca lc iu m -ch a n n e l 
fun ctio n  in the central nervous system .22 T h is m echanism  m ay contribute to 
neuronal excitability.
We hypothesized that a sim ilar state of increased cerebral ROS fo rm ation may 
be present in hum an CH F patients and that reducing ROS co ncentratio ns should 
reduce central sym p athetic output. In this stud y we attem pted to reduce central 
sym pathetic output by oral adm inistration of ascorbic acid in a dosage of 2 gram s/ 
day for a period of 3 days. We choose this approach for a num ber of reasons. First, 
ascorbic acid is a w ell-kn o w n  scavenger of ROS. Second, ascorbic acid is able to 
pass the b lo o d -b ra in  barrier, w hich is essential as the sym pathetic nuclei located 
in the brain were the target of our interventio n.23 A d d itio n ally, treatm ent w ith 
ascorbic acid at dosages up to 2 gram s a day has been studied ex tensively in 
d ifferent trials and has been proven to be safe and effective.24 The latter has 
im portant clin ical im p licatio ns, as ascorbic acid, if proven effective, can be 
adm in istered safely in a broad varie ty  of patients. Conversely, dosages h igher 
then 2 g ra m s/d a y have show n to cause s id e -e ffe cts , thus lim it in g  clin ical 
a p p lica b ility . From previous studies it is know n that the p h arm acokinetic profile 
of orally adm inistered ascorbic acid demonstrates a rapid uptake with a subsequent 
s ig n ifica nt rise in plasm a v itam in  C levels (<2-3 hours).7 Effects of oral ascorbic 
acid adm in istration  on flo w -m ed ia ted  vaso d ilatio n , exercise capacity, plasm a 
no rep inep h rin e  levels and heart rate have been described w ithin  2 to 3 hours 
after oral ing e stio n.25 26 For this reason we reasoned that a 3-d a y  treatm ent period 
should  be sufficient to result in a rapid and adequate rise in plasm a v itam in  C 
levels w ith subsequent effects. However, despite a s ig n ifica nt rise in plasm a 
v ita m in  C levels, no effects on sym pathetic a ctiv ity  were fo und. There are a 
num ber of potential explanatio ns. First, from literature it is w ell-kn o w n  that 
v ita m in  C is stored w ithin  the brain at levels of up to 10-fold  the norm al plasm a 
co ncentratio ns.27 In our study, altho ugh s ig n ifica n tly  increased, plasm a v itam in  C 
levels still rem ained w ithin the norm al physiological range. As vitam in C uptake in 
the brain is in part gradient driven and facilitated by the different transporters, 
the rise in plasma vitamin C might have been too small to influence this gradient.28,29 
A num ber of studies have show n, however, that w ith ascorbic acid dosages 
exceeding 2 gram s, further increm ents in steady state plasm a levels are lim ite d .30 
In ad d itio n , dosages of m ore than 2 gram s a day are associated w ith side-effects, 
lim iting  clin ical a p p lica b ility . A d ifferent explanatio n m ight be that w ith norm al
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d ieta ry  intake, a d m in istering a high dose of ascorbic acid w ill n o tfu rth e r enhance 
the central antio xidant effect. Finally, reactive oxygen m ight not play a role at all 
in the increased sym p athetic nervous system  a ctiv ity  associated w ith chronic 
heart fa ilure in hum ans.
Our stud y has lim itations. There was a clear in tra -in d iv id u a l variation  in m uscle 
sym p athetic burst fre q u e n cy during the tw o treatm ent periods. W hile this is not 
reported from the literature, it does decrease the statistical pow er of the study.31 
The absence of any s ig n ifica nt change could therefore be interpreted as a typ e I 
statistical error. However, the absolute m eans were v irtu a lly  identical during 
vitam in C and during placebo, rendering this possibility highly unlikely. In addition, 
we calculated the m axim al possible betw een group difference for the effect of 
ascorbic acid on sym p athetic activity, using the values of variation  found in our 
study. Based on our values the m axim al potential betw een group difference was 
12.8  b u rsts/10 0  beats, w hich is less than the 2 0 %  reduction considered statistical 
sig n ifican t. Increasing our sam ple size w ould o n ly further reduce variation and 
therefore no statistical significant effect should be expected. Unlike the conditions 
in anim al studies, our patients used different m edicatio ns that m ight have 
influenced sym pathetic activ ity  and co nfounded the results. A C E -in h ib ito rs and 
statins m ay suppress central sym pathetic activ ity.1620 B eta-b lockers have been 
proven to affect HRV.3233 All patients, however, were on identical m edication 
during ascorbic acid and p lacebo treatm ent, and it w ould p robably be considered 
unethical to stud y patients off m edication.
In co nclusion, we show  that adm in istration  of ascorbic acid in CHF patients for 
a period of 3 days has no effect on sym pathetic a ctiv ity  as m easured by m icro ­
neurography, HRV and plasm a norep inep h rin e  levels. It rem ains possib le that 
prolonged adm in istration  of ascorbic acid could have resulted in an effect on 
central sym pathetic activity, although the pharm acological profile does not make 
this likely. Using higher oral dosages does not seem to be feasible, as accom panying 
s id e-effects w ill lim it c lin ical app lica b ility .
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CHAPTER 7
Abstract
Background Alpha-adrenergic receptor mediated vasoconstriction might underlie 
the insulin resistance seen in conditions associated with increased sympathetic 
tone, like chronic heart failure (CHF). Alpha-adrenergic receptor blockade by 
phentolamine could improve forearm blood flow (FBF) and forearm glucose 
uptake (FGU) in CHF patients.
Methods In eight CHF patients and 12 healthy volunteers FBF (plethysmography) 
and FGU were measured in both forearms during a 150 minutes hyperinsulinemic 
euglycemic clamp procedure. During the final 30 minutes of the clamp, 
phentolamine was infused into one arm at a dose of 5.0 microgram/min per dL of 
forearm volume.
Results Insulin infusion (t=0-120 min.) increased FGU in the two groups, without 
affecting FBF. In the CHF-group, a-adrenergic receptor blockade by phentolamine 
(t=120-150), further increased FGU in the experimental arm from 3.0±0.7 to 5.0±0.9 
lamo^min'^dL'1 (P=0.03). FGU in the contralateral forearm remained unchanged. 
In the control group, phentolamine infusion did not increase FGU in the 
experimental forearm. The increase in blood flow in response to phentolamine 
was similar in both groups (CHF: 2.1 ±0.3 to 7.5±1.7 mL*min'1*dL'1, P<0.001; controls 
1.5±0.2 to 5.5±0.8 mL*mm'1*dL'1, P<0.001 for both, CHF vs. control, P=0.2). 
Phentolamine did not affect FBF in the control arm in either group.
Conclusion Alpha-adrenergic receptor blockade improves forearm glucose uptake 
in CHF patients. As the increase in FBF is similar in controls and CHF patients, this 
might be explained by an improved glucose extraction capacity in CHF patients.
ALPHA-ADRENERGIC RECEPTOR BLOCKADE AND GLUCOSE UPTAKE
Introduction
Sympathetic nervous system activity is increased in chronic heart failure (CHF).1 
One of the consequences of high sympathetic tone is a reduction in skeletal 
muscle blood flow by a-adrenergic vasoconstriction. With the reduction of 
skeletal muscle perfusion, tissue delivery of glucose and insulin is also reduced 
(reduced nutritive flow).2 Muscle glucose uptake depends on the amount of 
glucose delivered to the tissues and the fraction of glucose extracted.3 If vasocon­
striction mainly occurs in the capillary compartement of the muscle, in addtion to 
the reduction inflow, the ability to extract glucose is reduced. So, by counteracting 
the a-adrenergic system, skeletal muscle perfusion and nutritive blood flow may 
be improved, ultimately resulting in a stimulation of skeletal muscle glucose 
uptake and a reduction in insulin resistance.
This hypothesis was tested by investigating the effect of a-adrenergic receptor 
blockade by phentolamine on forearm skeletal muscle blood flow and forearm 
glucose uptake in CHF patients. Results were compared to those obtained in 
normal controls.
Methods
Participants
Two groups of subjects were included in the study. The first group consisted of 8 
patients diagnosed with CHF according to the modified Framingham Clinical 
Criteria for the diagnosis of heartfailure (CHF-group).4 Inclusion criteria were: CHF 
severity between NYHA 11 - IV, left ventricular ejection fraction (LVEF) < 40% as 
assessed by 2D echocardiography, age ranging between 18 and 75 years. A second 
group consisting of 12 non-matched normal healthy subjects (normal-group) 
which met the following criteria: no relevant medical history, non-smoking, no 
medication (oral contraceptives were allowed), body-mass index 18-26 kg/m2, 
blood pressure below 140/90 mmHg, normoglycemia and a negative family 
history for diabetes.The following exclusion criteria were defined for both groups: 
chronic disease of the autonomic nervous system, diabetes mellitus, use of 
tricyclic antidepressant drugs, a  -adrenergic receptor antagonists or (3-adrenergic 
receptor antagonists with a  -adrenergic receptor antagonizing properties. The 
study complied with the declaration of Helsinki, was approved by the institutional
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review committee and informed consent was obtained from all patients before 
participation in the study.
Study protocol
Experiments were conducted at 8.30 AM after an overnight (10-hour) fast with the 
patient in supine position in a quiet, temperature-controlled room (23 -  24 °C). 
Subjects had to abstain from caffeine, tea, alcohol, chocolates and smoking for at 
least 12 hours prior to the test procedure. All experiments were carried out after 
voiding to prevent reflex sympatho-excitation. Forearm volume of both arms was 
measured prior to the experiment by water displacement technique. A catheter 
(Angiocath: 20-gauge, 48 mm, Becton Dickinson and Co., Sandy, Utah) was 
inserted under local anesthesia (lidocaine 2 %) into the brachial artery of one of 
the arms to obtain arterial blood samples and for intra-arterial infusion of 
phentolamine. The brachial artery catheter was connected to an arterial pressure 
monitor (Hewlett Packard 78353B monitor, Hewlett Packard GmbH, Boblingen 
FRG) for continuous blood pressure monitoring. This arm was defined as the 
experimental arm and consequently the contralateral arm was defined as the 
control arm. In both arms, a catheter (Venflon: 18-gauge,45 mm, Becton Dickinson, 
Helsingborg, Sweden) was inserted retrogradely into a deep forearm vein for 
blood sampling. Arteriovenous difference in blood glucose (GluA_v) was calculated 
for the experimental arm and the control arm. Finally, a catheter (Venflon: 
18-gauge, 45 mm, Becton Dickinson, Helsingborg, Sweden) was inserted into a 
vein on the dorsal side of a foot for the infusion of insulin and glucose 20%. This 
experimental set-up allowed us to measure GluAV and calculate FGU from the 
product of GluA and FBF, both at the intervention and at the control side. Heart 
rate was determined from an electrocardiographical signal. Blood pressure was 
measured intra-arterially. After complete instrumentation, 30 minutes of rest were 
included before baseline measurements including FBF, GluA V, plasma insulin level 
and hematocrit were performed. Hereafter the hyperinsulinaemic euglycemic 
clamp was started. Forearm blood flow (FBF) was measured using venous occlusion 
plethysmography. Measurements were performed at 30 minute intervals during 
the first 120 minutes of the clamp and a 15 minute interval during the last 30 
minutes (phentolamine infusion).
a. Forearm  blood flow
Forearm blood flow (FBF) was measured in both arms using venous occlusion 
plethysmography with mercury-in-silastic strain gauges placed at the upper third
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of the forearm  and a H okanson EC-4 P lethysm ograph. The arm was slightly 
elevated (10 cm) above heart level to ensure rapid recovery of forearm  volum e 
after deflation of the upper arm cuffs. One m inute before the start of the 
m easurem ents, a w rist cuff is inflated to 100 m m Hg above systolic blood pressure 
to exclude blood flow  to the hands. Venous outflow  from  the forearm  is prevented 
by the placem ent of a cuff around the upper arm using an inclusio n  pressure of 
40 m m Hg (E-20 Rapid Cuff Inflator, Hokanson). At least six co nsecutive FBF 
m easurem ents were perform ed in 2 m inutes and were averaged to a single 
value.
b. H y p e r in s u lin e m ic  e u g ly c e m ic  c la m p
Forearm  glucose uptake was m easured during a h yp erinsu lin em ic eug lyce m ic 
clam p procedure of 150 m inutes.5 Insulin (A ctrapid, N ovoN ordisk, D enm ark; 
d iluted in NaCI 0.9%  to a concentration of 1 U-ml'1, w ith the addition  of 2 ml w hole 
blood per 50 ml) was infused at a rate of 60 m U -m in'1-m'2 bo d y surface area (430 
p m ol-m in'1-m'2). Arterial plasm a glucose determ inations were perform ed at 5 -m in  
intervals, m easured in d up licate by the g lucose oxidation m ethod (Beckm an 
G lucose A nalyser II, Beckm an, Fullerton, CA, USA). Plasm a glucose was clam ped at 
the fasting level by a variab le  infusion of glucose 20%  solution. Blood sam ples for 
m easurem ent of insulin concentrations were collected in tubes containing lith ium - 
heparin and stored on ice. Plasma insulin was assessed by radio im m unoassay (RIA) 
using 125 l-la  be led hum an insulin  and an ti-h u m a n  insulin  antiserum  raised in 
guinea pigs. Bound and free tracers were separated by sheep a n ti-g u in e a  pig 
antiserum ; hum an insulin  (Novo Biolabs, C o p en h ag e n, Denm ark) was used for 
standards. The interassay co efficient of variation  (CV) for the insulin  m easurem ent 
was 10.3%  at a level of 20.7 m U/L.
c. F o re arm  g lu co se  u p ta ke  (FGU)
Forearm  glucose uptake (FGU) was calculated as FBF (m l/m in/d L  tissue) tim es the 
forearm  G lu A V (m m ol/L). M atched arterial and veno us blood sam ples from both 
arm s were collected every 30 m inutes for ca lculatio n  of arteriovenous glucose 
gradients. During the intra-arterial phentolam ine adm inistration, the arteriovenous 
glucose gradient were determ ined at 15 and 30 m inutes after start of substrate 
infusio n. Arterial plasm a glucose determ inations were m easured in d up licate by 
the g lucose oxidation m ethod (Beckm an G lucose A nalyser II, Beckm an, Fullerton, 
CA, USA).
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d. Intra-arterial phentolam ine infusion
Phento lam ine 5.0 m icrog r/m in  per dL of forearm  vo lu m e was infused intra- 
arteria lly  for 30 m inutes by an autom atic infusion pum p. Infusion started after a 
120 m in. h yp erinsu lin em ic eug lyce m ic clam p. Th e dose of p hento lam ine infused 
into the brachial artery was chosen to act se lective ly in the experim ental forearm  
w itho ut causing system ic effects. In previous experim ents no s ig n ifica nt changes 
in heart rate or blood pressure were seen after infusion of this dose of phentolamine 
for 30 m inutes ("unpublished"). To exclude a possib le effect of the 0,9 %  saline 
infusion on forearm  glucose uptake, ve h ic le  infusion in the experim ental arm 
started at the sam e tim e and at the sam e infusion rate as during the clam p 
procedure.
Statistical analysis
Data are expressed as m ean±SEM  unless ind icated otherw ise. To assess treatm ent 
and tim e effect, repeated m easurem ents ANOVA analysis was used. Differences 
betw een the group of healthy volunteers and CHF patients regarding the effect of 
insulin  and p hento lam ine on FGU were tested using the General Linear Model 
repeated m easures fu nctio n  of the SPSS 16.0 softw are package. Betw een group 
differences in (baseline) characteristics were assessed by unpaired Student's t-test 
or M an n-W h itn ey U test as appropriate. W ithin group co m parison was perform ed 
using paired sam ples Student's t-test or W ilcoxon Rank test for not norm ally 
d istributed data. P  < 0.05 was considered statistically  sign ificant.
Results
Com parison o f heart failure (CHF-group) with the healthy controls
Baseline characteristics are show n in table I. In the C H F-g ro u p  all patients had 
ischem ic heart failure, w ith a m ean NYHA class of 2.8± 0.2. All patients used an 
ACE-inhibitor or an Angiotensin II receptor antagonist, 7 patients used (3-adrenergic 
receptor antago nists (atenolol n = 3, m ean dose 82±29 mg per day; m etoprolol 
n = 4, m ean dose 78±43 mg per day), 7 patients used d iuretics, 7 patients used 
aspirin, and 5 patients used statins. Mean fasting plasma glucose level at baseline 
was sign ificantly higher in the C H F-group as com pared with controls, 6 .4± 0.6 vs. 
5.0± 0.3 m m ol/L (P<0.05). As expected, steady state (90-120 min) glucose infusion 
rate (GIR) was sign ificantly lower in the C H F-group (23.4± 4.5 vs. 37.3± 3.05 |amol kg‘ 
'•min-1, P = 0.02). Insulin se n sitiv ity  index at steady state was 43 .2± 9.8 for the
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T a b le  1 Baseline characteristics
Variable CHF Control
(n=8) (n=12)
Age (years) 61 ±10 20±1
Sex (male/female) 6/2 6/6
BMI (kg/m2) 28.1±7.5 22.1±1.3
Fasting blood glucose (mmol/L) 6.4±1.6 5.0±0.3
GIR (|.imol*kg '*min ') 23.4±12.6 37.3±10.6
ISI 43.2±27.8 65.5±15.3
BMI = Body mass index; GIR = glucose infusion rate; ISI = insulin sensitivity index.
T a b le  2 CHF: base line e ch o card io g ra p hic data
Parameter Value (±SD)
EF (%) 29±9
LVIDd (mm) 58±8
RVIDd (mm) 33±4
LVESV (ml) 107+79
LVEDV (ml) 150±44
E/A 0.9±0.3
S/D 1.5±0.7
EF = ejection fraction; LVIDd = diastolic le ft ventricle internal diameter;
RVIDd = diastolic righ t ventricle internal diameter; LVESV = le ft ventricle end-systolic
volume; LVEDV = le ft ventricle end-diastolic volume; E/A = m itral valve E/A ratio;
S/D = pulmonary vein S/D ratio.
C H F-g ro u p  and 65.5± 4.4 for controls (P = 0.03), ind icatin g  insulin  resistance in the 
C H F-g ro u p . For both groups (experim ental versus control) m ean baseline FGU did 
not differ s ig n ifica n tly  betw een the two forearm s (CH F-g ro up; 0.51 ± 0.37 for the 
experim ental arm versus 0 .57± 0.26 lam o ^m in'^dL'1 for the control arm , (P =0.3) 
and controls; 0.49± 0.07 for the experimental arm vs. 0.44± 0.14 lam o^m in'^dL'1 for 
the control arm (P=NS).
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Effects o f  insulin alone
In response to 120 m in. of insulin  infusion, FGU was eq u ally  increased in the two 
groups (figure 1). Forearm glucose uptake reached a stable level betw een 90 and 
120 m in of c lam p in g. Mean FGU in the experim ental arm during insulin  was slightly 
low er in the control group as com pared w ith the CH F group (CHF: 3 .0± 0.8 versus 
control: 2 .6± 0.4 lam o ^m in'^dL'1, P = 0.2), but as is clear from  the analyses, this is 
not statistically  s ign ificant. The increase in FGU was m ain ly explained by a 5-6 fold 
increase in G lu A V in response to insulin  infusion (figure 2). Insulin infusion for 120 
m inutes had no effect on FBF (figure 2), b lood pressure or heart rate in either 
group. Baseline FBF was sim ilar betw een both groups and both arms.
FG U -C H F
FGU - Controls
Figure 1
Forearm glucose uptake (FGU) in the CHF group (top) and in healthy controls (bottom) 
during the hyperinsulinemic clamp procedure before and after phentolamine infusion. 
Exp. arm = experimental arm (phentolamine); con. arm = control arm.
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Figure 2
Left: Forearm blood flow  (FBF) in the CHF group (top) and in healthy controls (bottom) 
during the hyperinsulinemic clamp procedure before and after phentolamine infusion. 
Right: Arteriovenous glucose difference (Glua-v) in the CHF group (top) and in healthy controls 
(bottom) at baseline (t=0), before phentolamine infusion (t=120) and after phentolamine 
infusion (t=150). Exp. arm = experimental arm (phentolamine); con. arm = control arm.
Effect ofa-adrenergic receptor blockade on forearm glucose uptake during hyper- 
insulinaemia
After 120 m inutes of h yp erinsu lin em ia, p hento lam ine infusion was started in the 
experim ental forearm . In the C H F-g ro u p , a -a d re n e rg ic  receptor b lockade by 
p hento lam ine (t=120- 150), s ig n ifica n tly  increased FGU in the experim ental arm 
from 3.0± 0.7 to 5.0± 0.9 lam o^m in ^ d L 1 (P =0 .03). There was no change in FGU in 
the contralateral forearm . In the control group, p hento lam ine infusion did not 
increase FGU in the experim ental forearm  (2 .5± 0.4 to 3.0± 0.5 lam o ^m in'^dL'1, 
P = 0.40). M ixed m odel analysis assessing group vs. arm effect, supported the 
observaton that CHF patients had a s ig n ifica nt d ifferential FGU response to 
phentolam ine, w ith a p -va lu e  of 0.01 for interaction. In the C H F-g ro u p , FBF of the
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experimental arm was significantly increased by phentolamine infusion (2.1 ±0.3 
to 7.5±1.7 mL*mm'1*dL'1, P<0.001). However, a similar increase in FBF was found in 
the control group (1.5±0.2 before phentolamine infusion vs. 5.5±0.8 mL*min'1*dL'1 
after phenotolamine infusion, P<0.001). Phentolamine did not affect FBF in the 
control arm in either group.
Phentolamine infusion and the inherent increase in FBF further reduced GluAV 
in the experimental arm of both groups (CHF-group: 1.72±0.39 to 0.63±0.08 
mmol/L; controls 1.96±0.24 to 0.80±0.20 mmol/L). However, in the CHF-group the 
decrease in GluAV in the experimental arm did not fully counterbalance the 
increase in FBF, resulting in the significant increase in FGU in the experimental 
arm after phentolamine infusion. This was not the case in the control group. 
Phentolamine did not increase FGU in the controls.
In the given concentrations, intra-arterial infusion of phentolamine did not 
affect hemodynamic parameters in either group, suggesting the absence of a 
significant systemic hemodynamic effect. Steady state glucose levels and plasma 
insulin concentrations before and during phentolamine infusion were similar 
(data not shown). Glucose infusion rate (GIR) in the CHF group was 4.25±0.81 
mg*kg'1*min'1 (90-120 min) before phentolamine versus 4.59±0.71 mg*kg'1*min'1 
(120-150 min) after phentolamine, p=0.11. Insulin sensitivity index was the same 
before and after phentolamine infusion (43.2±9.8 versus 45.8±9.0, P=0.45). For the 
control group, GIR before phentolamine infusion was 6.79±0.56 mg*kg'1*min'1 
(90-120 min) and similar to after phentolamine infusion 7.18±0.55 mg*kg'1*min'1 
(120-150 min), P=0.63. Insulin sensitivity index was the same before and after 
phentolamine infusion, 65.5±4.4 vs. 66.1±4.8, respectively, P=0.92.
Discussion
The present study demonstrates that a-adrenergic receptor blockade increases 
insulin-induced forearm skeletal muscle glucose uptake in CHF patients. This 
increase in glucose uptake is the result of an obvious increase in forearm blood 
flow, which was not offset by a drop in glucose extraction. A similar increase in 
blood flow in normal healthy volunteers by a-adrenergic receptor blockade does 
not increase FGU, as this is fully counterbalanced by a drop in the arteriovenous 
glucose gradient.
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In literature, there is a well established association betw een insulin  resistance 
and card io vascular d isease.6'8 In CHF the high a ctiv ity  of the sym pathetic nervous 
system , m ay be one of the explanatio ns. Increased plasm a no rep inep h rin e  levels 
have been show n to reduce glucose to lerance and induce insulin  resistance. There 
are a n um ber of potential m echanism s by w hich the SNS could interact w ith 
insulin  sensitivity. At the system ic level, increased sym p athetic nervous a ctiv ity  
m ay induce lipo lysis (leading to increased fatty acid concentrations) and increase 
basal hepatic glucose output.9'11 A drenergic receptor stim ulatio n m ay also 
influence the in su lin -s ig n a lin g  pathw ay or glucose uptake at the cellu lar level.12'14 
As there is evidence that the a b ility  of insulin  to increase m uscle glucose uptake is 
partly due to its a b ility  to increase blood flow, an alternative explanation is that 
SNS a ctiv ity  m odifies skeletal m uscle glucose uptake by influ en cin g  skeletal 
m uscle nutritive flow .1516 Th is p o ssib ility  is reasonable as sym pathetic nerve 
a ctiv ity  im p o rtantly contributes to the regulation of blood flow .217 A ltho ug h 
rem ain ing partly controversial, several studies have suggested that part of the 
stim ulato ry effect of insulin  on g lucose uptake is m ediated by its a b ility  to induce 
vaso d ila tio n .18 Glucose uptake is determ ined by the product of arteriovenous 
difference and g lucose delivery. Thus an increase in blood flow , by enhancing 
glucose delivery, m ay increase total g lucose uptake. Th is is o n ly true if the increase 
in blood flow  is acco m p anied by an increase in m icrovascular perfusion ,18 Som e 
vaso dilato rs, such as n itroprusside, m ain ly increase blood flow  by opening 
arterio veno us shunts, w hich is not accom panied by an increase in m icrovascular 
perfusion.19 On the other hand, the m icrovascular perfusion m ay be stim ulated 
w itho ut m ajor effects on total blood flow.
In the present study, phentolam ine, an a -a d re n e rg ic  receptor antagonist, 
stro ng ly increased skeletal m uscle blood flow  (FBF). The increase in blood flow  
m ay occur in tw o-w ays. A lp h a-ad re n e rg ic  receptor blockade could counteract 
ca p illary  vaso co nstrictio n  and hence im prove skeletal m uscle ca p illa ry  perfusion 
("capillary recruitm ent"). Such an increase in m icrovascular perfusion w ould 
enlarge the availab le  endothelial surface for glucose exchange and an increase in 
perfusion w ill then be acco m p anied by a m uch less pronounced fall or even 
increase in glucose extractio n.20 On the other hand, under co nditio ns of uniform  
ca p illary  perfusion (the 'n o n cap illa ry  recruitm ent m odel') and a fixed degree of 
cellu lar p e rm e ab ility  to glucose, an increase in perfusion w ould be accom panied 
by a largely co m pensato ry fall in glucose extraction w ith little or no effect on 
glucose uptake. In our study, the a -a d re n e rg ic  receptor b lo cking effect of
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phento lam ine on FGU was obvious in CH F patients, w hereas it was absent in 
healthy controls, sup p o rtin g  ca p illa ry  recruitm ent in CHF. Th e present fin d in g s 
suggest that a m ore pronounced skeletal m uscle a -a d re n e rg ic  receptor-m ediated 
ca p illa ry  vaso co nstrictio n  m ight be present in CHF. U nfortunately, currently 
a p p lica b le  m ethods to m easure skeletal m uscle blood flow , like the p leth ysm o g ­
raphy used in our study, cannot d istin g u ish  betw een increases in nutritive flow  
and n o n -n utritive  flow . M ethods to q u an tify m icrovascular perfusion are not 
su itable  to be used in hum an subjects, d ifficu lt to be used for a prolonged 
experim ental period, or have a poor inte r-in d iv id u al rep ro d ucib ility , rendering 
them  less suited for co m parison betw een groups.18
The fin d in g  that acute pharm aco lo gica l sym p athetic b lockade does not have 
an effect on skeletal m uscle glucose uptake in healthy, insulin  sensitive in d iv id u als 
is in accordance w ith literature.2122 Regarding the effect of a -a d re n e rg ic  receptor 
blockade in co nditio ns associated w ith high sym p athetic tone, results are 
co nflicting . A num ber of studies, assessing the effect of carved ilo l and doxazosine 
on g lucose uptake in hypertension and CHF patients w ith or w itho ut diabetes 
fo und no effect on insulin  sen sitiv ity.2324 Others, however, have reported an 
im pro vem ent in g lycem ic control.25 In a CO M ET substudy, co m paring the effects 
of m etoprolol and carved ilo l on p re-ex istin g  and new onset diabetes in patients 
w ith CHF, researchers found that new onset diabetes is m ore likely to occur during 
treatm ent w ith m etoprolol than during treatm ent w ith ca rve d ilo l.26 The present 
stud y is the first in w hich effects of intrabrachial infusion of p heno to lam ine was 
m easured in insulin  resistant CHF patients.
C o n flictin g  results have been reported regarding the effect of a h yp e rin su lin e - 
m ic e u g lycaem ic clam p itself on FBF and ca p illary  recruitm ent.2728 In our study 
insulin  did not affect FBF, neither in the CHF patients nor in healthy controls. W hile 
absence of vaso d ilatatio n  w ould be expected in CHF, as it is an insulin  resistant 
state, several, but not all studies have reported vaso d ilatatio n  in healthy co ntro ls.29 
The fact that blood flow  did not increase, however, does by no m eans exclude an 
in su lin -in d u ce d  increase in skeletal m uscle nutritive flow .30 Several investigators 
inclu d in g  ourselves have dem onstrated by various te chniq ues insulin's a b ility  to 
prom ote ca p illary  recruitm ent in m uscle.2031
The CH F group differs from  the controls in m edication use, age and BMI. 
A C E -in h ib ito rs and statins do not effect or im prove insulin  sensitivity, w hereas
120
A LPH A -A D R EN ER G IC  REC EPTO R BLO C K A D E  AN D  G LU C O SE  UPTAKE
th iazides and (3-b lo c k e rs  decrease insulin  sen sitiv ity.3233 B eta-b lockers have been 
im plicated in altering glucose hom eostasis, p rim arily  through inh ib itio n  of 
pancreatic insulin  secretion and prom oting insulin  resistance. B -b lo ckers w ith a 
vaso d ila to ry effect (e.g., nevibo lo l and carved ilo l), however, appear to m in im a lly  
affect glucose hom eostasis. In our stud y CHF patients were m ore insulin  resistant 
than controls. The subjects in the C H F-g ro u p  were older and had a h igher BMI. 
O b esity has show n to affect the interaction betw een insulin, haem o d yn am ics and 
autonom ic control. Physio lo gical h yp erinsu lin em ia  causes sym pathetic shift of 
autonom ic balance, and a h ig h -o u tp u t, low -resistance h em o d ynam ic state. In the 
obese, these changes are a lready present in the basal state, and are therefore 
linked w ith chronic h yp e rin su lin e m ia .34 In our study this should have lim ited the 
vaso dilato r effect of phentolam ine. Basal flow  and vaso d ilatatio n  how ever was 
sim ilar to controls. Hum an aging is associated w ith a reduction in forearm  
p o stjunctio nal a -a d re n e rg ic  responsiveness to en d o g eneo us no rep inep hrine, 
w hich m ight be specific to a ,-a d re n e rg ic  receptors. Furtherm ore, the co ntributio n 
of sym p athetic a -a d re n e rg ic  vaso co nstrictio n  to basal forearm  vascular tone is 
reduced w ith age in healthy m en.35 In our stud y the relatively o lder CHF populatio n 
dem onstrated a larger vaso dilato r effect of a -a d re n e rg ic  receptor blockade as 
com pared w ith controls. A pparantly, this is due to the co nditio n  of heart failure 
rather than to age.
A h ig her BMI is associated w ith a s lig h tly  h ig her FBF, explained by a 
h yp erd yn am ic circulatio n  and a slig htly  lower vascular resistance.36 Data on 
glucose extraction are m issing in these studies. Therefore, we can not rule out 
that the h ig her BMI in the C H F-g ro u p  contributes to the specific fin d in g s on 
p hento lam ine in these patients.
The fin d in g  that b lockade of peripheral a -a d re n e rg ic  receptors im proves 
skeletal m uscle glucose uptake e sp ecia lly  in the insulin  resistant CHF group m ight 
have clin ical relevance. W hether m ediated by d irect cellu lar effects or by an effect 
on skeletal m uscle perfusion, a -a d re n e rg ic  b lockade m ay reflect a beneficial 
intervention in insulin  resistance associated w ith CHF. U nfortunately, use of 
a -a d re n e rg ic  receptor antago nists is associated w ith s ig n ifica nt side effects such 
as orthostatic hypotension and in long-term  studies in hypertension has not been 
associated w ith a beneficial outcom e (ALLHAT).37 Th e results of the present study 
do support the use of carvedilol, a b eta-b lo cker w ith a lp h a-an ta g o n istic  properties 
in patients w ith chronic heart fa ilure and hypertension.
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In sum m ary, a -a d re n e rg ic  receptor b lockade by p hento lam ine increases 
forearm  skeletal m uscle glucose uptake in CHF patients, as a result of an obvious 
increase in forearm  blood flow  accom panied by a m ore effic ient g lucose uptake. 
T h is effect of a -a d re n e rg ic  receptor b lockade m ight be explained by restoration 
of ca p illary  recruitm ent, and did not occur in insulin  sensitive healthy ind iv id u als.
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CHAPTER 8
Abstract
Backg ro un d  Systemic insulin infusion elicits vasodilation in and increased sympathetic 
outflow to skeletal muscle. Sympathetically-m ediated vasoconstriction could offset 
in su lin -in d u ce d  vaso d ilatio n . If so, then b lockade of sym p athetic p o st-g a n g lio n ic  
outflow  should aug m ent the vaso d ilato r effect of insulin . Because vaso d ilatio n  
supports insulin-induced glucose uptake, sym pathetic blockade m ight also increase 
insulin  sensitivity.
M e th o d s  Six norm al volunteers underw ent g ang lio n  blockade produced by i.v. 
infusion of the NN-n ico tin ic  receptor blocker trim ethap han for 60 m in. On a 
separate day, in the sam e subjects, a h yp e rin su lin e m ic eu g lyce m ic clam p was 
perform ed for 180 m in, w ith trim ethap han co -infuse d  during the last 60 m in. 
Eight other subjects underw ent o n ly the clam p for 180 min.
R e su lts  NN-n ico tin ic  receptor b lockade decreased arterial and forearm  venous 
no rep inep h rin e  levels, total bo d y and forearm  no rep inep h rin e  spillovers 
(m easured using 3H -no rep inep hrine), and forearm  vascular resistance. D uring the 
clam p, trim ethaphan decreased both forearm  resistance and d iastolic blood 
pressure m ore than did trim ethaphan alone (by 59 ±  8 vs. 29 ±  6 % , and by 17 ±  4 
vs 5 ±  3% ,  both P <0 .05). W hole bo d y and forearm  glucose uptake increased 
s ig n ifica n tly  during autonom ic blockade.
C o n c lu s io n  Sym pathetic p o st-g a n g lio n ic  b lockade unm asks a potent vaso dilato r 
effect of insulin  in hum ans and increases insulin  sensitivity.
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Introduction
System ic h yp erinsu lin em ia  increases skeletal m uscle blood flow  by 20 - 60%  
g ra d ua lly  over the course of hours.12 Because tissue extraction and blood flow  
both determ ine glucose uptake (Fick's principle), the vaso d ila tio n  elicited by 
insulin  can itself aug m ent the stim ulato ry effect of insulin  on glucose uptake.3 In 
response to system ic insulin  infusion, however, arterial and venous plasm a 
n o rep inep h rin e  (NE) concentrations, total bo d y and forearm  NE spillovers, and 
d ire ctly  m easured skeletal m uscle sym p athetic neural outflow  all increase.4'9 One 
of the co nsequences of high sym pathetic tone is a reduction in skeletal m uscle 
blood flow  by alpha -a d renerg ic vaso co n strictio n . W ith the reduction of skeletal 
m uscle perfusion, tissue d e live ry of g lucose and insulin  is also reduced (reduced 
nutritive flow).1011 By this w ay the co nsequent increase in sym p athetic activ ity  
m ay lim it the in su lin -in d u ce d  vaso d ila tio n  and its beneficial effect on glucose 
uptake.
The sym p athetic activation m ay occur by several m echanism s, one of w hich is 
via inh ib itio n  of baroreflexes as a co nsequence of in su lin -in d u ce d  vaso d ilatio n . 
Consistent w ith this suggestion, im paired in su lin -in d u ce d  vaso d ila tio n  occurs 
to gether w ith im paired in su lin -in d u ce d  sym p athetic activation in o besity and 
after dexam ethasone adm in istratio n .1213 Som e evidence ind icates the converse 
that sym p athetic activation in h ib its in su lin -in d u ce d  glucose uptake and thereby 
ind uces a state of insulin  resistance. In heart fa ilure (CHF) there is a well 
estab lished  association betw een increased sym p ath etic  a ctiv ity  and insulin  
resistance.1014 O rthostatic stress (e.g., low er bo d y negative pressure) produces 
insulin  resistance in forearm  skeletal m uscle, and m ental stress produces insulin 
resistance in patients w ith typ e 1 d iabetes.1516 Sym pathetic activation  m ay 
therefore not only offset the vaso dilato r effects of insulin  but also decrease insu- 
lin -in d u ce d  glucose uptake.
To exam ine these possib ilities m ore directly, we m easured the effects of insulin  
infusion on forearm  vascular resistance and glucose uptake in norm al volunteers, 
w itho ut and w ith concurrent b lockade of p o st-g a n g lio n ic  autonom ic outflow s 
using the NN-n ico tin ic  receptor blocker, trim ethap han.17
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Methods
Subjects
A total of 14 healthy subjects (9 m en, 5 w om en) were studied at the National 
Institutes of Health in the US (n=6) and at the U niversity Hospital in N ijm egen, The 
N etherlands (n=8). Th eir m ean age (±SD) was 31 ±  14 years, office sup ine blood 
pressure 122± 12 / 76 ± 10 m m H g , and bo d y mass index 23.2 ±  2.0 kg /m 2. The two 
groups did not differ s ig n ifica n tly  in valu es for these param eters. All subjects had 
a norm al m edical h istory and physical exam ination and gave w ritten inform ed 
consent to participate in the protocols, w hich were approved by the Institutional 
Review  Board of the National Institute of N euro lo gical D isorders and Stroke, or by 
the U niversity Hospital N ijm egen, The N etherlands. Experim ental Procedure (see 
Flow  D iagram , Fig 1).
All subjects underw ent insertion of a brachial arterial catheter, after local 
anesthesia of the overlying skin. E lectro card io g rap h ic leads w ere attached. 
C ard io tacho m eter m easurem ents of b eat-to -b ea t heart rate w ere recorded. 
V eno us catheters were inserted into a deep forearm  vein in each arm; proper 
position was verified  by palpation. Forearm  blood flow  (FBF) was m easured by 
stra in -g au g e  venous occlusio n p leth ysm o grap h y at the n o n -ca nn u la ted  side. For 
each tim e point, 6-8 flow s were m easured using an autom ated data acquisitio n 
system . D uring FBF m easurem ents, hand circulatio n  was excluded by inflation of 
w rist cuffs to su p rasysto lic  pressure. A rterial blood for g lucose levels was 
obtained at 5-m in  intervals during the clam ps, and venous sam ples for blood 
glucose m easurem ents were obtained (with inflated w rist cuff) every 30 min 
(0-120 min) or 15 m in (120-180 min).
Group I: Six subjects underw ent ganglion blockade with i.v. trim ethaphan (TRI, 
Roche Laboratories, Nutley, NJ) on 2 separate test days (figure 1). After placem ent 
of catheters, [^H ]-n o rep in ep hrine  (levo-[2,5,6]-^ H -n o re p in e p h rin e , New England 
Nuclear, Boston, MA) was infused i.v. at a rate of 0.75 |iC i/m in . After at least 20 min, 
b lood was sam pled from the artery and the antecubital ve in .18 Trim ethaphan 
(2 m g /m L norm al saline) was then infused i.v., b e g in n in g  at a rate of 15 m L/hour, 
until sym ptom s and signs of g ang lio n  blockade were attained, as the [^H ]-nore- 
p ine p h rine  infusion co ntinued. S igns of g ang lio n  blockade were a d ry m outh, 
nasal stuffiness, co nju nctival vaso d ilatio n , and an increased and constant pulse 
rate.17 The infusion of trim ethaphan was co ntinued for at least 15 m in at the dose 
p ro ducing g ang lio n  blockade. D iastolic arterial pressure was allow ed to decrease
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by a maximum of 10 mm Hg. Arterial and venous forearm blood samples were 
then taken again.
On the second test day, after the same setup, [^H]-norepinephrine was infused, 
and after 20 min, blood samples and hemodynamic measurements were obtained. 
The infusion of [^H]-norepinephrine was discontinued. Then insulin was infused 
at 60 mU/m2/min (360 pmol/m2/min), for 180 min. Glucose 20% W/V was infused
i.v. at a variable rate to maintain euglycemia. After 100 min, [^H]-norepinephrine 
was started again and continued until the end of the study. After 120 min of the 
insu I in/glucose infusion (I NS120'), blood samples and hemodynamic measurements 
were taken. As the insulin/glucose infusion continued, trimethaphan was infused 
for 60 min, at the same dose and for the same duration as on the first study day. A 
final set of blood samples and hemodynamic measurements was obtained 
(INS+TRI). All subjects were studied in the same order, because the amount of 
trimethaphan needed to obtain ganglion blockade varies among individuals, and 
needed to be assessed in the first experiment.
Group 2: Eight sex- age and weight matched subjects underwent a similar 
euglycemic hyperinsulinemic clamp for 180 minutes (INS180'), including insertion 
of an arterial and venous line for hemodynamic monitoring and blood sampling, 
but without ganglion blockade. These subjects were only studied once. At similar 
time intervals, FBF, forearm glucose uptake and whole body glucose infusion were 
measured. Part of the studies (those including [^H]-norepinephrine) were 
performed at the NIH, the rest of the studies at the University Medical Center, 
Nijmegen. All studies were performed by the same investigator.
Laboratory Assays
Glucose was measured using the glucose oxidation method (Beckman Glucose 
Analyzer 2, Beckman Instruments, Fullerton, CA). Arterial and venous plasma was 
assayed for endogenous and ^H-labeled norepinephrine by batch alumina 
extraction and liquid chromatography with electrochemical detection orfraction 
collection and liquid scintillation spectrometry.19
Data Analysis and Statistics
Forearm vascular resistance (FVR) was expressed in units of mm HgmL'dL tissue min, 
called "resistance units" (RU). Forearm glucose uptake was calculated by AGIucos 
eAVx (1-0.3 x Hematocrit) x FBF, where AGIucoseAV was the arteriovenous decrement
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in plasm a glucose, and assum ing w ho le blood g lucose =  (1 -  0.3 x Hem atocrit) x p 
lasm a blood g luco se.20 Forearm no rep inep h rin e  spillover was quantified  from the 
arterial and venous co ncentrations of total and 3H -N E and from forearm  plasm a 
flow .21 Statistical testing included paired f-tests if data m et the criterion of 
h o m o g e n e ity  of variance; otherw ise the n o n -p ara m etric  W ilcoxon test for paired 
observations was used. Statistical sig n ifica n ce  was defined at P<0.05.
Results
Effects o f  NN-nicotinic receptor blockade (TRI)
Trim ethaphan increased FBF s ig n ifica n tly  from 3.2 ±  0.6 to 4.3 ±  0.8 m L/d L /m in  
and decreased FVR sig n ifica n tly  from  33 ±  7 to 22 ±  3 RU (Fig 2). Systolic blood 
pressure decreased from 124 ±  8 to 107 ±  3 mm Hg (Fig 3) w hereas d iastolic blood 
pressure decreased n o n -s ig n ifica n tly  from 66 ±  2 to 63 ±  1 mm Hg. Heart rate 
increased sig n ifica n tly ,fro m  62 ±  3 to 86 ±  5 bpm (Fig 3). Trim ethaphan decreased 
arterial and forearm  veno us n o rep inep h rin e  levels and total bo d y and forearm  
no rep inep h rin e  sp illovers in all subjects (Table 1).
Effects o f  insulin infusion (INS120')
In all subjects, euglycem ia was m aintained throughout the clam p procedure (Fig 4). 
Insulin  co ncentrations during the clam ps were sim ilar in the tw o groups (Fig 4) 
and not affected by g ang lio n  blockade (IN SI20' 599 ±  73 vs INS+TRI 606 ±  69 
pm ol/L). D uring insulin  infusion (n =14), w hole bo d y and forearm  glucose uptake 
increased as expected (Fig 5). After 120 m inutes, FBF was unchang ed com pared 
to baseline (n =14, base line 2.3±  1.2 to 2.5± 1.2 after 120 minutes).
FVR tended to decrease (from 46 ±  7 to 37 ±  7 RU, P = 0.09). D iastolic blood 
pressure decreased s ig n ifica n tly  (from 72 ±  5 to 64 ±  4 mm Hg, P = 0.01), w hereas 
systolic blood pressure did not change. Heart rate increased n o n -s ig n ifica n tly  
from 59 ±  3 to 64 ±  5 bpm . Arterial NE and total body NE spillover tended to 
increase (INS120' vs. Baseline, Table 1). In group 2, insulin  for 180 m inutes did not 
further increase FBF nor caused furhter h em o d ynam ic changes.
Effects of hyperinsulinemia and concurrent NN-nicotinic receptor blockade (INS+TRI) 
G a ng lio n  b lockade decreased FVR s ig n ifica n tly  m ore during insulin  (TRI+INS 
59± 8%  vs 29± 6%  TRI alone, P<0 .03, Fig 2), and vaso dilato r response tended to be 
m ore pronounced during INS+TRI than during TRI alone (P =0.09). D uring INS+TRI,
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Figure 1
Flow diagrams o f the experiments. Abbreviations: TRI=trimethaphan alone; 
INS120'=insulin/glucose infusion for 120 min: INS+TRI=insulin/glucose infusion combined 
w ith trimethaphan infusion i.v.; INS180'=insulin/glucose infusion for 180 min.
Table 1 N orepinephrine K inetic Param eters
TEST DAY 1 TEST DAY 2
BASELINE TRIMETHAPHAN
(TRI)
BASELINE INSULIN 
(INS120')
TRIMETHAPHAN
(INS+TRI)
NEfl 1.10 ± 0.35 0.47 ±0.16* 1.07 ±0.21 1.25 ± 0.20 0.64 ±0.15«
NEV 1.08 ±0.30 0.45 ±0.18* 1.35 ±0.41 1.34 ± 0.31 0.52 ± 0.12+
ANEflv -0.02 ±0.07 -0.02 ±0.03 0.28 ±0.21 0.10 ±0.20 -0.10 ±0.05
FBF 3.18 ±0.55 4.32 ±0.83* 2.20 ±0.29 2.85 ±0.69 7.87 ±0.71*
Arm NE spillover 0.62 ±0.17 0.30 ±0.10* 0.64 ±0.16 0.61 ±0.10 0.19 ±0.18*
Total body NE SO 2.82 ±1.21 1.01 ±0.40* 2.32 ±0.57 2.90 ±0.50 1.59 ±0.43«
Total body 
NE clearance
2303 ± 241 2092 ±150 2119 ± 130 2328 ±75 2440 ±116
(*) P<0.05 TRI vs BL, (+) P<0.05 TRI vs Insulin, (40 P<0.05 TRI alone vs TRI w ith Insulin.
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diastolic blood pressure fell s ig n ifica n tly  m ore than during TRI alo ne (10 ±  2 mm 
Hg, vs 4 ±  2% ) . Changes in HR were sim ilar in the INS+TRI and TRI condition (Fig 3). 
A s during TRI infusion alone, during INS+TRI, arterial and venous norep inep h rin e  
and total bo d y and forearm  n o rep inep h rin e  sp illovers decreased in all sub jects 
(Table 1), but both arterial n o re p ine p h rin e  and total bo d y n o rep inep h rin e  
spillover were sign ificantly higher during INS+TRI than during TRI alone (Table 1). 
The vaso d ilato r response to co m bined INS+TRI was m ore pronounced than 
during insulin  alone. D uring INS+TRI, the rate of g lucose infusion needed to 
m aintain  euglyce m ia, increased su b stantia lly  com pared to insulin  alone (INS180', 
Fig 5). The correlation coefficient betw een the observed decrease in FVR during 
INS+TRI and the increase in w hole bo d y glucose during INS+TRI was very high 
(r=0 .85, P = 0.03). Calcu lated forearm  glucose uptake increased during INS+TRI 
com pared to INS alone (Fig 5).
F o r e a r m  B l o o d  F l o w  ( m L / d L / m i n )
Figure 2
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Forearm blood flow  (top) and forearm vascular resistance (bottom) in response to 
trimethaphan alone (open circles), or trimethaphan combined w ith insulin/glucose infusion 
(filled squares). (*) significant difference between INS+TRI and TRI, (t) P=0.09.
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S y sto lic  B lood P re ssu re
Figure 3
Systolic blood pressure (top), diastolic blood pressure (bottom) and heart rate (right) 
in response to trimethaphan alone (open circles), or trimethaphan combined w ith insulin/ 
glucose infusion (filled squares). (*) significant difference between INS+TRI and TRI.
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Figure 4
Glucose and insulin plasma concentrations during euglycemic hyperinsulinemia, in the 
INS180' (open diamonds), INS120' (open squares), and INS+TRI (filled squares) conditions.
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Glucose Infusion Rate
Forearm glucose Uptake
Time (min)
Figure 5
Glucose infusion rate (GIR) in the INS180' (open diamonds), INS120' (open squares), and 
INS+TRI (filled squares) conditions. (*) significant difference between INS+TRI and INS180', 
(t) significant difference from INS120'.
Discussion
T h e present results ind icate  that b lo ckad e of sym p a th e tic  p o st-g a n g lio n ic  
outflow  unm asks a pronounced vasodilator effect of insulin and augm ents insulin 
se n sit iv ity . W hereas e u g ly c e m ic  h y p e rin su lin e m ia  and trim e th a p h a n  each 
produced sm all increases in FBF and decreases in FVR, the co m bination  elicited 
m arked forearm  v a so d ila tio n . T rim ethap han  alo ne d id  not decrease d iasto lic  
b lood pressure, but the co m b in a tio n  of trim etha p ha n  w ith  h yp e rin su lin e m ia  
produced hypotension in all subjects. Blockade of p o stg a ng lio n ic sym pathetic 
outflo w s also increased the rate of g luco se infusio n  required to m ainta in
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euglyce m ia. Since attained insulin  levels during insu lin /g lu co se  infusion did not 
chan ge as a result of co ncom itant g ang lio n  b lockade, the results ind icate that 
sym pathetic po st-ganglio nic blockade increases insulin sensitivity. Trim ethaphan 
infusion decreased valu es for neuro chem ical ind ices of n o rep inep h rin e  release in 
the forearm  and in the total body, co n firm in g  sym p a th e tic  p o st-g a n g lio n ic  
b lockade, as noted p revio usly by our group and by others.1722
M any studies have noted a vaso dilato r effect of system ic insulin  adm in istration  
in skeletal m uscle in m an however, this has not been a universal f in d in g , and 
studies assessing responses of forearm  blood flow  to brachial intra-arterial 
infusion of insulin  have often reported negative results.1'2'9'2324 The vaso d ilatio n  
m ay depend on the level and duration of h yp erinsu lin em ia. In m ost studies that 
have found a large vaso dilato r action, attained insulin  levels were at or above 
m axim um  p h ysio lo g ic a l v a lu e s. System ic h yp e rin su lin e m ia  o n ly  g ra d u a lly  
increases skeletal m uscle blood flow, w ith vaso d ilatio n  often not apparent until 
60-90 m in insulin  infusio n.29 The p hysio lo g ical relevance, if any, of in su lin - 
ind uced vaso d ila tio n  therefore has also incited controversy.2527 The present 
results provide a potential explanatio n for w hy previous studies have not alw ays 
agreed about w hether system ic insulin  acts as a vasodilator. In subjects with 
intact baroreflexes, recru itm en t of sym p a th e tic  outflo w s co uld  buffer the 
d ire c t-in su lin  ind uced  v a so d ila tio n . Conversely, interference w ith reflexive 
increases in sym p athetic outflow s, w hether as a result of a drug or a disease 
process, w ould lead to m ore clear ev idence of in su lin -in d u ce d  vaso d ilatio n .
G lucose uptake depends not o n ly on cellular m echanism s for transm em brane 
entry of glucose, w hich insulin  receptors in skeletal m uscle activate, but also on 
d e live ry  of g lucose to the cells by w ay of blood perfusion.1128 V aso dilatio n  from 
any cause— inclu d in g  from insulin  itself— m ay therefore prom ote tissue uptake 
of glucose. Studies, however, have disagreed m arkedly on this point.1'2 29 In the 
present study, insulin  elicited a larger increase in calculated glucose uptake 
during concurrent g a n g lio n ic  b lockade than in the setting of intact p o st-g a n g li- 
onic sym p athetic outflow s. A ttained insulin  plasm a levels were the sam e in the 
tw o co nditio ns. Thus, unless NN-n ico tin ic  receptors m odulate cellu lar effects of 
insulin  on glucose uptake, the present fin d in g s support the v iew  that in su lin - 
ind uced vaso d ila tio n  prom otes tissue uptake of glucose. T h is v iew  is also 
supported by the high correlation betw een the decrease in vascular resistance 
and the increase in total bo d y glucose uptake.
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Recent studies have suggested that increased local blood flow  during hyper- 
insulinem ia  supports glucose uptake only if accom panied by tissue recruitm ent.11 
Such an increase in m icro va scu la r p erfusion  w ould  en large the a va ila b le  
endothelial surface for g lucose exchange. As ca p illa ry  recruitm ent increases the 
endothelial surface a vailab le  for substrate exchange, an increase in perfusion will 
be accom panied by a m uch less pronounced fall in glucose extraction, or even 
w ith an increase in g lucose extractio n.30 The present fin d in g s thus suggest that 
b lockade of sym pathetic outflow s increases tissue perfusion. The h ig her values 
for arterial no rep inep h rin e  and for total body no rep inep h rin e  sp illover in the 
INS+TRI co nditio n, com pared to TRI alone, could have resulted from in su lin - 
ind uced stim ulatio n  of sym pathetic outflow s in the setting of o n ly partial 
g ang lio n  b lockade. A lternatively, at least theo retically, insu lin /g lu co se  infusion 
could increase the rate of entry of norep inep h rin e  into the bloodstream  for a 
given  rate of n o rep inep h rin e  release from  sym p ath etic  nerves, such as by 
in h ib itin g  neuronal reuptake of norep inep h rin e. From the know n depen d en ce of 
the m em brane norepinephrine transporter on extracellular sodium  concentrations, 
and the fact that insulin  stim ulates so d iu m -p o ta ssiu m  ATPase, this explanation 
seem s unlikely. Insulin m ight also affect the fu nctio n  of presynaptic receptors 
that m odulate norepinephrine release; however, brachial intra-arterial infusion of 
insulin  does not affect forearm  n o rep inep h rin e  spillover.31
Several observations suggest a link between insulin sensitivity and sym pathetic 
n ervous system  activity.151632 C lo n id in e  treatm ent prevents insulin  resistance and 
hypertension in obese dogs, ind icating that sym p athetic b lockade increases 
insulin  sensitiv ity. A lp h a-ad re n o ce p to r blockers such as doxazosin, and the 
centra lly  acting sym p a th o lytic, m oxonid ine, both used in the treatm ent of 
hypertension, also increase insulin  sensitivity, in contrast w ith other antih yp er­
tensive agents. Conversely, several d isorders characterized by insulin  resistance, 
such as o besity , prim ary hypertension , a g ing , and CHF are associated w ith 
sym p athetic a ctivatio n .33'40 W hether increased sym p athetic outflow s actually  
u nd e rly the re lationship betw een insulin  resistance and hypertension, w hile 
attractive, rem ains unproven.
An alternative experim ental design to stud y the effect of g ang lio n  blockade 
on insulin  infusion w ould have assessed effects of trim ethaphan on responses to 
in su lin /g lu co se , rather than effects of in su lin /g lu co se  on responses to trim e ­
thaphan. The form er design, however, w ould have required prolonged infusion of
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trim e th a p h a n , w hich  th e o re tica lly  co uld  lead to a u p re g ula tio n  of vascu lar 
a -ad ren o cep to rs.
A ltho ug h the present results ind icate that in su lin -in d u ce d  increases in 
sym p athetic vaso constrictor outflow s n orm ally  oppose and to som e extent mask 
in s u lin -in d u c e d  v a so d ila tio n , the results do not n ece ssa rily  m ean that the 
sym p a th e tic  stim u latio n  a ctu a lly  results from  the v a so d ila tio n . For instance, 
anim al stud ies have sugg e sted  that insu lin  can act in the brain  to increase 
sym p athetic outflow .41 One m ight test this notion by m easuring sym pathetic 
responses to insulin  in the setting of b lockade of in su lin -in d u ce d  vaso d ilatio n , 
such as by NG-m o n o m e th y l-L -a rg in in e , w hich  attenuates in s u lin -in d u c e d  
vaso d ila tio n  by decreasing productio n of nitric oxide. W hether m echanism s other 
than nitric oxide generation contribute to in su lin -in d u ce d  vaso d ilatio n  rem ains 
inco m p lete ly understood.42
In sum m ary, in the a bsence of p o st-g a n g lio n ic  sym p a th e tic  outflow s, 
system ically  adm in istered insulin  acts as a vaso d ilato r and a depressor agent. 
Sym pathetic b lockade appears also to increase in su lin -in d u ce d  g lucose uptake, 
but w hether this results from in su lin -in d u ce d  vaso d ilatio n  rem ains unproven.
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CHAPTER 9
Abstract
Background  Percutaneous coronary  in te rven tions  (PCI) evoke an in fla m m a to ry  
response and have been rep o rted  to  decrease a d ip o n e c tin  levels. If pe rs is ten t 
over tim e , the  in fla m m a to ry  response and low  a d ip one c tin  levels w o u ld  induce 
insu lin  resistance, rende ring  PCI p o te n tia lly  hazardous fo r  glucose m etabo lism . 
We investiga ted  w h e the r PCI decreased insulin  se n s itiv ity  a fte r one m on th  and if 
so, w h e th e r th is  was re la ted to  a lasting e leva tion  o f in fla m m a to ry  m arkers and 
decrease in a d ip one c tin  levels.
Methods Insulin sens itiv ity  (euglycem ic hyperinsulinaem ic clamp) was measured 
in 19 pa tien ts  w ith  stab le corona ry  a rte ry  disease be fore  and one m on th  a fte r PCI. 
Also levels o f in fla m m a to ry  m ed ia to rs  and ad ip one c tin  were assessed.
Results Insulin sensitiv ity  was no t a ffected by the  PCI procedure. There were no 
pe rs is ten t increases in IL-6, hs-CRP and a d ip o n e c tin  levels a fte r PCI.
Conclusion The in fla m m a to ry  response seen im m e d ia te ly  a fte r PCI does no t 
translate to  a m ed iu m -te rm  negative  e ffe c t on insu lin  action .
EFFECT OF PCI ON INFLAMMATORY MARKERS, ADIPONECTIN AND INSULIN RESISTANCE
Introduction
Percutaneous coronary  in te rven tions  (PCI) induce an in fla m m a to ry  response early 
a fte r the  procedure , as re flec ted  by an e leva tion  o f plasma h ig h -se n s itiv ity  
C-reactive p ro te in  (hs-CRP) and in te rle u k in -6  (IL-6) levels.1 Recently, the  acute 
in fla m m a to ry  response evoked by PCI has been suggested to  also reduce levels o f 
a d ip o n e c tin .2 As in fla m m a tio n  and low  ad ip one c tin  levels are associated w ith  
insu lin  resistance, the  PCI-induced in fla m m a to ry  response itse lf m ig h t render 
pa tien ts  insu lin  resistant in th e  early phase a fte r PCI.3 Here w e re p o rt the  results o f 
a s tudy in w h ich  we assessed insulin sen s itiv ity  be fore  and one m on th  a fte r PCI. In 
a d d itio n , levels o f in fla m m a to ry  param eters and ad ip o n e c tin  were measured.
Methods
19 pa tien ts  w ith  stab le  angina referred fo r e lec tive  PCI, were inc luded  (m ale/ 
fem a le : 12/7, aged mean ±  SD 59±8 years, BMI 27.8±4.0 k g /m 2, Canadian 
C ard iovascu lar S ocie ty  class 2.9±0.6). Exclusion c rite ria  w ere: reduced le ft 
ve n tric u la r e jec tio n  fra c tio n  (<40%); un d e rly in g  in fe c tiou s , in fla m m a to ry  or 
m a lign an t disease; d iabetes and tre a tm e n t w ith  a n ti- in fla m m a to ry  or im m u n o ­
suppressive drugs.4 The in s titu tio n a l rev iew  co m m itte e  approved the  s tudy and 
in fo rm ed  consent was ob ta in ed  fro m  all pa tien ts  be fore  p a rtic ip a tio n  in the  
study.
PCI was pe rfo rm ed  accord ing to  standard procedures. Insu lin sen s itiv ity  was 
m easured by a hype rinsu linem ic  (60 m U /m 2/m in ) eug lycem ic  clam p p rocedure .5 
IL-6, hs-CRP and a d ip o n e c tin  were measured p rio r to  the  s ta rt o f the  clam p 
procedure , in a rte ria l b lood  samples. Samples were im m e d ia te ly  cen trifu ge d  and 
serum was co llec ted  in 2 ml m icro tubes and stored at -8 0  degrees Celsius un til 
batch analysis. A d ip o n e c tin  was m easured using a Hum an A d ip o n e c tin  (Acrp30) 
enzym e-linked  im m u noso rbe n t assay (ELISA) K it (DuoSet®; R&D D eve lopm ent 
Systems, M inneapo lis , USA), assay range 61.5-4000 p g /m l. H igh -se ns itiv ity  
C-reactive p ro te in  (hsCRP) was m easured by enzym e-im m unoassay accord ing to  
the  in s tru c tion s  from  th e  m anu fac tu re r (Dako, G lastrup, Denm ark), assay range 
0.049-25 ng /m l. 11-6 was m easured by ELISA (PeliPair™ Reagent Set Sanquin; 
Sanquin, A m sterdam , Netherlands), assay range 1.56-200 pg /m l. M easurem ents 
were pe rfo rm ed  the  m orn ing  p rio r to  PCI and 1 m on th  a fte r PCI. All experim ents
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were conducted  at 8.00 AM a fte r an o v e rn ig h t (10-hour) fast w ith  the  p a tie n t in 
sup ine po s ition  in a q u ie t te m p e ra tu re -co n tro lle d  room  (23 -  24 °C). A fte r 
com p le te  in s tru m en ta tion , 30 m inutes o f rest were inc luded  to  a tta in  stab le 
baseline be fore  data co llec tio n .
Statistica l analysis
Data are expressed as mean±SEM unless ind ica ted  o therw ise . Serum levels o f IL-6, 
hs-CRP and ad ip one c tin  were n o t norm al d is tr ib u te d  and were sum m arized by 
m edians and in te rq u a rtile  ranges. D ifferences be tw een vis its  were assessed using 
pa ram etric  (s tuden t f-tes t fo r  pa ired observations) or no nparam e tric  (pa ired 
W ilcoxon) tests as appropria te . A tw o -ta ile d  p-va lue o f <0.05 was considered to  be 
s ta tis tica lly  s ig n ifica n t. C orre la tions be tw een  param eters were ca lcu la ted using 
Spearm an co rre la tion  coe ffic ien ts .
Results
All pa tien ts  com p le ted  the  s tudy and PCI was successful in all pa tien ts. M ost 
pa tien ts  had sing le  vessel disease, mean nu m ber o f im p lan ted  stents 1.4±0.6. 
M ed ica tion  was iden tica l at bo th  v is its  (aspirin n=19, be ta -b locke r n=18, sta tin  
n=16, ACEI n=4, calcium  channel b lockers n=5), except fo r  5 pa tien ts  w h o  used 
c lo p id o g re l due to  d ru g -e lu tin g  s ten t im p la n ta tio n  at the  second v is it. No 
d iffe rence  was fo u n d  be tw een  the  pa tien ts  w ith  ou r w ith o u t c lo p id o g re l. There 
was no s ig n ifica n t d iffe rence  in body  w e ig h t be fore and one m on th  a fte r PCI.
Glucose levels du rin g  the  clam ps were stab le (mean coe ffic ien ts  o f variance, 
before: 4.2±0.6 and a fte r PCI 3.7±0.4 %). 4 Weeks a fte r PCI, insu lin  se n s itiv ity  was 
s im ila r to  baseline: glucose in fus ion  rate (GIR), re fle c tin g  w h o le -b o d y  glucose 
u tiliza tio n , was alike be fore  and one m on th  a fte r PCI (figu re  1). A na logously, PCI 
had no e ffe c t on the  insulin se n s itiv ity  index (43.9±5 vs. 45.3±5.1 m g /k g /|iU /m in , 
P=NS).
One m o n th  a fte r PCI, IL-6 and hs-CRP levels w ere no t pe rs is ten tly  e levated, b u t 
re tu rned  to  baseline values (m edian <3.0 be fore PCI vs. <3.0 pg /m L  1-m onth  a fte r 
PCI fo r  IL-6, m ed ian 1.5 be fore  PCI vs. 1.1 m g/L  1 -m onth  a fte r PCI fo r  hs-CRP). IL-6 
and hs-CRP levels were w e ll corre la ted (baseline, rho=0.48, p<0.05 and a fte r PCI, 
rho=0 .44, p=0.06). PCI had no m ed iu m -te rm  e ffe c t on a d ip o n e c tin  levels (m edian
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2.8 be fore  PCI vs. 2.9 m g /m L  1-m onth  a fte r PCI). Hs-CRP and IL-6 levels d id  no t 
co rre la te  w ith  a d ip one c tin  levels.
Glucose infusion rate (GIR)
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Glucose infusion rate (GIR) before and after PCI.
Discussion
Our data show  th a t the  increase in IL-6 and hs-CRP seen im m e d ia te ly  (<48h) a fte r 
PCI does no t persist one m on th  a fte r PCI. A lso ad ip one c tin  levels were s im ilar 1 
m on th  a fte r PCI. Insu lin se n s itiv ity  was n o t a ffec ted  by the  PCI procedure. This is 
in accordance w ith  the  absence in change in in fla m m a to ry  m arkers and 
a d ip o n e c tin  levels.
W hen com pared to  pub lished  values using an iden tica l set-up, g lucose in fus ion  
rates d u rin g  the  clam p in th is  g roup  were clearly be lo w  no rm a l.15Thus as a g roup  
the y  were ob v ious ly  insulin resistant, w h ich  is consisten t w ith  the  s itua tion  o f 
chron ic  m yocardia l ischem ia.
Our s tud y  was no t designed to  de te rm in e  im m ed ia te  changes in in fla m m a to ry  
markers a fte r PCI, nor can s ta tem ents be m ade regard ing  cause-e ffec t re la tionsh ips 
be tw een  the  d iffe re n t param eters as on ly  co rre la tions were assessed. A ltho ug h  
re la tive ly  sm all-sized, the  clear eq u a lity  o f our data shou ld  make d iffe re n t results
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fro m  a la rger cohort, h ig h ly  un like ly. It was ca lcu la ted th a t the  s tudy had enough 
s ta tis tica l pow er to  ru le o u t any po ten tia l c lin ica lly  re levant changes in hs-CRP 
and IL-6. As the  in fla m m a to ry  response (<48-72h) im m e d ia te ly  fo llo w in g  PCI has 
been s tud ied  extensive ly, it was the  focus o f th e  present s tudy to  assess 
m ed iu m -te rm  (one m on th ) e ffec ts  o f PCI on insu lin  resistance. We d id  con firm  the  
sho rt-te rm  in fla m m a to ry  response to  PCI in our ow n in s titu tio n  (data no t shown). 
Irrespective  o f the  change in in fla m m a to ry  m arkers o r u n d e rly in g  m echanism , our 
s tudy  prov ides evidence th a t PCI has no e ffe c t on insu lin  se n s itiv ity  one m on th  
a fte r th e  procedure. Suggested PCI hazards on insu lin  se n s itiv ity  via the  
in fla m m a to ry  o r ad ip one c tin  pa thw ay seem the re fo re  h ig h ly  un like ly.
In conclus ion , the  in fla m m a to ry  response seen im m e d ia te ly  a fte r PCI in CAD 
patients, does no t pe rs is tfo r one m onth after PCI. In accordance, plasma ad iponectin  
levels and insulin sensitiv ity  remain unaffected . Thus, the  in flam m ato ry  response 
seen im m ed ia te ly  a fte r PCI does no t translate to  a m ed ium -te rm  negative e ffec t 
on insu lin  action .
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Summary and conclusions

SU M M A R Y  AN D  C O N C LU S IO N S
An increase in sym pa the tic  a c tiv ity  is a key fea tu re  o f m any card iovascular 
con d itions  and it has been shown th a t on the  lo ng -te rm  th is  increase has 
de trim e n ta l hem odynam ic  and m e tab o lic  e ffec ts  in pa tien ts  su ffe ring  from  these 
con d itions . The f irs t pa rt o f th is  thesis focuses m a in ly  on ways to  reduce th is  
increased sym pa the tic  ac tiv ity , especia lly by the  novel concep t o f HMG-CoA 
reductase in h ib it io n  by statins. We describe the  d iffe re n t pa thophys io log ica l 
m echanism s responsib le  fo r  the  increase in sym pa the tic  a c tiv ity  in m yocardia l 
ischem ia, heart fa ilu re  and hypertens ion . We conc luded th a t based on anim al 
stud ies, tw o  m ajor pathways exist th a t regu la te  and m odu la te  centra l sym pa the tic  
o u tflo w , the  ang io tens in  II and NO pathway. S ym p a th o in h ib itio n  by statins is 
suggested to  be the  resu lt o f in te rven ing  w ith  these pathways. The second pa rt o f 
th is  thesis focuses on an im p o rta n t adverse e ffe c t o f increased sym pa the tic  
a c tiv ity : reduced insu lin  sens itiv ity . This e ffe c t seems in p a rt m ed ia ted by the  
a-ad rene rg ic  recep to r and rem ains the re fo re  una ffec ted  w hen pa tien ts  are 
trea ted  w ith  (3-blocker therapy. The e ffe c t o f the  pharm aco log ica l in te rven tions  
to  reduce sym pa the tic  a c tiv ity  and im prove  insu lin  se n s itiv ity  are described in 
th is  pa rt o f the  thesis. This chap te r provides a sum m ary o f our m ain find in gs , 
fo llo w e d  by a general discussion and fu tu re  perspectives.
Part I: In tervening w ith  sym pathetic activ ity  at a central level
Chapter 2 provides a sho rt de scrip tion  o f the  pa thop hys io lo g ica l m echanism s 
held responsib le  fo r  the  increase in sym pa the tic  a c tiv ity  in th ree  d iffe re n t 
card iovascular con d itions : m yocard ia l ischem ia, congestive  heart fa ilu re  (CHF) 
and p rim a ry  hypertens ion . An increase in sym pa the tic  a c tiv ity  is o ften  due to  
tr igg e rs  s tim u la tin g  sym pa the tic  a ffe ren ts .T he  trans la tion  o f sym pa the tic  a ffe ren t 
s tim u la tio n  in to  an actual increase in centra l sym pa the tic  ac tiv ity , h ig h ly  depends 
on tw o  centra l ac ting  m echanism s, th e  ang io tens in  II and NO pathways. The 
ang io tens in  II and NO pathways de te rm ine , at least pa rtia lly , the  degree to  w h ich  
a ffe re n t sym pa the tic  signals are "a m p lifie d " and trans la ted  in d iffe re n t degrees o f 
sym pa the tic  o u tp u t. A com m on s y m p a th o m o d u la to ry  pa thw ay w ith in  the  centra l 
nervous system enables us to  in te rvene  w ith  sym pa the tic  o u tflo w  at a centra l 
level.
To reverse sym pa the tic  o ve ra c tiv ity  in card iovascular disease, a log ica l in itia l step 
w o u ld  be rem oval o f the  tr ig g e r fo r  the  increase in sym pa the tic  ac tiv ity . In 
m yocard ia l ischem ia, s tim u la tio n  o f sym pa the tic  a ffe rents resid ing in the
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m yocard ia l w a ll is due to  ischem ia-induced release o f a num ber o f a ffe re n t-s tim u - 
la ting  substances. This w ill resu lt in an increase in sym pa the tic  o u tflo w . In 
m yocard ia l in fa rc tio n  as w e ll as in unstab le  angina th is  state o f sym pa the tic  
h y p e ra c tiv ity  appears to  be p ro tra c ted  fo r several m onths a fte r the  occurrence o f 
th e  ischem ic event, suggesting  a p ro lo nge d  change in centra l au tono m ic  balance. 
In chapter 3 we describe a s tudy w h ich  assessed w h e th e r im p ro v in g  m yocardia l 
pe rfus ion  by pe rcuteneous corona ry  in te rve n tio n  (PCI) decreases sym pa the tic  
o u tp u t. Tw en ty  pa tien ts  w ith  m yocardia l ischem ia o f at least class II accord ing to  
th e  Canadian Cardiovascular Society (CCS) and pe rs is ten t sym ptom s desp ite  
op tim a l pharm aco log ica l the ra py  were investiga ted . S ym pathetic  a c tiv ity  was 
m easured be fore and one m on th  a fte r PCI by a num be r o f techn iques: m ic ro neu ­
rog raphy  fo r  d ire c t m uscle sym pa the tic  nerve reco rd ing  (MSNA), heart rate 
v a r ia b ility  analysis (HRV) and m easurem ent o f a rte ria l plasma n o rep ine ph rine  
concen tra tions. M uscle sym pa the tic  nerve a c tiv ity  (MSNA) was s ig n ifica n tly  
reduced a fte r PCI. This e ffe c t was sup po rte d  by a clear red uc tio n  in lo w -frequ en cy / 
h ig h -fre q u e n cy  ra tio  w ith  pow er spectra l analysis, in d ica ting  reduced sym pa the tic  
dom inance .T he  change in sym pa the tic  nerve a c tiv ity  d id  no t transla te in a change 
in plasma n o rep ine ph rine  concen tra tions. The red uc tio n  in sym pa the tic  a c tiv ity  
a fte r co rona ry  revasculariza tion by PCI suppo rts  the  concep t th a t rem oval o f an 
(ischem ic) tr ig g e r reduces sym pa the tic  a c tiv ity  in pa tien ts  w ith  established 
m yocard ia l ischemia.
In several cond itions , like CHF, m icrovascular ischem ia or hype rtens ion , the  tr ig g e r 
o f sym pa the tic  a c tiv ity  is m u ltifa c to ria l, irrevers ib le  or no t accessible fo r 
in te rve n tio n . There fore, in these con d itions  the  on ly  a lte rna tive  is to  t ry  to  reduce 
centra l sym pa the tic  o u tflo w  by means o f pharm aco log ica l agents. Since, centra l 
ac ting  ang io tens in  II and NO pathways are suggested to  m odu la te  centra l 
sym pa the tic  o u tflo w , s y m p a th o in ib it io n  m ig h t be ob ta in ed  by in te rven ing  w ith  
th e  ang io tens in  II and NO pathways. A lth o u g h  p rim a rily  lim ite d  to  experim enta l 
an im al data, HM G-coA reductase in h ib ito rs  (statins) seem to  a ffec t these key 
pathways, reduc ing  the  s y m p a th o -s tim u la to ry  e ffe c t o f ang io tens in  II and 
im p ro v in g  the  s y m p a th o -in h ib ito ry  e ffe c t o f NO, resu lting  in in h ib it io n  o f centra l 
sym pa the tic  o u tflo w . In chapter 4 we s tud ied  the  e ffec ts  o f sta tins on sym pa the tic  
a c tiv ity  in a small g ro up  o f CHF pa tien ts. S ym pathetic  a c tiv ity  was assessed du rin g  
s ta tin  trea tm e n t, e ig h t w eeks a fte r d iscon tinua tion  and fo u r weeks a fte r res tart o f 
s ta tin  tre a tm e n t by m ic ro neu rog rap hy  and m easurem ent o f a rte ria l plasma 
no rep ine ph rine  concen tra tions. D uring  d iscon tinua tion  o f s ta tin  the ra py  MSNA
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s ig n ifica n tly  increased, w h ile  it re tu rned  to  baseline levels a fte r re ins ta llm en t o f 
the  s ta tin . A rte ria l plasma n o rep ine ph rine  levels were una ffec ted . These results 
s tro n g ly  suggest th a t s ta tin  the ra py  may in h ib it e ffe re n t sym pa the tic  nerve tra ffic  
in CHF pa tien ts  as m easured by MSNA.
In p rim ary  hypertens ion , increased sym pa the tic  a c tiv ity  m ig h t be caused by over­
a m p lific a tio n  o f "n o rm a l" sym pa the tic  trigge rs . The pe rs is ten t increase in 
sym pa the tic  ton e  m ig h t exp la in  w hy in som e pa tien ts  hype rtens ion  rem ains 
re frac to ry  to  usual pharm aco log ica l trea tm e n t. In chapter 5 we tested the  
hypothesis  w h e th e r statins are also able to  reduce the  enhanced sym pa the tic  
a c tiv ity  in hum an pa tien ts  w ith  p rim a ry  hypertens ion . Using a prospective, 
random ized , p lace bo -co n tro lled , d o u b le -b lin d , cross-over design, we pe rfo rm ed  
a p ro o f-o f-p r in c ip le  tria l in 13 pa tien ts  w ith  m ild  to  m odera te  p rim a ry  hypertens ion , 
w h o  were ran do m ly  assigned to  e ith e r a to rvas ta tin  80 m g/day or p lacebo, each 
fo r  3 weeks. A to rva s ta tin  s ig n ifica n tly  reduced MSNA, w h ile  it had no s ig n ifica n t 
e ffec ts  on plasma no rep ine ph rine  levels, b lood  pressure or heart rate. The 
decrease in MSNA was un re la ted to  the  decrease in plasma cho leste ro l levels. In 
pa tien ts  w ith  m ild  to  m odera te  p rim a ry  hypertens ion , a to rvas ta tin  at a dose o f 80 
m g /day  seems the re fo re  ab le to  in h ib it  sym pa the tic  ac tiv ity .
A key e lem en t o f the  ang io tens in  II pa thw ay in m o d u la tin g  sym pa the tic  a c tiv ity  at 
a centra l level is the  fo rm a tio n  o f reactive oxygen species ROS by NAD(P)H oxidase, 
the  fina l step in the  ang io tens in  II pathway. In CHF rabb its , NAD(P)H oxidase 
expression and ac tiv ity , the  main enzym e fo r reactive oxygen fo rm a tio n  (ROS) 
fo rm a tio n , is up regu la ted  in the  rostral ven te ro la te ra l m edulla  (RVLM), the  p rim ary  
centra l site fo r  the  m aintenance o f sym pa the tic  nerve ac tiv ity . Reducing cerebral 
ROS m ig h t the re fo re  be a po ten tia l m echanism  fo r  cou n te ra c ting  h igh centra l 
sym pa the tic  o u tflo w . A scorb ic acid (v itam ine  C) is a w e ll-kn o w n  scavenger o f ROS 
and able to  pass th e  b lo o d -b ra in  barrier. Chapter 6 describes the  results o f a 
prospective , random ized , p lace bo -co n tro lled , d o u b le -b lin d , cross-over tria l, in 
w h ich  the  e ffec ts  o f ascorbic acid 2g /day or p lacebo fo r  3 days in a g roup  o f CHF 
pa tien ts  is described. Despite a s ig n ifica n t increase in plasma v ita m in  C levels, no 
s ig n ifica n t e ffe c t cou ld be dem onstra ted  on sym pa the tic  ac tiv ity . The lack o f 
e ffe c t m ig h t be exp la ined in several ways. First, a lth ou gh  s ig n ifica n tly  increased, 
plasma v ita m in  C levels s till rem ained w ith in  the  norm al phys io log ica l range. As 
v ita m in  C uptake in the  bra in is in pa rt g ra d ien t d riven  and fa c ilita te d  by the  
d iffe re n t transporte rs , the  rise in plasma v ita m in  C m ig h t have been to o  small to
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in fluence  th is  g rad ien t. A dd itio na lly , if w ith  norm al d ie ta ry  in take plasma v ita m in  
C levels are a lready o p tim a l, ad m in is te ring  a dose o f ascorbic acid w h ich  does no t 
increase levels above norm al phys io log ica l range, m ig h t n o t fu r th e r  enhance the  
(centra l) an tio x id a n t e ffec t.
Part II: sym pathetic activ ity  and insulin resistance
The second pa rt o f the  thesis focuses on im p rov in g  insu lin  se n s itiv ity  by 
in te rven ing  in the  sym pa the tic  nervous system a c tiv ity . One o f th e  consequences 
o f h igh  sym pa the tic  ton e  is a red uc tio n  in skeletal m uscle b lood  f lo w  w h ich  is 
m ed ia ted by the  a -ad renerg ic  receptors. W ith  the  red uc tio n  o f skeletal m uscle 
pe rfus ion , tissue de live ry  o f g lucose and insulin is also reduced (reduced n u tritiv e  
flow ). This m echanism  may unde rlie  the  insu lin  resistance seen in d iffe re n t 
con d itio n s  w ith  increased centra l sym pa the tic  tone , in c lud in g  CHF. In Chapter 7, 
w e hypothesized th a t in pa tien ts  w ith  CHF the  associated increase in sym pa the tic  
a c tiv ity  is (in part) responsib le  fo r a reduced skeletal m uscle glucose uptake and 
th a t th is  e ffe c t is m ed ia ted by the  a -ad renerg ic  receptor. Phento lam ine, a 
w e ll-kn o w n  a-ad rene rg ic  recep to r blocker, may the re fo re  increase n u tritiv e  f lo w  
and im prove  glucose uptake by the  skeletal m uscle. We com pared the  e ffec ts  o f 
p h en to la m ine  in e ig h t CHF pa tien ts  and 12 hea lthy  vo lun teers . Forearm b lood  
f lo w  (FBF) and fo rea rm  glucose uptake (FGU) were m easured in bo th  forearm s 
d u rin g  a 150 m inutes hype rinsu linem ic  eug lycem ic  clam p procedure . D uring  the  
fina l 30 m inu tes o f the  clam p, p h en to la m ine  was in fused in to  one fo rearm . 
P hento lam ine s ig n ifica n tly  increased FGU in the  CHF-group, b u t d id  n o t a ffec t 
FGU in th e  hea lthy  con tro ls  desp ite  a com parab le  rise in FBF. Thus, a -adrenerg ic  
recep to r b lockade im proves fo rea rm  glucose uptake in CHF pa tien ts  desp ite  a 
s im ila r rise in FBF. This e ffe c t m ig h t be exp la ined by the  fa c t tha t, in con trast to  
hea lthy  subjects, the  increased sym pa the tic  a c tiv ity  in CHF pa tien ts  m a in ly  
reduces cap illa ry  perfus ion.
A n o th e r w ay by w h ich  the  sym pa the tic  nervous system m ig h t induce insulin 
resistance is th a t th e  vasoconstric tive  e ffe c t o f h igh  sym pa the tic  ton e  counteracts 
th e  vaso d ila to r e ffe c t o f insu lin  in the  skeletal m uscle, reducing n u tritiv e  flo w . If 
so, the n  b lockade o f sym pa the tic  po s t-g an g lion ic  o u tf lo w  should augm en t the  
vaso d ila to r e ffe c t o f insu lin . Because vasod ila tion  suppo rts  insu lin -induced  
glucose uptake, sym pa the tic  b lockade m ig h t also increase insulin  sens itiv ity . In 
Chapter 8 th is  hypothesis was tested using the  NN-n ic o tin ic  ga ng lio n ic  receptor
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blocke r trim e th a p h a n . First, tr im e th a p h a n  was in fused fo r  60 m in in six norm al 
vo lun tee rs  to  assess the  e ffec ts  on vascular resistance and b lood  pressure. 
Hereafter, a hyperinsu lim aem ic eug lycem ic clam p was pe rfom ed  fo r  180 m inutes, 
w ith  trim e th a p h a n  co-in fused du rin g  the  last 60 m inutes. D uring  the  clam p, 
trim e th a p h a n , on to p  o f h igh  insu lin  levels, decreased bo th  fo rearm  vascular 
resistance and d iasto lic  b lood  pressure m ore than did  trim e th a p h a n  alone. W hole 
b o dy  and forearm  glucose uptake increased s ig n ifica n tly  du ring  ga ng lio n ic  
b lockade. Thus, sym pa the tic  ga ng lio n ic  b lockade unm asked a p o te n t vasod ila to r 
e ffe c t o f insu lin  and increased insu lin  se n s itiv ity  in hea lthy hum an sub jects. In 
Chapter 3 we re p o rt th a t im p ro v in g  m yocard ia l pe rfus ion  by PCI reduces 
sym pa the tic  a c tiv ity  in stab le angina. This red uc tio n  in sym pa the tic  a c tiv ity  m ig h t 
be bene fic ia l fo r  insu lin  sens itiv ity . However, the  PCI p rocedure  itse lf m ig h t prove 
d isadvantageous fo r on insu lin  se n s itiv ity  as it induces an in fla m m a to ry  response 
and fa ll in a d ip one c tin  levels. In C h ap te r 9, we describe the  e ffec ts  o f PCI on 
in fla m m a to ry  markers, ad ip one c tin  levels and insu lin  sen s itiv ity  in 19 pa tien ts  
w ith  stab le  corona ry  a rte ry  disease be fore  and one m on th  a fte r PCI. Levels o f 
in fla m m a to ry  m ed ia to rs  and ad ip o n e c tin  were assessed. In th is  s tudy PCI d id  no t 
adverse ly a ffec t glucose uptake and insulin sensitiv ity .
General discussion
An increase in sym pa the tic  a c tiv ity  is c losely associated w ith  a num ber o f 
card iovascular cond itions . The increase can be the  resu lt o f a clear tr ig g e r like 
ischem ia, o r due to  a num be r o f pa thop hys io lo g ica l changes in w h ich  the  cause o f 
increasing sym pa the tic  a c tiv ity  is irrevers ib le  or no t accessible fo r  in te rven tion . 
D espite its d ive rs ity  in cause or m echanism , the  u ltim a te  level o f sym pa the tic  
o u tp u t seems, at least in pa rt, regu la ted th ro u g h  a com m on pa thw ay in w h ich  
centra l ang io tens in  II and NO play an im p o rta n t role. A pa rt from  rem oving 
w e ll-kn o w n  tr igg e rs  o f an inceased sym pa the tic  ac tiv ity , a ffe c tin g  the  ang io tens in
II and NO pathways seems an a ttra c tive  o p tio n  to  reduce sym pa the tic  ac tiv ity . In 
th is  con tex t, HM G-coA reductase in h ib ito rs  (statins) d isp lay the  a b ility  to  m odu la te  
cerebral ang io tens in  II and NO pathways and reduce sym pa the tic  o u tflo w . In th is  
thesis w e dem onstra ted  th a t s tatins can reduce sym pa the tic  a c tiv ity  in pa tien ts  
w ith  CHF and p rim ary  hypertens ion . The exact m echanism  how  statins reduce 
sym pa the tic  a c tiv ity  can n o t be established by ou r stud ies bu t, based on anim al 
experim ents , it can be speculated th a t the  centra l ang io tens in  II and NO pathways 
are invo lved.
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A p p ly in g  a ROS scavenger (ascorbic acid) to  reduce cerebra l ROS fo rm a tio n  in an 
e ffo r t  to  reduce sym pa the tic  a c tiv ity  was unsuccessful. Current an ti-sym pa th e tic  
the rap ies have m a in ly  focused on sh ie ld ing  organs from  h igh sym pa the tic  tone, 
m ost o ften  by b lock in g  (3-adrenergic receptors. W ith  th is  s tra tegy sym pa the tic  
nerve a c tiv ity  itse lf rem ains increased. An im p o rta n t adverse e ffe c t o f th is  
increased sym pa the tic  a c tiv ity  is a dec line  in insu lin  se n s itiv ity  because the  
a -ad rene rg ic  receptors rem ain s tim u la ted . In th is  thesis w e re p o rt on som e stud ies 
th a t assessed the  e ffec ts  o f b lock ing  sym pa the tic  a c tiv ity  on insu lin  sensitiv ity . 
B locking sym pa the tic  a c tiv ity  im p roved  insulin  se n s itiv ity  in CHF pa tien ts  and 
hea lthy  subjects. This e ffe c t is m ost like ly  exp la ined by the  fa c t th a t du rin g  
increased sym pa the tic  a c tiv ity  cap illa ry  vaso con stric tion  occurs, reducing 
n u tritiv e  f lo w  to  the  skeletal m uscle. Relieving sym pa the tic  a c tiv ity  results in 
cap illa ry  re c ru itm e n t and increased skeletal m uscle g lucose e x trac tio n  capab ility , 
lead ing to  im proved  insu lin  sensitiv ity .
Future perspectives
One cou ld ques tion  w h e the r an in te rve n tio n  in centra l sym pa the tic  a c tiv ity  
p rovides a bene fic ia l c o n trib u tio n  to  cu rre n t (3-blocker or ACE in h ib ito r  the ra py  in 
pa tien ts  w ith  card iovascular disease. Beta-blockers and ACE in h ib ito rs  have 
proven th e ir e ffectiveness on e n dp o in ts  like card iovascular m o rta lity  and 
m o rb id ity  in num erous random ized tria ls. In con trast, b e n e fit o f stra teg ies th a t 
focused on reducing sym pa the tic  a c tiv ity  has no t ye t been proven in large 
random ized tria ls. Nevertheless, the  de trim en ta l ro le o f an enhanced sym pa the tic  
a c tiv ity  th a t is associated to  several card iovascular d isorders is w e ll-es tab lished . 
The increase in insu lin  resistance as w e ll as the rapy-res is tan t hypertens ion  are 
clear exam ples o f these adverse e ffec ts  o f increased sym pa the tic  tone. Therefore, 
reduc ing  centra l sym pa the tic  a c tiv ity  in these pa tien ts  seems a ju s tif ie d  tre a tm e n t 
goal so th a t surviva l and q u a lity  o f life  m ay be im proved . Our stud ies suggest th a t 
apart from  cho leste ro l low ering , sta tins also reduce sym pa the tic  a c tiv ity  in 
pa tien ts  w ith  CHF and p rim a ry  hypertens ion . S tatin the ra py  is safe and re la tive ly  
cheap and in m any o f these pa tien ts , statins are a lready pa rt o f the  the ra pe u tic  
reg im en. It rem ains to  be established however, w h e th e r th e  w e ll-p rove n  bene fic ia l 
e ffec ts  o f s ta tin  the ra py  in term s o f card iovascular m o rb id ity  and m o rta lity  are 
no t o n ly  due to  the  cho leste ro l lo w e ring  perse, b u t also due to  long te rm  red uc tio n  
in sym pa the tic  ac tiv ity . Larger c lin ica l tria ls  w ith  m ore sim ple, b u t re liab le  
m easurem ent m ethods o f sym pa the tic  ton e  and insu lin  se n s itiv ity  are required 
fo r  th is  purpose.
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Samenvatting en conclusies

SA M EN VA TT IN G  EN C O N C LU S IES
Patiënten m et ha rt- en vaa taandoen ingen  hebben een ve rh oo gde  a c tiv ite it van 
he t sym path isch zenuw ste lsel. Het sym path isch zenuw ste lsel w o rd t ook wel 
aangedu id  als he t o n w ille keu rige  o f au tonom e zenuw ste lse l en d raag t zorg voo r 
ta l van lichaam sfuncties w aaronder de regu la tie  van de harts lag en b loe ddru k . 
Een ve rh oo gde  a c tiv ite it  van he t sym path isch zenuw ste lse l, hoew el guns tig  op 
de korte  te rm ijn , b lijk t  op de lange te rm ijn  nade lige  e ffec ten  te  hebben op het 
ha rt en op de s to fw isse ling . Het eerste deel van d it  p ro e fsch rift rich t zich op de 
versch illende  m anieren om de a c tiv ite it  van het sym path isch zenuw ste lse l te 
ve rm inde ren . Daarbij is ge b ru ik  gem aakt van een n ieuw  concep t: rem m ing  van 
he t enzym  HMG-CoA d o o r de geneesm idde lenklasse: statines. In d it  deel van het 
p ro e fsch rift w o rden  ook de versch illende  m echan ism en beschreven die  ten 
g rondslag lijken te liggen  aan de ve rh oo gde  sym path ische a c tiv ite it zoals die 
w o rd t gezien b ij aandoen ingen  als z u u rs to fte k o rt van he t hart, ha rtfa len  en hoge 
b loe dd ru k . Op basis van gegevens die  z ijn  verkregen u it d ie rp roeven  kom en w ij 
to t  de conclusie da t er tw ee  hoofdsystem en lijken te  z ijn  d ie  de u its troo m  van het 
sym path isch zenuw ste lse l v a n u it he t cen tra le  zenuw ste lsel regu leren en aan­
passen: he t A ng io tens ine  II en s tiks to fm o n o o x id e  (NO). Het rem m ende e ffe c t dat 
s tatines hebben op he t sym path isch zenuw ste lse l zou te verk la ren z ijn  d o o rd a t 
deze m idde len  op deze system en in g rijp e n . In he t tw ee de  deel van d it  p ro e fsch rift 
lig t  de nadruk op een b e la ng rijk  ne vene ffec t van een ve rh oo gde  a c tiv ite it van het 
sym patische zenuw ste lse l, te w e ten  een ve rm inde rde  in su linegevoe lighe id . D it 
e ffe c t li jk t  g ro tendee ls  te lopen via de a lfa -adrenerge receptor. Dat ve rk laa rt ook 
waarom  de behande ling  m et een bè tab lokke r h ie r geen inv loed  op hee ft. B innen 
d it  deel w o rden  de e ffec ten  beschreven van fa rm aco log ische  in te rven ties  d ie  de 
a c tiv ite it  van he t sym path ische zenuw ste lse l ve rlagen en d ien te ng evo lge  de in ­
su linegevoe lighe id  kunnen verbe te ren . In d it  h o o fds tuk  w o rden  de be lang rijks te  
b e v in d in ge n  van he t p ro e fsch rift sam engevat, gevo lgd  do o r een discussie en 
m oge lijke  toekom stpe rspec tieven .
Deel I: Op centraal niveau ingrijpen op sympathische activ ite it
Hoofdstuk2 g e e ft een korte  beschrijv ing  van de p a tho fys io log ische  m echanism en 
die v e ra n tw o o rd e lijk  z ijn  vo o r de toenam e in de a c tiv ite it van he t sym patische 
zenuw ste lse l b ij d rie  ve rsch illende  card iovascula ire  aandoen ingen: zuu rs to f 
te k o rt van de ha rtsp ie r (ischem ie), chronisch ha rtfa len  en essentië le hypertensie . 
Een ve rh oo gde  sym patische a c tiv ite it  w o rd t ve roo rzaak t d o o r fac to re n  die de 
on tvang en de  zen uw u ite ind en  (a fferenten) van he t sym path ische zenuw ste lsel
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stim u le ren . De ve rta lin g  van s tim u la tie  van een sym patische a ffe re n t naar een 
daadw erke lijke  ve rh o g in g  van centraal sym path ische a c tiv ite it hang t ech ter nauw  
samen m et een tw e e ta l m echan ism en m et een centraal aa ng rijp ing spu n t: de 
ang io tens ine  II en NO paden. Het ang io tens ine  II en NO systeem bepaa lt ten  dele 
de m ate w aarin  de s ignalen van de sym path ische a ffe ren ten  ve rs te rk t ve rtaa ld  
w o rde n  naar de u itgaande a c tiv ite it  van he t sym path ische zenuw ste lse l. Het 
bestaan van een enkel, centraal w erkend systeem da t de a c tiv ite it van het 
sym patische zenuw ste lse l b ijs tu u rt b innen  he t centra le  zenuw ste lse l m aakt het 
m o g e lijk  om op een centraal niveau in te  g rijp e n  in de sym patische o u tp u t.
Om de ve rh o g in g  in a c tiv ite it  van he t sym patische zenuw ste lse l b ij ca rd io ­
vascula ire aandoen ingen  te rem m en, li jk t  he t een log ische eerste stap om de 
fa c to r die ve rh o g in g  in de a c tiv ite it  ve roorzaakt, w eg te  nem en. Bij z u u rs to fte ko rt 
in de ha rtsp ie r s tim u le ren  de s to ffen  die  h ie rd oo r v r ijkom en  de a ffe ren ten  van het 
sym patische zenuw ste lse l d ie  zich in de ha rtsp ie r ze lf bev inden . D it resu ltee rt in 
een ve rh oo gde  u its tro o m  van a c tiv ite it van he t sym patische zenuw ste lsel. 
Het b lijk t  da t b ij een h a rtin fa rc t en b ij ins tab ie le  angina pecto ris  deze vers te rk te  
a c tiv ite it  ook to t  een aantal m aanden na he t eerste z u u rs to fte k o rt nog aanwezig 
is. D it suggereert een langer aanhoudende onbalans van he t centra le  au tonom e 
zenuw ste lse l. In h o o fd s tu k  3 beschrijven w ij een onde rzoek  w aarin  w ij hebben 
gekeken o f ve rb e te rin g  van de d o o rb lo e d in g  van de ha rtsp ie r d o o r percutane 
corona ire  in te rven tie  (PCI) tevens le id t to t  een ve rlag ing  van de a c tiv ite it van het 
sym patische zenuw ste lsel. W ij hebben vo o r d it  onde rzoek  een aantal m etingen  
v e rrich t b ij tw in t ig  pa tiën te n  m et een bekend zuu rs to fgeb rek  van de ha rtsp ie r 
m et k lachten en m et een ernst van ten m ins te  klasse 2 op de schaal van de 
Canadian Cardiovascular Society (CCS) d ie  k lachten h ie lden ondanks op tim a le  
m ed icam enteuze the rap ie . De a c tiv ite it  van he t sym patisch zenuw ste lsel werd 
voo ra fgaand aan de PCI procedure  en ve rvo lgens een maand na de procedure 
beoo rdee ld . De a c tiv ite it  van he t sym path ische zenuw ste lse l hebben w ij m et 
behu lp  van een aantal techn ieken  gem eten : m ic ro neu rog ra fie  om  de zenuw - 
a c tiv ite it  r ich tin g  de spier te m eten (MSNA), de va ria tie  in h a rtfre q u e n tie  (heart 
rate va ria b ility , HRV) en m e ting  van de no rad rena lineconcen tra ties  (ho rm oon  dat 
w o rd t u itgesche iden  do o r he t sym patisch zenuw ste lsel) in he t b loed. Bij deze 
pa tiën te n  was de a c tiv ite it  van he t sym patisch zenuw ste lse l na de PCI s ig n ifica n t 
a fgenom en . D it resu ltaa t w erd gesteund do o r een overeenkom stige  afnam e in de 
ve rh o u d in g  tussen de laag -frequen te  en ho og -fre q u e n te  pow er ra tio  b innen  de 
HRV, die d u id t op  een a fgenom en d o m in a n tie  van he t sym patisch zenuw ste lsel.
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De gevonden verandering  in ze n u w a c tiv ite it ve rtaa lde  zich ech ter n ie t in een 
verandering  in no rad rena lineconcen tra ties  in he t b loed . De afnam e in zenuw ­
a c tiv ite it  van he t sym patische zenuw ste lsel na ve rb e te ring  van de d o o rb lo e d in g  
van de ha rtsp ie r d o o r een PCI procedure  on de rs te un t he t concep t da t do o r 
he t u itschake len van een z u u rs to fte k o rt ge re la teerde u itlo kke nde  fa c to r de 
sym path ische a c tiv ite it w o rd t verlaagd b ij pa tiën te n  m et zuu rs to fgeb rek  van de 
hartsp ier.
Bij een aantal aandoen ingen  zoals ha rtfa len , z u u rs to fte k o rt d o o r a fw ijk in g e n  
in de k le ine  b loedva ten  o f hoge b loe dd ru k , li jk t  de p rikke l vo o r he t ve rhogen  van 
de sym patische a c tiv ite it  vaak bepaald te  w o rden  do o r m eerdere fac to ren . Tevens 
b lijk t  deze prikke l vaak onom keerbaar en n ie t to e gan ke lijk  vo o r versch illende 
in te rven ties . O nder deze om stan d ighe de n  is he t en ige a lte rn a tie f een p o g ing  te 
w agen de sym patische a c tiv ite it op een centraal niveau te  verlagen m et behu lp  
van geneesm idde len . Aangezien de centraal w erkende ang io tens ine  II en NO 
system en inv loed  lijken te hebben op de ho og te  van de centra le  sym patische 
a c tiv ite it, lig t he t v o o r de hand de centra le  sym patische a c tiv ite it  te verlagen door 
in te g rijpe n  op deze tw e e  system en. Hoewel d it to t  op  heden voo ra l onde rzoch t 
is b ij d ieren, lijken HM G-coA reductase rem m ers (statines) inv loed  u it  te  kunnen 
oefenen op deze tw ee  be langrijke  system en, w aarb ij de sym patisch zenuw ste lse l- 
s tim u le rende  rol van ang io tens ine  II w o rd t g e d e m p t en he t sym patisch zenuw - 
ste lse l-rem m ende e ffe c t van NO w o rd t ve rs te rk t. D it resu ltee rt u ite in d e lijk  in een 
afnam e van de centra le  sym patische a c tiv ite it. In h o o fd s tu k  4 bestuderen w ij het 
e ffe c t van statines op de a c tiv ite it  van he t sym patische zenuw ste lsel b ij een kle ine 
g roep  van pa tiën te n  m et ha rtfa len . De a c tiv ite it van he t sym pa tischezenuw ste lse l 
w erd gem eten gedurende behande ling  m et statines, 8 w eken na he t staken van 
statines en 4 w eken na he t he rva tten  van de sta tines m et behu lp  van m icro - 
neu rog ra fie  (d irecte  m e tin g  zen u w a c tiv ite it) en he t bepa len van norad rena line  
concen tra ties in he t b loed. T ijdens he t staken van de s ta tine  w erd een s ign ifican te  
s tijg in g  gezien in z e n u w a c tiv ite it, deze daalde w eer naar de u itgangsw aarde 
nadat de sta tine  w erd  hervat. Er w erd geen verandering  gezien in de concen tra ties 
no rad rena line  in he t b loed . De resu lta ten  van deze s tud ie  wekken sterk de in d ru k  
da t statines de ze n u w a c tiv ite it van he t sym patische zenuw ste lsel, zoals gem eten 
m idde ls m ic roneu rog ra fie , kunnen verlagen bij pa tiën ten  m et ha rtfa len .
Bij m ensen m et een ve rh oo gde  b loe dd ru k , li jk t  de ve rh oo gde  a c tiv ite it  van het 
sym patische zenuw ste lsel he t gevo lg  te z ijn  van he t on n o d ig  versterken van het
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e ffe c t van "n o rm a le " prikke ls van de a c tiv ite it van he t sym patisch zenuw ste lsel. 
D it zou kunnen verk laren w aarom  b ij som m ige  pa tiën ten  een ve rh oo gde  
b lo e d d ru k  n ie t reageert op norm ale  m ed icam enteuze behande ling . In h o o fd s tu k  
5, testen w ij de hypothese da t statines ook in staat z ijn  de ve rh oo gde  a c tiv ite it 
van he t sym patische zenuw ste lse l te  verlagen b ij m ensen m et een ve rh oo gde  
b loe dd ru k . Door ge b ru ik  te m aken van een p rospectieve, gerandom iseerde, 
p lacebogecon tro lee rde , du b b e lb lin d e , cross-over opzet, hebben w ij een "p roo f- 
o f-p r in c ip le " s tud ie  u itgevoerd  b ij 13 pa tiën ten  m et een m ild  to t  m atig  ve rh oo gde  
b loe dd ru k , d ie  w ille ke u rig  w erden verdee ld  naar he tz ij eerst behande ling  m et 
a to rvas ta tine  80 m g/dag  m et daarna p lacebo elk vo o r een pe riode  van 3 weken, 
he tz ij de om gekeerde vo lgo rde . Het ge b ru ik  van a to rvas ta tine  verlaagde de 
z e n u w a c tiv ite it van he t sym patische zenuw ste lse l s ig n ifica n t, zonder da t d it 
inv loed  had op de concen tra ties  norad rena line  in he t b loed, de b lo e d d ru k  o f de 
h a rtfre q u e n tie . De m ate w aarin  de ze n u w a c tiv ite it w erd verlaagd was ona fhanke lijk  
van de verandering  in cho leste ro lw aarde  in he t b loed. Bij pa tiën te n  m et een m ild  
to t  m atig  ve rh oo gde  b lo e d d ru k  li jk t  a to rvas ta tine  in een dosis van 8 0 m g / dag dus 
instaat de a c tiv ite it  van he t sym patisch zenuw ste lse l te verlagen.
Een b e la ng rijk  e lem en t in de m anier w aarop he t ang io tens ine  II systeem de 
centra le a c tiv ite it van het sym patische zenuwstelsel be ïnv loed t is de vorm ing  van 
zuu rs to frad ica len  do or he t enzym  NAD(P)H-oxidase, w a t de laatste stap in het 
ang io tens ine  II pad v o rm t. Bij kon ijnen  m et ha rtfa len  is de expressie en a c tiv ite it 
van he t enzym  NAD(P)H-oxidase, he t be lang rijks te  enzym  v o o r de vo rm in g  van 
zuu rs to f rad ica len (ROS), ve rh oo gd  in he t ros troven tro la te ra le  deel van de 
hersenstam  (RVLM), de be lang rijks te  plaats vo o r de regu la tie  van de a c tiv ite it  van 
he t sym patische zenuw ste lse l. Het kunnen verlagen van de zuu rs to frad ica len  
concen tra tie  in de hersenen zou daarm ee een b e la ng rijk  m echan ism e kunnen zijn 
om  de ve rh o g in g  in a c tiv ite it  van he t sym patisch zenuw ste lsel tegen  te  kunnen 
gaan. A scorb inezuur (v itam ine  C) is een bekende s to f d ie  in staat is zuu rs to f­
radicalen weg te vangen en daarnaast in staat is de bloed-hersenbarrière te passeren. 
H o o fd s tu k  6, be sch rijft de resu lta ten  van een p rospectie f, gerandom iseerde, 
p lace bo-gecon tro lee rde , d u b b e lb lin d e , cross-over s tud ie  naar he t e ffe c t van de 
to e d ie n in g  van ascorb inezuur in een dosis van 2 g ram /dag  o f p lacebo vo o r een 
pe riode  van 3 dagen b ij een g roep  ha rtfa le n p a tië n te n . O ndanks he t fe it  da t de 
v ita m in e  C concen tra tie  in he t b loed s ig n ifica n t w erd  ve rh oo gd , w erd er geen 
e ffec t op het sym patisch zenuwstelsel gevonden. Het fe it  dat er geen e ffec t werd 
gevonden kan op een aantal m an ier w o rde n  verk laard . Ten eerste g e ld t dat.
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ofschoon de concen tra ties v ita m in e  C in he t b loed s ig n ifica n t stegen, de waarden 
nog steeds b innen  de norm ale  fys io log ische  grenzen bleven. Aangezien de 
opnam e van v ita m in e  C in de hersenen gedreven w o rd t d o o r he t versch il in 
concen tra tie  in he t b loed en de concen tra tie  in de hersenen en p laa tsv ind t via 
specia le tra n s p o rte iw itte n , zou he t kunnen z ijn  da t de s tijg in g  van de v ita m in e  C 
concen tra tie  in he t b loed on vo ldoe nd e  was om een be teken isvo lle  inv loed  te 
hebben op d it  transp o rt. Daarnaast zou he t zo kunnen zijn dat, als de norm ale 
innam e van v ita m in e  C in de voe d in g  al op tim aa l is en er ve rvo lgens een 
ascorb inezuur hoevee lhe id  toe g e d ie n d  w o rd t die de b loedconcen tra ties  n ie t 
boven de no rm a le  waarden w ee t te  ve rhogen, er geen ve rb e te ring  van het 
centra le  an tio x id a n t e ffe c t m eer kan w o rden  bew erks te lligd .
Deel II: sympatische activ ite it en insulineresistentie
Het tw ee de  deel van he t p ro e fsch rift r ich t zich op de ve rb e te ring  van de 
ge voe lighe id  van he t lichaam  vo o r insu line d o o r in te g rijpe n  in he t sym patische 
zenuw ste lse l. Een van de gevo lgen  van een ve rh oo gde  sym patische a c tiv ite it  is 
een afnam e van de d o o rb lo e d in g  van de skeletsp ieren via s tim u la tie  van de 
a lfa -adrenerge receptor. Door de ve rlag ing  van de d o o rb lo e d in g  van de 
skeletsp ieren neem t de aanvoer van glucose en insu line naar deze weefsels af 
(reduced n u tritiv e  flow ). D it m echan ism e kan de oorzaak z ijn  van de insu line ­
res is tentie  die w ij vaak zien b ij ve rsch illende  z iek tebee lden  w aarb ij de centra le  
a c tiv ite it  van he t sym patische zenuw ste lsel is ve rh oo gd , zoals ha rtfa len . In 
hoofdstuk 7 stellen w ij da t b ij pa tiën te n  m et ha rtfa len  de h ierm ee geassocieerde 
ve rh o g in g  in sym patische a c tiv ite it, (ten dele) v e ra n tw o o rd e lijk  is voo r de afnam e 
in g lucoseopnam e d o o r de ske letsp ier en da t d it  e ffe c t v e rlo o p t via de 
a lfa -adrenerge receptor. Ind ien d it  k lop t, zou fen to lam ine , een bekende b lokker 
van de a lfa -adrenerge receptor, de "n u tr it iv e  f lo w "  kunnen verhogen  en de 
g lucoseopnam e d o o r de ske letsp ier kunnen verbe te ren . We hebben de e ffec ten  
van fe n to la m in e  verge leken tussen 8 pa tiën ten  m et ha rtfa len  en 12 gezonde 
v r ijw illig e rs . De d o o rb lo e d in g  (FBF) en g lucoseopnam e (FGU) in de onderarm  
w erden tijd en s  een 150 m inu ten  du rende  hyperinsu linem ische  euglycem ische 
clamp procedure gem eten in beide onderarm en. Gedurende de laatste 30 m inuten 
van de c lam pp rocedure  w erd  fe n to la m in e  via een in fuus to e ged ie nd  in een van 
de onderarm en . Fento lam ine ve rb e te rd e  de FGU s ig n ifica n t in de ha rtfa leng roep , 
maar had geen e ffec t op de FGU in de groep gezonde vrijw illigers, ondanks het fe it 
da t de d o o rb lo e d in g  van de onderarm  in be ide g roepen op ve rge lijkba re  w ijze
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verbe te rde . H ierop conc ludeerden  w ij da t b lokkade  van de a lfa -adrenerge 
receptor, de opnam e van glucose in de onderarm  v e rb e te rt b ij pa tiën ten  m et 
ha rtfa len . D it resu ltaa t kan verk laard w o rden  doorda t, de ve rh oo gde  a c tiv ite it 
van he t sym patische zenuw ste lse l b ij pa tiën ten  m et ha rtfa len  le id t to t  een afnam e 
van de d o o rb lo e d in g  van de kle ine b loedva ten . D it e ffe c t bestaat n ie t b ij gezonde 
personen.
Een andere m anier w aarop he t sym patische zenuw ste lsel kan le iden to t  insu line 
res is tentie  is he t fe it  da t he t vaa tvernauw ende e ffe c t van een hoge sym patische 
z e n u w a c tiv ite it he t vaa tve rw ijde nd e  e ffe c t van insu line op de ske letsp ier te n ie t 
doe t. Als d it  k lo p t, dan zou he t b lokkeren van de po s t-gang liona ire  sym patische 
z e n u w a c tiv ite it he t vaa tve rw ijde nd e  e ffe c t van insu line b ij deze pa tiën te n  m oeten 
versterken. Ind ien va a tve rw ijd in g  de d o o r insu linegedreven  g lucoseopnam e 
v e rb e te rt, dan zou de b lokkade  van he t sym patische zenuw ste lsel een s tijg ing  
van de in su linegevoe lighe id  m oeten geven. In h o o fd s tu k  8 w o rd t deze hypothese 
ge test d o o r g e b ru ik t te maken van trim e ta fa n , een Nn-n ico tin e  ga ng lion  receptor 
blokker. Bij aanvang van de stud ie , w erd gedu rende een pe riode  van 60 m inu ten  
tr im e ta p h a n  via een in fuus to e ged ie nd  aan 6 gezonde v r ijw illig e rs , om he t e ffec t 
op  de vaa tw eers tand  en b lo e d d ru k  in te  kunnen schatten. Een dag la ter w erd  een 
hyperinsu linem ische  euglycem ische clam p procedure  van 180 m in u ten  gestart, 
w aarb ij tr im e ta p h a n  gedurende de laatste 60 m inu ten  via he t in fuus werd 
toe gevoegd . G edurende de c lam pp rocedure  b leek trim e ta p h a n , to e ged ie nd  
boven op de ve rh oo gde  insu lineconcen tra ties  in he t b loed, de vaa tw eers tand  in 
de onderarm  en de d iasto lische b lo e d d ru k  sterker te verlagen, dan w anneer 
tr im e ta p h a n  alleen w erd  to e ged ie nd . De g lucoseopnam e in de onderarm  en in 
he t hele lichaam  ve rb e te rd en  s ig n ifica n t gedurende  b lokkade  van he t gang lion  
van he t sym patische zenuw ste lsel. H ie ru it kon w o rden  geconc ludeerd  dat 
b lokkade  van he t sym patische ga ng lio n  een p o te n t va a tve rw ijd e n d  e ffe c t van 
insu line  en een ve rb e te ring  van de in su linegevoe lighe id  w is t b lo o t te  leggen bij 
gezonde v r ijw illig e rs . In h o o fds tuk  3, beschrijven we da t de ve rb e te ring  van de 
d o o rb lo e d in g  van de ha rtsp ie r d o o r m idde l van een PCI b ij pa tiën ten  m et stab ie le  
angina pecto ris  de a c tiv ite it  van he t sym patische zenuw ste lse l verlaagt. Deze 
ve rlag ing  in sym patische a c tiv ite it  zou een gunstig  e ffe c t kunnen hebben op 
in su line ge voe ligh e id . De PCI ze lf daarentegen, zou nade lige  e ffec ten  kunnen 
hebben op de insu linegevoe l ighe id , om d a t he t een on ts tek ingsreac tie  ve roorzaakt 
en de spiegels van he t ho rm oon  ad ip o n e c tin e  verlaag t. Een de rge lijke  reactie is 
beschreven o n m id d e llijk  na een d o tte rb e h a n d e lin g . In h o o fd s tu k  9, beschrijven
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w ij he t e ffe c t van een PCI op on ts tek ingsw aarden , ad ipone c tine con cen tra tie s  en 
in su linegevoe lighe id  b ij 19 pa tiën ten  m et s tab ie l co ro na irlijde n  v o o r en een 
m aand na hun d o tte rb e h a n d e lin g . De concen tra ties van de on ts tek ingsw aarden  
en a d ip one c tine  w erden  h ie rb ij gem eten . In deze s tud ie  had een PCI geen nega tie f 
e ffe c t op de g lucoseopnam e o f de insu linegevoe lighe id .
Algem ene beschouwing
Een toenam e in a c tiv ite it  van he t sym patische zenuw ste lse l is nauw  ve rb on den  
m et een aantal ha rt -en vaa tz iek ten . De toenam e kan he t gevo lg  z ijn van een 
du id e lijke  prikke l, zoals z u u rs to fte ko rt, o f he t gevo lg  z ijn van een aantal pa tho - 
fys io log ische  ve randeringen , w aarb ij de oorzaak van de ve rh o g in g  van de 
a c tiv ite it  van he t sym patische zenuw ste lse l onom keerbaar o f n ie t to e gan ke lijk  
v o o r een in te rve n tie  is. O ndanks he t fe it  da t er een g ro te  d ive rs ite it aan oorzaken 
en m echan ism en z ijn  d ie  v e ra n tw o o rd e lijk  lijken v o o r de ve rh o g in g  in a c tiv ite it, 
li jk t  he t u ite in d e lijke  niveau van de sym patische a c tiv ite it, op z ijn  m inst ten  dele, 
te  w o rde n  ge regu leerd  do o r een enkel gem eenschappe lijk  m echanism e waarin 
he t centra le  ang io tens ine  II en NO een be langrijke  rol spelen. Naast he t w egnem en 
van bekende prikkels van een ve rh oo gde  sym patische a c tiv ite it, li jk t het in g rijpe n  
op d it  centraal w erkende ang io tens ine  II en NO systeem een aan trekke lijk  
a lte rn a tie f om sym patische a c tiv ite it  op een centraal niveau te verlagen. In deze 
con tex t b lijken  HM G-coA reductase rem m ers (statines) in staat de ang io tens ine  II 
en NO system en in de hersenen te be ïnv loeden, m et als gevo lg  een ve rlag ing  in 
sym patische a c tiv ite it. In d it  p ro e fsch rift tonen  w ij aan da t sta tines de sym patische 
a c tiv ite it  b ij pa tiën ten  m et ha rtfa len  en essentië le hypertensie  kunnen verlagen. 
Het exacte m echanism e w aarm ee statines sym patische a c tiv ite it kunnen verlagen 
kan n ie t w o rden  bepaald m et onze stud ies, maar gebaseerd op d ie re xpe rim en ­
tee l onderzoek lijk t he t erop da t deze be ïnv loed ing  via he t ang io tens ine  II en NO 
systeem ve rlo o p t. Het toevoegen  van een an tio x id a n t (ascorbine zuur), m et het 
doel de vo rm in g  van zuu rs to frad ica len  in de hersenen te  verm inde ren , b leek n ie t 
succesvol. De h u id ige  the rap ieën  hebben zich er voo ra l op ge rich t om organen af 
te  scherm en van de hoge a c tiv ite it, m eestal do o r de be ta -ad renerge  recep to r te 
b lokke ren. M et deze aanpak b l i jf t  de ve rh oo gde  a c tiv ite it van he t sym patische 
zenuw ste lse l ze lf onaangetast. Een b e la ng rijk  ne ga tie f e ffe c t van deze ve rh oo gde  
activ ite it is een afname in insulinegevoeligheid, om dat de alfa-adrenerge receptoren 
d o o r he t zenuw ste lsel gestim u lee rd  b lijven . In d it  p ro e fsch rift beschrijven w ij een 
aantal stud ies d ie  he t e ffe c t van he t b lokkeren van he t sym patische zenuw ste lsel 
op in su linegevoe lighe id  onde rzoch t hebben. Het b lokkeren van he t sym patische
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zenuw ste lse l op m eer centraal niveau v e rb e te rt de in su linegevoe lighe id  b ij 
pa tiën te n  m et ha rtfa len  en b ij gezonde v r ijw illig e rs . D it e ffe c t kan he t meest 
w a a rsch ijn lijk  verk laard w o rden  d o o r h e t fe it  da t d o o r de ve rh oo gde  a c tiv ite it  van 
he t sym patische zenuw ste lse l de d o o rb lo e d in g  van de k le ine  b loedva ten  af neem t, 
he tgeen resu ltee rt in een afnam e van de "n u tr it iv e  f lo w "  naar de skeletspier. Het 
w egnem en van die ve rh oo gde  a c tiv ite it  le id t to t  een ve rb e te rin g  van de 
d o o rb lo e d in g  van de kle ine b loedva ten  en een toenam e van he t ve rm ogen  van 
de ske letsp ier om  glucose op te  nem en en da t le id t to t  een ve rb e te rin g  van de 
insu linegevoe lighe id .
Toekom stperspectieven
M en kan zich afvragen o f he t in te rven ië ren  in de centra le  sym patsiche a c tiv ite it 
een toe gevo eg de  waarde h e e ft ten opz ich te  van de h u id ige  behande ling  m et 
bèta b lokkers en ace-rem m ers b ij pa tiën ten  m et h a r t-e n  vaa tz iek ten . Bèta blokkers 
en ace-rem m ers hebben te n s lo tte  in een g ro o t aantal ge random iseerde stud ies 
bewezen e ffe c tie f te  z ijn  op e ind pun ten , zoals s te rfte  en m o rb id ite it  do o r hart 
-e n  vaa tz iek ten . De toe gevo eg de  waarde van s tra teg ieën die  zich rich ten op het 
ve rlagen van de sym patische a c tiv ite it  ze lf hebben zich daarentegen, nog n ie t 
bewezen in gro te , gerandom isee rde  stud ies. D esa ln ie ttem in  is he t schadelijke 
e ffe c t van een ve rh oo gde  a c tiv ite it  van he t sym patische zenuw ste lse l zelf, b ij een 
g ro o t aantal ha rt -e n  vaa taandoen ingen  a lgem een bekend. Een ve rh oo gde  insu- 
line res is ten tie  en een the rap ie res is ten te  ve rh oo gde  b lo e d d ru k  z ijn h ier een 
d u id e lijk  vo o rbe e ld  van. Om deze reden, li jk t  he t ge rech tvaa rd igd  een po g ing  te 
w agen de centra le  a c tiv ite it  van he t sym patische zenuw ste lsel te  verlagen, m et 
he t doel de ove rlev ing  en de kw a lite it van leven te verbe te ren . Onze onderzoeken 
suggereren da t naast he t cho les te ro lve rlagende  e ffe c t van statines, zij ook de 
sym patische a c tiv ite it kunnen verlagen b ij pa tiën ten  m et ha rtfa len  en essentië le 
hoge b loe dd ru k . Het behande len m et statines is ve ilig  en re la tie f go ed koo p  en bij 
vee l van deze pa tiën ten  z ijn  statines al een onderdee l van de standaard therap ie . 
Het d ie n t ech ter nog w el te  w o rden  vastgeste ld  o f de bewezen guns tige  e ffec ten  
van statines op card iovascula ire  s te rfte  en m o rb id ite it  n ie t alleen he t gevo lg  z ijn 
van een ve rlag ing  in cho leste ro l, maar ook kan w o rden  toegeschreven aan een 
lang du rige  ve rlag ing  van de a c tiv ite it  van he t sym patische zenuw ste lsel. Er zu llen 
g ro te  k lin ische stud ies nod ig  z ijn d ie  ge b ru ik  m aken van eenvoud ige , maar 
b e tro uw ba re  m e tho de n  om sym patische a c tiv ite it  en in su linegevoe lighe id  te 
m eten, om d it u it te  zoeken.
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Nu he t e inde van m ijn  p ro m o tie tra je c t nadert, on ts ta a t er een ge legenhe id  om 
te rug  te b likken op een hele b ijzonde re  en unieke pe riode  u it m ijn  leven. D oor de 
bu itens taander w o rd t p rom overen  vaak geassocieerd m et he t doen van onde r­
zoek, he t ve rvo lgens schrijven van verslagen over de u itkom sten  van d it onderzoek 
(de artike len) en he t u ite in d e lijk  bunde len  van deze noeste arbeid to t  een w a t w ij 
dan noem en p ro e fsch rift. M ensen die  een p ro m o tie  op deze w ijze  de fin ië ren  zijn 
zeer w a a rsch ijn lijk  n ie t geprom oveerd . P rom overen is m eer dan w a t dan ook een 
in tensie f persoonlijk  on tw ikke lingstra ject. Tijdens je  p rom otie tra jec t word je  jeze lf 
enerzijds bew ust van je  capacite iten en ta len ten , maar anderzijds gecon fronteerd  
m et je  bepe rk ingen . Er w o rd t een beroep gedaan op je  c rea tiv ite it, f le x ib il ite it,  
incasseringsverm ogen en "last b u t n o t least" je  ve rm ogen  te vo lha rden  en n ie t op 
te  geven. Als ik he t zou m oeten ve rge lijken  m et he t bek lim m en van een hoge 
berg, dan zijn de a rtike len  de ogen waaraan ik m ij zeker naarm ate ik ve rder klim , 
is de vlag aan de to p  m ijn  p ro e fsch rift, maar is de tro ts  en vo ld o e n in g  die ik ervaar 
als ik daar op de to p  sta, gestoe ld  op de o ve rw in n in g  van m ijn  hoog tevrees, m ijn  
c re a tiv ite it om de scherpe ro tspu n ten  te om ze ilen en m ijn  ve rm ogen  om m ijn  
p ijn tje s  en ve rm o e id he id  te negeren en stug d o o r te k lim m en. En de prijs die ik 
mag ontvangen? Dat is he t geg roe ide  ve rtro u w e n  in een goede a flo op  als de 
vo lgende , w a a rsch ijn lijk  nog hogere berg zich a lw eer aand ien t. De be lang rijks te  
les heb ik u ech ter nog on th o u d e n . Een succesvolle p ro m o tie  is slechts dan 
m o g e lijk  als deze gesteund w o rd t d o o r een groep to e g e w ijd e  en enthousiaste 
m ensen die o n voo rw aa rde lijk  voo r jo u  klaar staan. O fschoon ik m ij b ij voo rbaa t 
realiseer da t he t o n m o g e lijk  is alle m ensen te noem en die  ik zou w ille n  bedanken 
vo o r hun b ijd rage  aan d it  p ro e fsch rift, zou ik toch  b ij een aantal m ensen w ille n  
stilstaan.
Als eerste zou ik alle pa tiën te n  en p roe fpe rsonen w ille n  bedanken die  zich bereid 
hebben  verk laa rd  m ee te doen aan m ijn  on de rzoek . Z ond e r u is onde rzoek  
s im pe lw eg n ie t m og e lijk . M et d iepe  respect heb ik m ogen ervaren hoe u bereid 
was vaak urenlange m e tin ge n  te ondergaan, w aarb ij soms ge b ru ik  w erd gem aakt 
van m eerdere in fusen, naalden en apparaten . O fschoon uw  b ijd rage  fo rm ee l in 
a n o n im ite it p laa tsv ind t, v o rm t u o n u itw isba a r een van de g ronds lagen v o o r de 
toe kom stige  on tw ikke lin g e n  b innen  de Geneeskunde. Dank daarvoor.
Prof. dr. C.J. Tack, best Cees, sam enva ttend kan ik zeggen: zonder jo u  geen 
prom otie . M ijn grootste  waardering gaat u it naar de ru im te  die j i j  m ij hebt gegeven 
om m ijze lf te on tw ikke len  en "e igenw ijs" te  zijn, zonder dat j i j  m ij o o it u it het oog
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verloo r. Ik ben ervan ove rtu ig d  da t j i j  rege lm a tig  hoo fdschuddend  en m et een 
g lim lach  op je  gez ich t naar m ij heb t z itte n  k ijken, te rw ijl ik w eer een e igengere id  
idee lanceerde. M et o n g e lo fe lijk  veel p lez ie r heb ik m et jo u  z itte n  discussiëren 
over onderzoek, maar ook over financ iën , p lann ing  en organ isatie . Jij he b t m ij 
a ltijd  als jo u w  ge lijke  behande ld  en da t ve rtro u w e n  is onm isbaar geweest. Ik heb 
o n tz e tte n d  veel van jo u  ge leerd en ik heb respect vo o r jo u w  steun, c rea tiv ite it, 
onderzoeksgeest en ve rm ogen  m ensen en thous iast te  m aken en te houden. 
Ik kon a ltijd  bij jo u  te rech t en hoewel d it  m isschien vreem d k lin k t om te zeggen, 
v o o r m ijn  gevoel heb ik er een v rie nd  v o o r he t leven bij.
Prof. dr. J.W.M. Lenders, beste Jacques, nog n o o it in m ijn  leven ben ik iem and 
tegen  gekom en die op een zu iverder m anier w etenschap b e d r ijf t  dan zoals j i j  dat 
doe t. Jouw  oog v o o r de ta il en w a a rhe idsv ind ing  z ijn  ongeëvenaard. Van jo u  heb 
ik ge leerd da t ik n o o it m eer mag ste llen , dan da t ik kan bew ijzen . Jouw  frons zal ik 
n o o it ve rge ten  als ik w eer eens conclusies tro k  d ie  verder g ingen  dan m ijn  data 
konden dragen. Daar waar ik vaak al bezig was m et de verkoop , m aakte j i j  je  
zorgen om  de garan tie . Naast een goede m ento r, ben je  ook een o n tze tte n d  f ijn  
persoon om mee te pra ten. O fschoon reeds in ru im e m ate aanwezig, zal ik a ltijd  
van m en ing  b lijven  da t de w aardering  die  j i j  o n tva n g t, n o o it recht zal doen aan de 
w aardering  die  j i j  ve rd ie n t. Bedankt voo r alles.
Prof. dr. F.W.A. V erheugt, beste Freek, b ij u is he t allem aal begonnen. Daar zat ik 
dan, een jo n g e n  u it Am sterdam , onbekend in de N ijm eegse con tre ien , die d irec t 
de o p le id in g  in w ild e  en ook nog eens in een ve rk o rt tra je c t en gecom b ineerd  
m et een p rom otie . Dat m oest wel Am sterdam se branie z ijn . Toch he e ft u he t m et 
m ij aangedurfd  en he e ft u b innen  de C ard io log ie  de ru im te  vo o r m ij gecreëerd 
die  er toe  he e ft kunnen le iden da t w ij nu staan waar we staan. Veel bew onde ring  
heb ik v o o r de w ijze  w aarop u zich b innen  he t w e tenschappe lijke  ve ld  bew eegt. 
Ik ben u dankbaar vo o r uw  on voo rw aa rde lijke  steun en de w arm e w ijze  waarop 
ik a ltijd  w erd  on tva n g e n . Ik zal onze geze llige  d iners  t ijd e n s  de b u iten lan dse  
congressen n o o it ve rge ten  en ik hoop  in de toe kom st nog eens van de p a rtij te 
m ogen zijn.
Prof. dr. P. Smits, beste Paul, j i j  he b t aan de basis gestaan van m ijn  p ro m o tie tra je c t. 
Jou w  onde rzoekse rva ring  en ve rm o ge n  p ro je c te n  fe illo o s  op po ten  te  ze tten , 
hebben m ijn  ag iko cons truc tie  v lo tg e tro kke n . Hierna w a s je  a ltijd  aanwezig, op de 
ach te rg rond  als he t goed g ing  en p ro m in e n t vooraan als jo u w  hu lp  nod ig  was.
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Jij z ie t m eer in m ij dan alleen een d o k te r o f onderzoeke r en d it  was dan ook de 
reden da t j i j  m ij in de ge legenhe id  he b t geste ld  m ijn  eerste m anagem en tervaring  
op te  doen als m edisch d irec teu r a.i. van he t C linical Research Centre N ijm egen. 
Ik ben zeker van plan deze kant van m ijze lf ve rde r vo rm  te geven en ben op rech t 
vereerd da t j i j  he b t aangeboden m ij daar ve rder bij te w ille n  he lpen. In m ijn  ogen 
ben j i j  naast een goede arts, een bev logen  onderzoeker en een begenad igd  
m anager. Jouw  ster is nog steeds aan he t rijzen en ju is t  da t m aakt da t ik je  heel 
dankbaar ben d a t je  er de sa ln ie tte m in  a ltijd  vo o r m ij was.
Dr. W. Aengevaeren, beste W im , elke keer als ik jo u  spreek heb ik a ltijd  he t gevoel 
da t j i j  jo u w  b ijd rage  aan m ijn  p ro m o tie  onderschat. Juist in he t beg in  w anneer de 
ideeën w o rden  geboren, ben j i j  er geweest. Samen op de ca the te risa tiekam er 
hebben we z itte n  zoeken naar gesch ikte  pa tiën ten . Jouw  passie en bev logenhe id  
v o o r he t vak en de w etenschap w erken aansteke lijk . Jij v e rd ie n t h ier een plekje . 
B edankt v o o r jo u w  hulp.
Naast de bovengenoem de personen, ben ik nog een heel aantal m ensen dank 
ve rschu ld igd .
Als eerste w il ik ook pro f. dr. J. van der M eer bedanken. U be n t de geeste lijk  vader 
gew eest van he t sam enw erk ingsverband tussen de a fde lingen  In terne Genees­
kunde en C ard io log ie . Daarnaast he e ft u m ij be lange loos en on voo rw aa rde lijk  
te rz ijd e  gestaan toen  w ij versch ilden  van inz ich t m et de MSRC aangaande m ijn  
ko rtingsve rzoek. Ik maak een d iepe bu ig in g  voo r u als persoon en v o o r m ij zal 
a ltijd  ge lden: als u praat, m oe t ik lu is teren. Bedankt voo r uw  hulp.
Prof. dr. P. S tuyt, beste Paul, sam en m e t pro f. Van der M eer z ijn  w ij de s tijd s  ten  
s tr ijd e  ge trokken . S indsdien heb ik jo u  nog m en igm aal om  raad m ogen vragen. 
Jouw  expertise op he t gebied van onderw ijs , jo u w  u itgebalanceerde a fw egingen 
en jo u w  gevoel voor (bestuurlijke) verhoudingen dw ingen respect af. M ijn grootste 
be w o nde rin g  gaat ech ter u it naar he t fe it  da t j i j  ondanks deze expertise , het 
pe rsoon lijke  aspect n o o it u it he t oog he b t ve rlo ren . Jij he b t een w arm e en 
harte lijke  w ijze waarop j i j  je  opste lt. Ik w erk al een tijd je  m et jo u  samen en ik hoop 
da t nog heel lang te m ogen doen.
Graag zou ik ook Louise Bellersen en de ha rtfa lenverp leegkund igen  Lisette en Lex 
w ille n  bedanken. Louise, j i j  was a ltijd  bereid onde rs te un ing  te b ieden waar dat
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nodig was. Lisette en Lex, de w ijze waarop ju llie  samen m et Louise, de hartfa lenpo li 
in vu llin g  geven en he t ve rtro u w e n  da t ju llie  daarm ee kweken b ij ju llie  pa tiën ten , 
m aakte he t m eer dan eenvoud ig  pa tiën ten  te v in de n  die  bere id waren mee te 
doen aan m ijn  onderzoek. Ik ben ervan ove rtu ig d  da t ju llie  rol in toe kom stige  
wetenschappelijke pro jecten alleen maar zal toenem en, aan ju llie  zal het n iet liggen.
Een speciale p lek  verd ienen  de researchverp leegkund igen Karin Saini en in het 
b ijzon de r A a rn ou t Jansen van Roosendaal. Je le e rt een goede researchverpleeg- 
kund ige  pas ech t w aarderen als je  als v o ls tre k t onervaren onderzoeker vo o r het 
eerst b ij een experim ent staat. Aarnout, ik zal vooral onze gezellige gesprekken en 
discussies over fu tie le  zaken missen. Je ben t een rots in de b rand ing  v o o r elke 
onderzoeker. Ze m ogen heel b lij m et jo u  z ijn  op de IC. In m ijn  gedachten b lijf  je  
ech ter a ltijd  onderdee l van de klin ische fys io log ie .
Graag zou ik ook de mensen w ille n  bedanken die  veel onde rs te un ing  hebben 
ge bo de n  b ij m ijn  ve rsch illen de  p ro je c te n . John, j i j  b e n t b ij m ij als s tu d e n t- 
onderzoeke r begonnen en ik heb intussen begrepen da t j i j  op  d it  m om e n t m et 
een eigen p ro m o tie tra jec t bezig bent op de O oghee lkunde. Jouw  tom eloze inzet, 
be tro u w b a a rh e id  en d isc ip lin e  z ijn  be w o nde ren sw aa rd ig . Daarnaast ben je  
gew oon een heel f ijn e  ven t waar je  erg mee kan lachen. Ik w e e t zeker da t j i j  een 
g ro o t oogarts  gaat w orden. M arjo, ook j i j  on tze ttend  bedankt voo r al jo u w  inzet. 
Dank gaat ook u it naar de m ensen van he t CRCN. Jackie, be da nk t voo r jo u w  
organ isa torische w erkzaam heden. Helen, gedurende  een aantal m aanden was j i j  
to ch  een be e tje  m ijn  secretaresse en ik had m ij geen be tere  kunnen w ensen. 
Ik w ee t da t j i j  een zware t ijd  he b t gehad en ik hoop  da t alles nu goed is gekom en. 
Ik hoop  je  snel te spreken. Stef M ien tk i, be da nk t v o o r jo u w  techn ische on de r­
steuning. Ik zal je  n ie t m eer bellen en ik heb je  vast een aantal malen to t w anhoop 
gedreven, maar he t is nu klaar, je  ben t van m ij af.
Dank gaat ook u it naar m ijn  co llega onderzoekers o.a. A lexandra, Stijn, A lexander, 
Patrick, Bas, Bastiaan en Niels. Bedankt voo r een o n ge lo fe lijk  gezellige en leerzame 
tijd . Ik heb de eer gehad deel u it te m ogen maken van een groep zeer getalenteerde 
onderzoekers en ik ben ervan o v e rtu ig d  da t ju llie  he t allem aal nog ver zu llen 
schoppen.
O nderzoek is ook n ie t m o g e lijk  als h ier geen goede in fra s tru c tu u r v o o r is. Ik w il 
dan ook graag de m ensen van de apo theek, o.a. David Burger, A ud rey Blenke en
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Sylvia Kok en de m edew erkers van de versch illende  labo ra toria , w aaronde r prof. 
dr. C.G.J. Sweep, Rob van den Berg, Berry van T its en Jan Verhagen, bedanken 
vo o r hun on de rs teun ing .
Dr. D o ffe rh o f (op le ider) en sta f van de a fde ling  In terne G eneeskunde van het 
Canisius W ilhem ina Z iekenhuis N ijm egen w il ik bedanken vo o r hun on tze tte n d  
fijn e  en be trokken  be ge le id ing  tijd en s  m ijn  v o o ro p le id in g  in de beg in  fase van 
m ijn  carrière als dokte r. Juist in deze t ijd  heb ik ook alle ru im te  m ogen on tvangen 
om m ijn  p ro m o tie tra je c t op  po ten  te ze tten .
Dank gaat ook zeker u itn a a rd r .  O ud eO phu is  (op le ider), s ta f en m edew erkers van 
de a fde ling  C ard io log ie  van het Canisius W ilhem ina Z iekenhuis. Ju llie  inzet voo r 
en be trokkenhe id  b ij de o p le id in g  van (jonge) assistenten, le g t he t onm isbare 
fu n d a m e n t om in de toe kom st een goede ca rd io loo g  te  w o rden . Ju llie  persoon lijke  
en toe gan ke lijke  m an ie r van opste llen , hebben er v o o r m ij v o o r gezorgd da t je  
he t a a n d u rft te  groe ien, fo u te n  te m aken en daar ve rvo lgens be ter van te w o rden . 
Bedankt v o o r alle w ijze  lessen.
De s ta f , assistenten en m edew erkers van de a fde ling  C ard io log ie  van he t UMC St 
Radboud w il ik ook graag bedanken v o o r de f ijn e  sam enw erk ing die ik a ltijd  mag 
en heb m ogen on tvangen . Zowel op klin isch, als op w e te nsch ap pe lijk  v lak  was er 
a ltijd  iem and te v in d e n  die  bere id  was mee te  denken o f te lu is teren. Het do o r m ij 
ge lopen  pad zal gehe id  een aantal geë igende w egen hebben d o o rk ru is t en ik 
ben dankbaar da t m ij a ltijd  de ge legenhe id  is geboden deze rou te  te  vo lgen .
De leden van de m anuscrip t com m issie, prof. dr. M.T.E. Hopm an, pro f. dr. J.W. 
Jukema en pro f. dr. M.J. Zw arts, w il ik ook graag bedanken vo o r de t ijd  en m oe ite  
d ie  zij hebben genom en om m ijn  m anuscrip t kritisch  te beoorde len .
Nu ik r ic h tin g  he t e inde  van m ijn  da n kw o o rd  ga, kom  ik u it b ij d ie  m ensen die  
de w o rte ls  vo rm e n  van m ijn  leven. Z ond e r hen geen stam , geen takken, geen 
bladeren en dus geen v ruch te n . W at ik ben en w a t ik mag zijn , ben ik d o o r hen.
Roy, M erel, lieve Nathan, bedankt, be da nk t da t ju llie  er z ijn . Roy, je  be n t m ijn  
broer, m ijn beste vriend en m ijn onm isbare kamerraad. M et jo u  ben ik opgegroe id , 
m et jo u  heb ik alles m eegem aakt en m et jo u  kan en w il ik  alles delen. Als ik ergens 
op kan ve rtro u w e n  is he t da t j i j  er a ltijd  bent, w a t er ook ge be urt. O ng e lo fe lijk
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bedankt voor de rust die dat gee ft. Jij bent slim m er en beter dan ik, maar je  hebt 
n o o it de be ho e fte  gehad da t te zeggen. Nu doe ik dat! M erel, j i j  he b t op een 
in d ru kw ekke nd e  w ijze  jo u w  p lek  ve rw o rven  b innen  ons gezin. Dat, in de ogen 
van bu itenstaanders, vaak hechte en o n d o o rd rin g b a re  ve rb on d , heb j i j  o p e n ­
gebroken en je  be n t vo l o ve rtu ig in g  b innen  gestapt. Ik kan o n g e lo fe lijk  lachen 
om jo u w  nuchtere en re la tiverende kijk op zaken, maar vooral dank ik je  voor jo u w  
w arm te , lie fde  en zorg. Zoals j i j  v o o r m ij m ijn  fa m ilie  bent, zo ben ik da t v o o r jo u . 
Lieve, k le ine  Nathan, vo o r jo u  is he t leven pas begonnen, maar jo n g e n  w a t ga 
j i j  het ver schoppen. Ik had n ie t gedacht da t zo'n kle in m anne tje  zoveel lie fde 
en em o tie  op kan w ekken. Ik hoop  da t he t m ij nog heel lang gegund is jo u w  
o n tw ik k e lin g  van d ic h tb ij te m ogen m eem aken en ja , ik ga je , v o lle d ig  op vo e d ­
kund ig  on ve ra n tw oo rd , ve rw ennen , kan m ij n ie t schelen, ik ben je  oom , dus dat 
m ag ...
M am , na de sche id ing  hebben onze w egen zich op o n fo r tu in lijk e  w ijze  w a t 
gescheiden, misschien n ie t door te we in ig liefde en betrokkenheid, maar misschien 
w el do o r te  veel. Jij z u lt jo u w  b ijd rage  a ltijd  baga te lliseren, maar da t ik h ier sta is 
en b l i jf t  ook jo u w  verd ienste . Jij v e rd ie n t een p lek je  in d it da nkw oord  en n ie t zo 
maar ergens, maar op deze plaats en onde r d it kopje.
Pap, dan kom ik bij jo u . Diepe, d iepe respect heb ik voo r de w ijze waarop j i j  instaat 
was de zorg vo o r ons, al van jo ng s  af aan, in je  een tje  te  com b ineren  m et een 
in d ru kw ekke nd e  carrière. In teg en s te llin g  to t  waar ve len fa len , hebben w ij n o o it 
een warm e, lie fhebbende vader hoeven te  missen. Jouw  p r io r ite it lag en lig t a ltijd  
b ij ons. M ijn norm en, m ijn waarden en m ijn k ijk  op hoe een gezin zou m oeten zijn, 
heb ik van jo u . Ik ben er o n ge lo fe lijk  tro ts  op als men zegt dat ik op m ijn vader lijk. 
Ook nu nog kan ik a ltijd  b ij jo u  te rech t voo r advies o f steun. Jouw  w ijze raad heeft 
m ij m eer dan eens w eer op w eg geho lpen . Ik houd o n tz e tte n d  veel van je  en 
waardeer je  enorm . Ik w eet dat ik dat door alle d rukte  weleens vergeet te zeggen, 
daarom  sch rijf ik he t hier nu vo o r eens en vo o r a ltijd  op. D it p ro e fsch rift draag ik 
aan jo u  op.
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Marc Gomes w erd  op 26 ju li 1977 geboren in Heemskerk. Na he t beha len van zijn 
e indexam en van het Gym nasium  aan he t A ugustinus College te Beverw ijk, 
studeerde  hij in 1995, als gevo lg  van een on gu ns tig e  lo ting , gedu rende  1 jaa r 
G eneeskunde aan de Katholieke U n ive rs ite it Leuven. Het ja a r daarop w erd  hij 
alsnog in g e lo o t in Nederland en s ta rtte  h ij z ijn  s tud ie  G eneeskunde aan de 
U n ive rs ite it van Am sterdam , a lwaar h ij z ijn  propedeuse, docto raa l en artsexam en 
allen Cum Laude w is t af te  ronden. Al tijd en s  zijn G eneeskundestud ie raakte hij 
geïnteresseerd in he t ve rrich ten  van w e te nsch ap pe lijk  onderzoek, he tgeen vorm  
kreeg toe n  hij naast z ijn  stud ie, onderzoek g ing  doen onde r le id ing  van prof. dr. D. 
Legem ate van de a fde ling  V aa tch iru rg ie  van he t Academ isch M edisch Centrum  
(AMC) te  A m sterdam . Z ijn  p ro je c t "Interobserver va ria tion  in duplex scanning o f  
in fra in gu ina l a rte ria l bypass gra fts " w erd gepub licee rd  in he t European Journal o f 
Vascular and Endovascular Surgery en kreeg in te rna tiona le  aandacht. T ijdens 
z ijn  co-schappen b leek sprake van een sterke v o o rlie fd e  v o o r de C ard io log ie . 
Aangezien zijn fa m ilie  do o r ve randering  van w e rk  in deze pe riode  was verhuisd 
naar de reg io  N ijm egen, bes loo t h ij zich reeds in deze vroege  fase te o riën te ren 
b innen  he t UMC St Radboud te N ijm egen. T ijdens deze oriën ta tie fase  kwam  hij in 
con tac t m et pro f. dr. F.W.A. V erheugt, op le ide r C ard io log ie  en pro f. dr. J.W.M. van 
der Meer, op le ide r In terne Geneeskunde. A angestoken do or z ijn  enthousiasm e, 
w erd  beslo ten hem de o p le id in g  to t  ca rd io loo g  in he t v o o ru itz ic h t te s te llen en 
daarnaast een gezam enlijke  subsid ieaanvraag vo o r p ro m o tie o n d e rzo e k  in te 
d ienen ten  e inde een sam enw erk ingsverband v o o r w e te nsch ap pe lijk  onderzoek 
op te  ze tten  tussen de a fde lingen  In terne G eneeskunde en C ard io log ie . Deze 
inspann ingen  w ie rpen  hun v ruch te n  af, w a n t naast een pu b lica tie  in de Lancet 
w erd  tevens een Z onM w  AGIKO s tipe nd ium  (assistent geneeskund ige  in o p le id ing  
to t  klin isch onderzoeker) ve rw orven . D it ste lde  hem in 2003 in de ge legenhe id  
d irect aansluitend op het afronden van zijn op le id ing  Geneeskunde in Amsterdam, 
in een ve rk o rt tra je c t, te  s ta rten  m et de o p le id in g  to t  ca rd io loog  en d it te 
com b ineren  m et p ro m o tie o n d e rzo e k  (p rom otores: pro f. dr. C.J. Tack, pro f. dr. 
J.W.M. Lenders, prof. dr. F.W.A. Verheugt). Zijn voorop le id ing Interne Geneeskunde 
vo lgd e  hij deels in he t Canisius W ilhe lm ina  Z iekenhuis te N ijm egen (op le ider: dr. 
T. D o ffe rh o f) en deels in he t UMC St Radboud (op le ider: pro f. dr. J.W.M. van der 
Meer). Z ijn  B-jaar ca rd io log ie  vo lg d e  h ij m et veel p lez ie r aan de a fde ling  ca rd io log ie  
van he t Canisius W ilhe lm ina Z iekenhuis (op le ider: dr. A.J.M. Oude Ophuis). Tijdens 
z ijn  o p le id in g  he e ft hij a ltijd  gep robee rd  zich zo breed m o g e lijk  te on tw ikke len , 
w aarb ij hij o.a. P rincipal en S ub investiga to r is gew eest van een aantal com m ercië le  
tria ls. Daarnaast is hij M edisch D irecteu r a.i. gew eest van het C linical Research
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Center N ijm egen. V oorts m aakt hij thans deel u it van de Centrale O p le id ings­
com m issie en com m issie Acute O pnam e. T ijdens z ijn  onderzoeksperiode  w on  hij 
verscheidene prijzen. Op 1 april 2011 zal hij zijn specialisatie to t card io loog afronden.
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